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Chronic Hepatitis B viral (HBV) infection has been epidemiologically linked to the 
development of Hepatocellular Carcinoma (HCC) in patients. A significant 
characterization of chronic HBV infection is the integration of HBV DNA into multiple 
locations within the host DNA. This integration of viral DNA into host genome has been 
implicated to contribute to hepatocarcinogenesis through either insertional-mutagenesis 
or the retention/expression of the original/modified HBV proteins. One viral protein, 
HBx, has been strongly suggested to play important roles in oncogenicity through the 
deregulation of host genes. However, the association between chronic HBV infection and 
HCC remains poorly understood. 
Our laboratory had enriched for HBV sequences in 48 HBV-associated HCC patients and 
employed the FLX Genome Sequencer to characterize variations in the HBV DNA as 
well as HBV integration events in these patients. In this thesis, I employed a 
computational workflow to analyze the high-throughput sequencing data, and identified 
60 contigs/reads with altered HBV DNA and 63 contigs/reads carrying both HBV and 
human DNA within the same read from which the HBV-HG junction sites were inferred. 
Various variations such as insertions, deletions, duplications and inversions were 
observed from the 60 altered HBV sequences. Interestingly, the HBV-HG integrations 
were found to preferentially occur at the HBx gene locus (27/63=42.9%) and the 3’ C-
terminal of HBx carrying p53 binding domain was often deleted to fuse with the human 
genome. Deletion of p53 binding domain of HBx may potentially promote carcinogenesis 
in HCC patients, as p53 is a well-known tumor suppressor. The N-terminal two third of 
HBx gene carrying transactivation domains were often retained in the integrated form. In 
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addition, most of the genome integrations were found to occur at the non-coding regions 
of human genome, such as, gene promoters (4/63), introns (21/63) and intergenic regions 
(30/63). Nevertheless, computational scanning of the integrated sequences for open 
reading frames have shown that the genome integration may either lead to early 
termination of HBV genes or expression of potential chimeric transcripts fusing HBV and 
human DNA. Significantly, our laboratory has successfully experimentally validated a 
subset of the integrated sequences and the expression of chimeric transcripts. By 
characterization of HBV genome integration sites using high throughput targeted genome 
sequencing, we are now better positioned to gain improved insights on how HBV genome 
integration may contribute to hepatocarcinogenesis in HCC patients. 
To further elucidate the role of the HBx gene in HCC, our laboratory employed 
chromatin immunoprecipitation and sequencing using the Solexa Genome Sequencer 
(ChIP-Seq) on immortalized liver cell line, THLE3 using HBx antibodies. I employed a 
computational workflow to integrate the high throughput ChIP-Seq data, microarray 
expression profiles for both cell lines (THLE3) and 100 HBV-associated HCC patients, 
and the clinical data of the 100 HCC patients. A total of 2860 potential HBx binding sites 
were identified and were found to be significantly enriched in exons and promoter 
regions of genes (p<0.00001). Interestingly, almost half of the predicted binding sites 
within exons/introns were localized in the first and last exons/introns, indicating the 
potential regulatory effect of HBx on gene expressions. 195 potential HBx-interacting 
transcription factors were predicted, of which 129 were commonly predicted from our 
previous ChIP-chip data on HepG2 cells. 143 potential HBx deregulated direct gene 
targets were identified in THLE3 cells, indicating the pleiotropic nature of HBx: interact 
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with a variety of transcription factors and deregulate a large set of genes. 18 of these 143 
HBx-associated deregulated genes were also consistently differentially deregulated in the 
100 HCC patients. Seven of these 18 genes were found significantly associated with 
various patients’ clinical features including survival, tumor grade, tumor invasion, liver 
cirrhosis, tumor capsulation and multifocality. By identification of clinically associated 
potential HBx deregulated direct gene targets, we are now in a better position to explore 
the role of HBx in hepatocarcinogenesis in HCC patients.  
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CHAPTER 1: Literature Review and Introduction 
1.1 HBV-Host Genome Integration  
Hepatocellular carcinoma (HCC) is the fifth most common subtype of liver cancer 
and is found to be the third leading cause of cancer death in the world due to late 
diagnosis and limited treatment options (Blum, 2005; Lupberger and Hildt, 2007). 
There are many risk factors that may cause the development of HCC, including 
chronic infections of hepatitis B or C virus (HBV/HCV), aflatoxin exposure and 
excessive alcohol consumption. However, the most epidemiologically associated 
risk factor is HBV infection, as it has been estimated that chronic HBV infection 
accounts for 50-55% of all HCC cases in the world (Arbuthnot and Kew, 2001; 
Chang, 2003; Lupberger and Hildt, 2007; Parkin et al., 2001). As HBV infection 
precedes the development of HCC by several years, the time gap could allow 
multiple cellular events such as genetic or chromosomal changes to occur which 
eventually lead to HCC. One of the key mechanisms in hepatocarcinogenesis 
involves the integration of HBV genome into the host genome, which is observed 
in 85-90% of HCC cases and has been reported by many isolated studies to play 
important roles in HCC development (Bonilla Guerrero and Roberts, 2005; 
Buendia, 1992; Robinson, 1994). HBV genome integration occurs at early stage 
after HBV infection and is reported to contribute to host chromosomal instability 
by various complex genome alteration events which may result in large inverted 
duplications, deletions, and chromosomal translocations (Tan, 2011). Studies also 
have shown that frequent HBV genome integrations and variations may disrupt 
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host genes that are essential for cell signalling, proliferation and apoptosis 
(Boyault et al., 2007; Kuang et al., 2004; Murakami et al., 2005; Paterlini-Brechot 
et al., 2003; Saigo et al., 2008; Tan, 2011). Therefore, HBV-host genome 
integrations and alterations may play a crucial role in HBV-induced development 
of HCC. However, the detailed mechanism of how HBV genome integration may 
gradually lead to hepatocarcinogenesis in HCC patients remains unclear (Ng and 
Lee, 2011; Tan, 2011). 
1.2 Limitation of PCR-based Methods to identify HBV-Host 
Genome Integrations 
Previously, many research groups have characterized HBV integrations using 
PCR-based (Polymerase Chain Reaction) methods such as HBV-Alu-PCR which 
designed one primer specific to HBV sequence and another primer directed to the 
most abundant mobile Alu elements/repeats of human genome to amplify the 
virus/cellular DNA junctions (Tu et al., 2006), cassette-ligation mediated PCR 
which used cassette-ligated human genome DNA fragments adjacent to the 
integrated HBV DNA as a template for nested PCR with the cassette- and HBV-
specific primers to identify HBV integration sites from the HBV DNA amplified 
from HCC patient liver tissues (Saigo et al., 2008; Tamori et al., 2003; Tamori et 
al., 2005), and low resolution southern blot which hybridized the HBV DNA 
extracted from HCC patient tumor tissues with the HBV DNA regions as probes 
to identify integrated HBV DNA sequences (Tamori et al., 2003; Urashima et al., 
1997) etc. These methods combining PCR and capillary sequencing have shown 
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that HBV integration sites might not be entirely random as generally believed, 
and more importantly, HBV was observed to be mutated or truncated in the 
integrated form.  
As a result, due to the lack of knowledge on the virus sequences retained in the 
integrated form and the extremely high sensitivity of PCR, a potential problem 
associated with PCR methods is that primers designed may reside at truncated or 
mutated or polymorphic regions of the virus genome, resulting in failure in 
amplification and thus leading to potential increased false negative rates in 
discovering virus-host integration sites. In addition, without prior knowledge of 
the virus integrated sequences, PCR primers and reactions covering the whole 
virus genome may be required in order to fully characterize the virus integration 
sites, and this would be extremely labour intensive to carry out. More efficient 
and higher resolution techniques are needed for detection of virus integration sites 
in a genome-wide scale in order to overcome the limited prior knowledge of 
integration sites. In recent years, targeted genome sequencing-based approaches 
have rapidly replaced PCR-based methods (combination of PCR and capillary 
sequencing) to discover genome structural variants including virus-host 
integrations (Ansorge, 2009; Mardis, 2009). 
1.3 Application of Targeted Deep Sequencing Techniques to 
Identify Viral-host Integration Boundaries 
The low throughput and high cost of the traditional Sanger capillary-based 
sequencing has been a key limiting factor for full-sequencing-based approaches. 
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There has been increased demand for the development of low-cost and high-
throughput sequencing technologies. In recent years with the emergence of "Next 
Generation Sequencing" (NGS) technologies such as Roche/454 Life Sciences™, 
Illumina/Solexa™ Sequencing and Applied Biosystems SOLiD™, sequencing 
costs have been brought down by several orders of magnitude and throughput has 
been raised by hundreds of folds (Shendure and Ji, 2008). In addition, third 
generation sequencing techniques, such as Ion Torrent™ semiconductor 
sequencing, Complete Genomics™ DNA Nanoball (DNB) sequencing (Drmanac 
et al., 2010; Porreca, 2010), etc. are providing another big boost to this approach 
with ever higher throughput and lower cost. These deep sequencing techniques 
enable parallelization of sequencing processes, producing millions of sequence 
reads at once. Table 1.1 compares the performances of three next-generation 
sequencing platforms and two third generation sequencing technologies.  
In particular, Roche 454 Life Sciences has the ability to sequence whole genomes 
in days, with 99% accuracy and at a cost of 100x less than using the capillary-
based sequencing methods. Besides, the Roche FLX 454 pyrosequencing 
technology can even achieve average read length of 400bp which has drastically 
increased the sequencing depth and capacity. Development of these high-accuracy, 
high-throughput and low cost sequencing techniques has improved the 
applications of sequence-based methods to a whole genome scale with fine-tuned 
resolution to single base precision (Mardis, 2008a, b; Schuster, 2008; Stephens et 
al., 2009).  
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Table 1.1: Comparison of metrics and performances of three next-generation 
DNA sequencing platforms and two third generation sequencing technologies: 
454 pyrosequencing, Illumina Solexa sequencing, Applied Biosystems SOLiD 
sequencing, Ion Torrent semiconductor sequencing and Complete Genomics 











































approach Emulsion PCR Bridge amplification Emulsion PCR Emulsion PCR rolling circle replication 
Mb per run 100 Mb 600,000 Mb 170,000 Mb 100 Mb 180,000 Mb 
Time per  run 7 hours 9 days 9 days 1.5 hours 12 days 
Read length 400 bp 2x100 bp 35x75 bp 200 bp 35 bp (mate-pair) 
Cost per run $8,438 USD $20,000 USD $4,000 USD $350 USD $20,000 USD per 
genome Cost per Mb $84.39 USD $0.03 USD $0.04 USD $5.00 USD 
Cost per 
instrument $500,000 USD $600,000 USD $595,000 USD $50,000 USD N.A 
Nowadays, a variety of techniques that specifically capture genomic genes or 
regions of interest from genomic samples coupled with ultra-high throughput 
NGS sequencers, has been increasingly adapted for and applied in cancer research 
for the detection of larger genome structural variants, including 
insertions/deletions, translocations and viral insertions (Abel et al., 2010; 
Duncavage et al., 2011; Hernandez et al., 2011; Mardis, 2009; Stephens et al., 
2009). Such targeted deep sequencing narrows down the sequencing to important 
genes or regions of interest instead of the entire genome. It allows analysis of 
interesting genomic sequence variants more efficiently and at even lower cost, 
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especially in the context that NGS has the capacity to sequence multiple 
experimental samples in a single run by using “barcodes” or indexed labels for 
individual samples (Mardis, 2008; Abel et al., 2010). To reduce costs, it is often 
necessary to select regions of interest before sequencing. There are several target 
enrichment methods, including standard PCR, ligation-based PCR or hybrid 
capture (Mamanova et al., 2010; Summerer, 2009). In the context of viral-human 
genome integration, hybrid capture enrichment adopts a basic principle that uses 
viral-specific probes to hybridize with DNA fragments containing viral sequences 
or viral-human integration boundaries. The un-hybridized DNA fragments 
containing only human sequences are washed away, and the captured DNA 
sequences of interest are then eluted for deep sequencing (See Fig 1.1). Analysis 
of the deep sequencing data can identify chimeric sequences which contains the 
viral-host integration boundaries. Hybrid capture is advantageous over PCR-based 
enrichment approaches by allowing identification of novel viral integration sites 
or translocation breakpoints (Abel et al., 2010; Mamanova et al., 2010). 
With limited knowledge of HBV-human integration sites and to fully characterise 
HBV-human integrations over whole genome, our laboratory has proposed to 
apply the hybrid capture enrichment strategy to capture DNA fragments 
containing HBV sequences or HBV-host integration sequences from the complex 
HCC patient genomic DNA samples, coupled with ultra-high throughput FLX 
454-pyrosequencer, to identify the chimeric sequences representing HBV-human 
integration sites. As part of a larger research project in our HBV research 
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laboratory, I have proposed an analysis pipeline for the ultra-high throughput FLX 
sequencing data to characterize HBV-human genome integration sites. 
 
Figure 1.1: Hybrid capture to capture viral-host integration sites. Human genomic 
DNA (green) containing inserted viral genome (red) is first fragmented to certain 
size. The fragmented DNAs are then hybridized with capture probes that are 
specific and complementary to viral DNA sequences, and subsequently fragments 
not containing virus DNA are washed away. The captured DNA containing viral 
sequences are then eluted for deep sequencing. By analyzing the sequencing data, 
chimeric reads consisting of the human/virus integration boundaries can be 
identified. 
1.4 Analysis of Targeted Deep Sequencing Data to Identify Viral-
host Integration Boundaries 
Targeted genomic regions of interest can be sequenced at great depth using next 
generation sequencing technologies. There have been several programs developed 
to date that analyse deep sequencing data for locating sequence variants, such as, 
Pindel (Ye et al., 2009), BreakDancer (Chen et al., 2009), MoDIL (Lee et al., 
2009), PEMer (Korbel et al., 2009), VariationHunter (Hormozdiari et al., 2010), 
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and SLOPE (Abel et al., 2010) etc. Pindel, BreakDancer, MoDIL, PEMer and 
VariationHunter are specifically designed to analyse sequence data generated 
from whole genomes while SLOPE is developed to analyse targeted sequence 
data. Pindel identifies insertions/deletions with single-base resolution but is not 
designed to detect virus insertion boundaries or sequence breakpoints. 
BreakDancer, MoDIL, PEMer, VariantionHunter and SLOPE rely on discordant 
mapping of paired-end diTag sequencing data to detect genome structural variants. 
Paired-end diTag sequencing of targeted DNA fragments is one of the popular 
strategies used to discover genome-wide sequence structural variations, based on 
the principle that the paired-end tags generated from high-throughput sequencer 
can be aligned back to the host reference genome sequences and abnormal 
separations or locations between the two reads of a pair suggest a potential 
genome structural variation, like insertion, deletion, rearrangements and 
translocation (Bashir et al., 2008; Korbel et al., 2007; Ng et al., 2006; Ruan et al., 
2007; Tuzun et al., 2005; Volik et al., 2003). However, the problem associated 
with these discordant paired-end strategies in characterizing virus-host integration 
boundaries is that they generally cannot achieve single-base resolution and might 
have relatively high false positive rates because of limited prior knowledge of the 
virus insertion size (Mardis et al., 2009). Hence, due to limited prior knowledge 
of the HBV virus insertion size in human genome and in order to 
comprehensively characterize the integration sites precisely in single-base 
resolution, we embarked single-end sequencing with FLX 454 pyrosequencer 
which is capable of generating significantly longer reads. 
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Analysis of the single-end high-throughput sequencing data usually begins with 
the alignment of the sequencing reads back to the entire host reference genome, 
and this mostly is the key limiting and time-consuming step in the analysis 
process. Currently, there are many available sequence assembly software 
designed for aligning deep sequencing data, including: 
a) de novo assemblers that merge sequences based on overlaps between sequence 
reads, such as, ABySS (Simpson et al., 2009), SSAKE (Warren et al., 2007), 
VCAKE (http://vcake.sourceforge.net/), EULER-SR (Chaisson and Pevzner, 
2008), Velvet (Zerbino and Birney, 2008), MIRA (http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html), and 
NextGENe (http://www.softgenetics.com/NextGENe_9.html); 
b) reference-guided assemblers that map sequence reads to a known reference 
genome, such as, RMAP (Smith et al., 2009; Smith et al., 2008), SeqMap 
(Jiang and Wong, 2008), SHRiMP (http://compbio.cs.toronto.edu/shrimp/), 
ZOOM (Lin et al., 2008), MAQ (http://maq.sourceforge.net/), NovoAlign 
(http://biowulf.nih.gov/apps/novocraft.html), GenomeMapper 
(http://1001genomes.org/downloads/genomemapper.html), MOSAIK 
(http://bioinformatics.bc.edu/marthlab/Mosaik#News), BWA (Li and Durbin, 
2009, 2010) and Bowtie (Langmead et al., 2009); 
c) assemblers that can do both de novo and reference-guided assembly, including 
SOAP (Li et al., 2008), CLC Genomics Workbench 
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(www.clcbio.com/genomics/), and DNASTAR SeqMan NGen 
(http://www.dnastar.com/t-nextgen-seqman-ngen.aspx).  
A common feature of these sequence assemblers is that they are computationally 
intensive requiring large computational power and processing memory. Besides 
being time-consuming, most of these assemblers are either only suitable for small 
genomes, or are restrained to a limited number of input sequences in each 
assembly run, or restricted to certain sequence read length. FLX 454 
pyrosequencer generates sequence reads of variable lengths ranging from thirty to 
thousands base pairs. A commercial assembler, the SeqMan NGen which is 
developed by the company DNASTAR, is fast, accurate and specifically designed 
for 454 pyrosequencing reads with no restrictions on the number of input 
sequences and sequence lengths. SeqMan NGen was found to be ideal for de novo 
assembly of 454 pyrosequencing data, permitting closely examination of the 
quality and reliability of the assembled sequences for post-assembly analysis. 
Although SeqMan NGen was designed for 454 sequencing data, it is less suitable 
for identifying virus-host integration boundaries compared to the standalone 
BLAST (Basic Local Alignment Search Tool) program (Altschul et al., 1997). 
This is because SeqMan NGen can only detect the alignments where the full 
length of the sequencing reads match to the reference genome when doing 
reference-guided assembly, while BLAST searches for local alignments between 
the reads and reference genomes allowing identification of reads with one part 
mapped to virus genome and the other part aligned to host genome, thereby 
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leading to the identification of virus-host integration sites. BLAST is the most 
commonly used tool to search against large genome sequence databases, and is 
perfectly suitable for sequencing reads of variable lengths. Also BLAST provides 
additional options for users to set the mapping thresholds to adjust the stringency 
of alignments, such as matching identities, E-values and low complexity filter etc. 
In this study, I implemented an analysis workflow utilizing BLAST to map the 
targeted high-throughput single-end deep sequencing reads of variable lengths to 
both human and virus reference genome sequences, in order to identify the virus-
human integration boundaries.  
1.5 HBx-Interacting Transcription Factors  
Due to unresponsiveness to treatment and late symptom recognition, HCC is one 
of the most common and lethal cancer in the world (Blum, 2005; Lupberger and 
Hildt, 2007). It is estimated that 50-55% of HCC cases in the world are associated 
with chronic infection of HBV (Parkin et al., 2001). The viral X-gene (HBx) of 
HBV is conserved among all mammalian hepadnaviruses and the HBx protein has 
been implicated to play a major role in the development of HCC in chronic HBV-
infected patients. 
HBx is a multifunctional protein of length 154-amino acids. It acts as a 
promiscuous transactivator that disrupts host cellular gene expressions and 
subsequent cellular pathways, such as, signalling pathways, DNA repair 
mechanisms, proliferation, and apoptotic cell death (Becker et al., 1998; 
Groisman et al., 1999; Lee and Lee, 2007; Matsuda and Ichida, 2009), which 
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ultimately may lead to tumorigenesis. HBx is implicated to modulate aberrant 
host gene expressions not by binding to DNA directly but through its interactions 
with transcription factors (Andrisani and Barnabas, 1999; Ganem, 2001; Wu et al., 
2001). Currently, various transcription factors (e.g. NF-kappa B, NF-AT, AP1, 
P53, E2F1, CREB, STAT3), as well as several general transcription machinery 
complexes in the cell (e.g. TATA-binding protein, TFIIB, TFIIH, RPB5), have 
been reported to interact with HBx (Benn et al., 1996; Cheong et al., 1995; 
Maguire et al., 1991; Qadri et al., 1995; Waris et al., 2001; Williams and 
Andrisani, 1995). Deregulating host gene expression through interaction with 
transcription factors has been known to be one of the major underlying 
mechanisms that HBx plays in carcinogenesis. Systematically identifying the list 
of transcription factors that interacts with HBx and the direct gene targets of HBx-
transcription factor complex could provide further insights into HBx functions in 
HCC. To address this, our laboratory had been the very first to generate 
antibodies against HBx protein and utilize chip-based chromatin 
immunoprecipitation technology (ChIP-chip) to identify genomic binding sites 
and candidate gene targets of HBx (Sung et al., 2009).  
1.6 Limitation of ChIP-Chip Methods to Profile Protein-DNA 
Interactions 
ChIP-chip, which is the coupling of chromatin immunoprecipitation with 
microarray chip technology, was initially described in 1999 and has been widely 
used in past few years to investigate protein-DNA interactions and determine the 
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binding sites of proteins in genome (Aparicio et al., 2004; Blat and Kleckner, 
1999; Buck and Lieb, 2004). Most ChIP-chip protocols first fragment the 
genomic DNA into small pieces, and then employ specific antibodies against 
DNA-binding proteins of interest to immunoprecipitate chromatin cross-linked 
with proteins of interest, before hybridizing the immunoprecipitated DNA 
fragments onto primarily promoter-sequence microarray chip (see Fig 1.2). ChIP-
chip is powerful enough to determine the binding sites of DNA-binding proteins 
at high resolution and on a genome-wide basis. Several studies have applied 
ChIP-chip using antibodies against specific transcription factors to identify 
binding sites and candidate gene targets of those transcription factors (e.g. E2F, c-
Myc, P53, and P65 etc)  (Li et al., 2003; Lim et al., 2007; Wei et al., 2006; 
Weinmann et al., 2001; Zeller et al., 2006). Similarly, to characterize DNA 
binding sites of HBx directly on a genome-wide basis, our laboratory has 
generated antibodies specifically against HBx protein which is useful for 
chromatin immunoprecipitation, and successfully predicted a list of DNA binding 
sites from ChIP-chip technique, direct gene targets of HBx and a list of potential 
HBx-interacting transcription factors obtained from motif enrichment analysis 







Figure 1.2: ChIP-chip and ChIP-Seq workflow. DNA-binding proteins are first 
cross-linked to double-stranded genomic DNA, including protein of interest 
(yellow) and other uninteresting proteins (purple). The protein-bounded DNA 
strands are then broken up into small pieces, using methods like sonication. 
Antibodies specifically against the protein of interest are added in to 
immunoprecipitate chromatin bound with the proteins of interest. After 
dissociation with the bound proteins, the immunoprecipitated DNA fragments are 
prepared either for hybridization on microarray DNA chip (ChIP-chip) or high-
throughput deep sequencing (ChIP-Seq). Both ChIP-chip and ChIP-Seq are 
designed to detect binding sites of DNA-binding proteins in high resolution on a 
genome-wide basis. However, ChIP-Seq is advantageous over ChIP-chip since 
ChIP-Seq can determine binding sites over the whole genome while ChIP-chip is 
limited to the genome regions tiled on microarray chip.  
However, one problem associated with ChIP-chip-based methods is that, these 
array-based methods are restricted to the genome regions tiled on the microarray 
chip, for example, tiled array of 1.5kb promoter regions of human genes (Sung et 
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al., 2009), and this would probably lead to increased false negative rates as true 
binding sites of HBx on the un-tiled regions of the genome will not be 
interrogated. As a consequence, the high false negative rates of ChIP-chip may 
cause bias in downstream analysis when predicting potential HBx-interacting 
transcription factor motifs based on the identified list of binding sites. 
Additionally, due to the existence of hybridization noise, spatial variation, dye 
bias, technical bias, dynamic intensity signal measurements, and lack of 
reproducibility associated with DNA microarray chip experiments, most 
published studies using ChIP-chip methods repeated their experiments at least 
three times (technical replicates) to maintain experimental accuracy, technical 
precision and biological significance (Dombkowski et al., 2004; Eklund and 
Szallasi, 2008; Febbo and Kantoff, 2006; Rosenzweig et al., 2004; Steger et al., 
2011). Though there are currently many software packages available aiming to 
minimize array background noises and artefacts, statistical analysis of the large 
amount of raw data with multiple technical replicates generated from arrays is 
always facing a challenge to extract biologically meaningful information. 
Therefore, with the need to reduce false negative rates and improve analysing 
accuracy for ChIP-chip method, a recent  advance that couples chromatin 
immunoprecipitation with ultra high-throughput deep DNA sequencing 
technology (ChIP-Seq) was employed to investigate protein-DNA interactions on 




1.7 Application of ChIP-Seq Methods to Profile Protein-DNA 
Interactions 
As shown previously in Fig 1.2, ChIP-Seq is a technique that consists of ChIP 
method that uses antibody specific to the protein of interest to immunoprecipitate 
and enrich for the DNA fragments bound by protein of interest, followed by size 
selection and ultra high-throughput deep sequencing of the enriched DNA 
fragments associated with the protein of interest (Johnson et al., 2007). Both 
ChIP-chip and ChIP-Seq require highly specific antibodies that could specifically 
recognize and immunoprecipitate chromatin crossed-linked with protein of 
interest. Nevertheless, with the advent of ultra high-throughput deep sequencing 
technique, ChIP-Seq offers many advantages over ChIP-chip with higher base-
pair resolution, greater genome coverage, increased sensitivity and specificity, no 
hybridization noise and dye bias generated from the cross-hybridization step in 
ChIP-chip (Park, 2009; Robertson et al., 2007). A review paper published by Park 
(2009) provides a detailed comparison of ChIP-chip and ChIP-Seq methods 
including experimental protocols and computational data analysis. Table 1.2 






Table 1.2: Comparison of metrics and performances of ChIP-chip and ChIP-Seq 
technologies. (Table updated from Park, 2009)  
Properties ChIP-chip ChIP-Seq 
Cost $400-800 USD per array; multiple array needed for large genome $1,000-2,000 USD per sample lane 
Genome coverage only on promoters, specific genes or certain chromosomal regions entire genome 
Genomic repeats can avoid repeats from array repeats are sequenced 
Platform noises die bias & hybridization noise possible GC bias 
Multiplexing no yes by using library index or barcode 
Amount of input IP DNA more less 
Peak detection fewer peaks with broader width larger number of more localized peaks 
Resolution array-specific (30-100 bp) single nucleotide 
Reproducibility microarray lower reproducibility (at least three technical replicates) high 
Signal-to-noise ratio lower better 
Bioinformatics analysis harder (multiple replicates) easier 
 
ChIP-Seq, first described in 2007, was one of the very early applications of next 
generation sequencing technologies (Barski et al., 2007; Johnson et al., 2007; 
Mikkelsen et al., 2007; Robertson et al., 2007). With the decreasing cost of ultra 
high-throughput sequencing, there has been an increasing trend nowadays to 
apply ChIP-Seq methods to systematically profile protein-DNA interactions and 
assess putative genome-wide binding sites of important proteins, including 
polymerases, transcription factors and tumor suppressor proteins, in the areas of 
cancer research, transcriptional regulatory networks studies and immune function 
studies  (Botcheva et al., 2011; Hawkins et al., 2010; Northrup and Zhao, 2011; 
Park, 2009; Scisciani et al., 2011; White, 2011; Xie et al., 2011). For example, 
Botcheva et al., (2011) was the first that successfully profiled genome-wide de 
novo mapping of the putative genomic binding sites of the tumor suppressor p53 
in normal and cancer-derived human cells, by applying ChIP-Seq experiments 
and computationally analysing ChIP-Seq data for high-confidence ChIP-Seq 
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peaks. It has been shown that ChIP-Seq is sufficiently powerful enough to 
identify genomic binding sites of DNA-binding proteins with large genome 
coverage. This gives our laboratory the incentive to apply ChIP-Seq methods 
instead of ChIP-chip using antibodies against HBx to profile genomic binding 
sites of HBx over the whole human genome.  
1.8 Analysis of ChIP-Seq Data to Identify DNA-binding Sites of 
Proteins  
ChIP-Seq experiments generate large quantities of high-throughput sequencing 
data. All profiling technologies would produce noise artefacts, and ChIP–Seq is 
also of no exception (Park, 2009). Thus, effective computational analysis of ChIP-
Seq data will be crucial to generate biologically meaningful results. The purified 
DNA fragments from ChIP experiments can be sequenced by any of the next-
generation platforms, such as Illumina Solexa Genome Analyzer, Roche 454 
platform, and  Applied Biosystems (ABI) SOLiD platforms (Shendure and Ji, 
2008). The image data generated from the sequencing platforms are converted by 
the base caller software into sequence tags, which are referred as ChIP-Seq 
sequencing data. Preliminary analysis of the ChIP-Seq data consists of two major 
steps: a) mapping the sequence tags into reference genome; and b) peak-calling to 
find enriched regions as potential binding sites of the protein of interest, as shown 




Figure 1.3: Analysis of ChIP-Seq sequencing data. The images from the next-
generation sequencing platform for chromatin immunoprecipitated DNA 
fragments using antibodies against protein of interest are first converted using 
base caller software into sequence tags, which will then be mapped to the 
reference genome. A step of peak calling comparing the ChIP-Seq profile with 
control sample profile will generate of list of enriched peak regions ranked by 
statistical significance measures representing the potential binding sites of the 
protein of interest in reference genome. Subsequently, the profiles of enriched 
regions can be further analyzed for more information, such as the binding motifs 
enriched, location of the binding sites in genome structures, integration of gene 
expression data, differential binding profile analysis, and so on. Processes for 
generation of sequencing data are highlighted in blue, while computational 
identification of genomic binding sites of proteins is highlighted in pink and post 
identification analysis is highlighted in yellow. 
Mapping of sequence reads into the reference genome will give the intensities or 
counts of reads mapped to genome regions, and analysing the read intensities over 
the genome will produce a list of regions with enriched mapped reads (“peak-
calling”), as the potential genome-wide binding sites of the protein of interest 
(Hoffman and Jones, 2009). With the profile of potential binding sites, further 
analysis can be done, such as, transcription factor binding motifs enrichment 
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analysis, location of the binding regions over the genome relative to genome 
structures, correlation of gene expressions, differential binding sites between 
different cellular conditions, and so on (Park, 2009).  
However, there are various potential sources of artefacts in ChIP-Seq experiments, 
which may result in the detection of insignificant peaks. For instance, shearing of 
DNA strands into fragments with a commonly used method like “sonication”, 
usually does not result in uniform fragmentation of the genome and thus leads to 
the uneven distribution of sequence tags across the genome, since some genome 
regions, such as open chromatin regions, are more easily fragmented than other 
genome regions, such as closed regions (Park, 2009). Therefore, in order to avoid 
such bias, control experiments are designed to pair up control profiles with the 
ChIP-Seq profiles so as to measure the significance of the peaks. These control 
samples used for sequencing are either input DNA which is a portion of the 
sheared DNA sample without immunoprecipitation, or mock DNA with DNA 
obtained from immunoprecipitation without antibodies, or DNA from nonspecific 
immunoprecipitation using an antibody against a protein that is not known to be 
involved in DNA binding. Input DNA has been used widely as the control sample 
in ChIP–Seq studies to remove the artefacts and bias from the ChIP-Seq 
experiments, such as the variable solubility of different regions, DNA shearing 
and amplification (Park, 2009). By comparing the read intensities in ChIP-Seq 
profile to the control sample profile at the paired-up genome regions, one can 
measure the significance of the peaks. Thus, the peak-calling step of the ChIP-Seq 
data analysis compares the ChIP sample profile to the control sample profile, and 
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detects the potential enriched regions ranked by statistical significance 
measurements. 
As for the very first step of analysis of the ChIP-Seq sequencing data, there are 
many different reference-guided short read mapping tools available, described 
earlier in Section 1.4, such as, Eland (part of the Illumina suite), GenomeMapper, 
RMAP, SeqMap, SHRiMP, ZOOM, NovoAlign, MOSAIK, MAQ, BWA and 
Bowtie. In particular, compared the other aligners, Bowtie is ultra-fast for 
Illumina short sequencing reads of uniform length of about 36bp, allowing 
multiple-core parallel processing and memory-efficient for large genomes, while 
maintaining a comparable mapping accuracy (Langmead et al., 2009). The 
Illumina sequencer produces single-end sequencing reads of short length, e.g. 
36bp, and when aligning millions of reads of such short length to a large reference 
genome, e.g. human genome, a remarkable portion of the reads would probably 
match to multiple positions in the genome. In order to maintain the mapping 
accuracy, thresholds usually are set to remove the sequence reads that match 
ambiguously to the reference genome. Bowtie provides options for users to set the 
mapping thresholds, such as gapped or un-gapped alignment, number of 
mismatches allowed in the alignment, number of hits to output for users, and so 
on (Langmead et al., 2009). By setting the various options, one can decide the 
thresholds for the alignments between the sequence reads and reference genome, 
and achieve a balance between the mapping accuracy and the number of 
sequencing reads remained for peak-calling and advanced analysis. 
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Mapping of the sequencing reads generate the read intensities or counts within 
genome regions, and comparing the read intensities over genome regions in ChIP 
sample to the control sample can produce a list of peak regions where the reads 
are significantly enriched in ChIP sample over control sample (Hoffman and 
Jones, 2009). There are many different peak-calling software packages that utilize 
control sample profile, such as, E-RANGE (Mortazavi et al., 2008), spp package 
(Kharchenko et al., 2008), MACS (Zhang et al., 2008), QuEST (Valouev et al., 
2008), SISSRs (Jothi et al., 2008), GLITR (Tuteja et al., 2009), PeakSeq 
(Rozowsky et al., 2009), CisGenome (Ji et al., 2011; Jiang et al., 2010), Sole-
Search (Blahnik et al., 2010), and CCAT (Xu et al., 2010). A detailed comparison 











Table 1.3: Comparisons of various peak-calling algorithms for ChIP-Seq data, 
including E-RANGE, spp package, MACS, QuEST, SiSSRs, GLITR, PeakSeq, 
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The peak-calling step in these software packages generally can be summarized 
into three basic sub-components: (i) generate signal profiles along each 
chromosome based on read/tag counts, (ii) find enriched peak regions in ChIP 
data relative to background control data (peak-calling) and (iii) assign statistical 
significance to filter out false positives and rank high-confidence peak calls 
(Pepke et al., 2009). Most algorithms generate smooth signal distributions/profiles 
using a fixed-width sliding window centered at each genome position and 
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replacing the read/tag count in that genome position with the summed read counts 
within the window or modified signal values based on some assumptions of the 
distributions. Since the immunoprecipitated DNA fragments are double-stranded 
with the two strands equally likely to be sequenced from 5’ to 3’, the single-ended 
sequencing reads/tags are expected to come from both strands and form two 
density distributions (one for forward strand, and the other for reverse 
complement strand), which occur upstream and downstream with true DNA-
protein crosslinking or binding sites in-between, as illustrated in Fig 1.4. Based on 
this bimodal enrichment pattern, programs like MACS, SiSSRs, spp package, 
QuEST, FindPeaks, E-RANGE, GLITR, and CCAT first shift the reads by half of 
the DNA fragment length (either user-defined or estimated from ChIP data) in a 
strand-specific manner and then build the signal profile based on the shifted read 
positions, such that, the corresponding distributions of two strands will overlay 
giving rise to a “summit” that has the local maximum and most likely represent 
the true DNA-protein binding sites. Some other programs may alternatively 
extend the genome location of the reads to accomplish the same goals. This 
strand-specific read shifting could considerably improve “summit” resolution and 





Figure 1.4: Bimodal enrichment pattern of ChIP-Seq sequencing data. Since the 
immunoprecipitated DNA fragments are double-stranded with the two strands 
equally likely to be sequenced from 5’ to 3’, the single-ended sequencing 
reads/tags are expected to come from both strands and form two density 
distributions (one for forward strand, and the other for reverse complement 
strand), which occur upstream and downstream with true DNA-protein 
crosslinking or binding sites in-between. In order to improve binding site 
detection resolution, some peak-calling algorithms first either shift the reads by 
half of the DNA fragment length or alternatively extend the genome location of 
the reads to the expected DNA fragment length in a strand-specific manner, and 
then build the signal profile based on the shifted or extended read positions, such 
that, the corresponding distributions of two strands will overlay giving rise to a 
“summit” that has the local maximum and most likely represent the true DNA-
protein binding sites. This could significantly improve the precise detection of 




When comparing the ChIP profile to control sample profile, most peak-calling 
programs calculate fold enrichment of reads in ChIP over control sample along 
genome regions, and assign statistical significance to each enriched peak in ChIP 
data. Different programs employed different methods to compute the significance 
to filter out false positives and rank for high-confidence peaks. For example, some 
built sophisticated statistical models from control data to assess the significance 
of ChIP peaks (Blahnik et al., 2010; Boyle et al., 2008; Ji et al., 2008; Mortazavi 
et al., 2008; Nix et al., 2008; Qin et al., 2010; Rozowsky et al., 2009; Spyrou et al., 
2009; Valouev et al., 2008; Xu et al., 2010; Zhang et al., 2008), some calculate 
empirical false discovery rate by swapping ChIP and control data to identify 
enriched peaks in control data (False Discovery Rate (FDR) = number of peaks in 
control / number of peaks in ChIP) (Kharchenko et al., 2008; Lun et al., 2009; Xu 
et al., 2010; Zhang et al., 2008), and some calculate FDR by partitioning control 
data to generate pseudo-ChIP data if control data is large enough (Tuteja et al., 
2009; Valouev et al., 2008). Among these peak-calling algorithms, MACS has 
been evaluated to be superior over others with good sensitivity and specificity that 
gives higher true positive rates, higher ranking accuracy, better peak positional 
accuracy and precision (spatial resolution) (Wilbanks and Facciotti, 2010). MACS 
algorithm will (1) first remove duplicate reads in the datasets that may arise from 
ChIP-DNA amplification and sequencing library preparation, (2) linearly scale the 
total number of reads in control data to be the same with that in ChIP data, (3) 
empirically model the size of the true protein binding site based on the bimodal 
enrichment pattern, (4) shift the genome locations of the reads in a strand-specific 
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manner by half of the estimated size of the protein binding site, (5) scan the 
genome using sliding windows of user-defined width to identify candidate peaks 
with significant read enrichment based on p-values calculated from dynamic 
Poisson distribution of reads, (6) swap ChIP and control datasets and call peaks in 
control data, and (7) calculate FDR for each detected peak in ChIP data and rank 
them using the p-values. CCAT applies similar algorithm with MACS but is 
superior to MACS as it estimates noise rate and resample the datasets to balance 
ChIP and control sample sizes instead of using linear scaling as in MACS (Xu et 
al., 2010).  
1.9 Motif Enrichment Analysis to Identify Co-Factors of Proteins 
With the profile of potential protein binding sites identified from peak-calling 
tools, further analysis can be done, such as, binding motifs enriched, location of 
the binding regions over the genome, correlation with gene expressions, 
differential binding sites between different cellular conditions, and so on (Park, 
2009). For example, motif enrichment analysis can predict the DNA-binding 
motifs for the protein of interest by first extracting the genomic sequences of the 
identified DNA-binding sites from the reference genome, and then scanning 
against known DNA-binding motifs, e.g. TRANSFAC database (Wingender et al., 
1996), or predicting novel binding motifs using de novo motif finding algorithms. 
Proteins such as transcription factors, generally do not work alone and usually 
function with other transcription factors (co-factors) in a combinatory fashion to 
regulate target gene expressions precisely. Particularly, in situations of where 
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factors co-associated with the protein of interest are present, ChIP-Seq protocol 
using antibodies against the protein of interest could immunoprecipitate the DNA 
fragments bound by the protein of interest that is meanwhile co-localized with its 
interacting factors (Liu et al., 2010). In such cases, motif enrichment analysis of 
the predicted DNA-binding sites against known motif databases will help identify 
the interacting DNA-binding co-factors for the protein of interest globally. 
Sequence motif discovery algorithms play an important part in order to better 
understand the protein-DNA interaction mechanisms, and the structures and 
functions of proteins (Bailey, 2008). There are various motif finding software 
tools available for ChIP-Seq data, including MDScan (Liu et al., 2002), Weeder 
(Pavesi et al., 2004), MEME (Bailey et al., 2009; Bailey et al., 2006), GALF-G 
(Chan et al., 2009), Tmod (Sun et al., 2010), HOMER (Heinz et al., 2010), HMS 
(Hu et al., 2010), recently published CENTDIST (Zhang et al., 2011) sand 
DREME (Bailey, 2011), etc. Most motif finding algorithms scan the genomic 
sequences of the DNA-binding regions identified from ChIP-Seq data, and search 
for either statistically overrepresented word-based oligonucleotide (motifs) with 
high occurrence frequency, or probabilistic sequence models with model 
parameters estimated from maximum-likelihood or by Bayesian inference (Das 
and Dai, 2007). The word-based algorithm guarantees global optimality and is 
suitable to identify short motifs in eukaryotic genomes, while the probabilistic 
approach involves representation of motif models by position weight matrix 
(Bucher, 1990) and is appropriate for longer motifs. All these algorithms 
mentioned have been reported to be able to correctly detect the motifs that were 
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previously detected by laboratory experimental approaches, and some de novo 
motif finding algorithms can find novel motifs. In particular, for eukaryotic 
genomes, HOMER (Hypergeometric Optimization of Motif Enrichment) motif 
enrichment algorithm against known motifs database comprises of the following 
steps: (i) first, the program randomly selects a set of background genomic 
sequences with similar length and GC content to the target sequences (potential 
binding sites), (ii) it then assigns weights to each background sequence to 
minimize the imbalance in sequence contents with the target sequences, (iii) it 
further calculates the occurrence of each known motif in the target and 
background sequences and (iv) then computes a significance value (e.g. p-value) 
for the enrichment of the motif in the target sequences over background sequences 
(Heinz et al., 2010). The motifs identified are ranked by their enrichment 
significance values produced by the motif finder algorithm, and usually 
significantly enriched motifs with significance measurement values passing 
defined threshold (e.g. p-value < 0.05) are selected as the potential co-factors that 
may interact with the protein of interest when binding to genomic DNA.  
In addition to identifying co-factors for protein of interest, ChIP-Seq data also has 
the capacity to permit further analysis to uncover protein-DNA interaction 
patterns and gene regulation mechanisms, such as correlation with gene 
expression profiles, relationship of DNA-binding sites to genome structures, 
differential binding sites of proteins in response to different cellular conditions, 
and so on. In summary, our laboratory has employed ChIP-Seq Illumina ultra 
high-throughput sequencing technique with antibodies specifically against HBx 
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protein for immunoprecipitation, and in this study, I implemented a computational 
workflow to analyse the ultra high-throughput ChIP-Seq sequencing data, identify 
potential genomic binding site of HBx in a genome-wide scale, discover 
transcription factors that potentially interact with HBx form motif enrichment 
analysis, and identify potential deregulated direct gene targets of HBx from 
integration of gene expression profiles, for a better understanding of the 
underlying mechanisms of HBV-induced hepatocarcinogenesis. 
1.10 Project Objectives 
Chronic HBV infections may gradually lead to the development of HCC in 
patients (Arbuthnot and Kew, 2001; Bonilla Guerrero and Roberts, 2005; Buendia, 
1992; Chang, 2003; Lupberger and Hildt, 2007; Parkin et al., 2001; Robinson, 
1994). However, the association between chronic HBV infection and HCC 
hepatocarcinogenesis remains incompletely understood (Ng and Lee, 2011), 
though a few underlying mechanisms have been proposed by numerous studies, 
such as, HBV genome integration into human genome (Bill and Summers, 2004; 
Bonilla Guerrero and Roberts, 2005; Buendia, 1992; Goto et al., 1993; Jiang et al., 
2012; Murakami et al., 2005; Pineau et al., 1998; Robinson, 1994; Saigo et al., 
2008; Tan, 2011; Tu et al., 2006), HBx deregulation of host genes expression 
through interactions with transcription factors (Andrisani and Barnabas, 1999; 
Ganem, 2001; Sung et al., 2009; Wu et al., 2001) or through deregulation of 
regulatory microRNA expressions (Kong et al., 2011; Shan et al., 2011; Wang et 
al., 2010; Wang et al., 2012; Wu et al., 2011; Yip et al., 2011; Yuan et al., 2012) 
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or through epigenetic modifications (e.g. DNA methylation status of genes) 
(Arzumanyan et al., 2012; Huang et al., 2010; Jung et al., 2010; Kim et al., 2010; 
Madzima et al., 2011; Park et al., 2011; Su et al., 2008; Um et al., 2011; Zhu et al., 
2010). In this project, we focused on two essential underlying mechanisms: HBV 
genome integration as described in Chapter 2, and HBx deregulation of host gene 
expression through interactions with transcription factors, as described in Chapter 
3 of this MSc thesis. 
1.10.1 Computational Analysis for Characterization of HBV-Host 
Genome Integration Sites 
HBV-host genome integration is very commonly observed in HBV-associated 
HCC cases, and is believed to be one of the key mechanisms involved in 
hepatocarcinogenesis. HBV integration into the host genome could result in 
possible disruption of host gene expressions, expression of modified viral proteins 
or viral-host chimeric proteins that are potentially oncogenic and contribute to 
hepatocarcinogenesis. Therefore studying where HBV genome integrates into the 
host genome will promote understanding of the underlying mechanisms of how 
HBV infection gradually leads to development of HCC. HBV genome integration 
into human genome has been reported for many years, however, the details of 
how HBV genome integration may contribute to hepatocarcinogenesis is still 
incompletely understood (Ng and Lee, 2011). To address it, the very first step is 
to know the locations where HBV DNA is inserted to human DNA. To 
comprehensively characterize HBV genome integration sites and study the 
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variations of HBV DNA in HCC patients, with limited prior knowledge on how 
HBV DNA fuses with human genome, our laboratory employed targeted high 
throughput FLX sequencing techniques on 48 HBV-associated HCC patients’ 
samples (tumor and adjacent non-tumor tissues) to enrich for HBV-containing 
DNA fragments. To maximize the targeted sequencing capacity, a set of 6bp 
“barcodes” was used to label for individual patient samples, allowing sequencing 
of multiple samples in a single run. Millions of sequencing reads of variable 
lengths were generated. In this project, I implemented a computational workflow 
to analyse the high-throughput sequencing data and identify sequences carrying 
both HBV and human DNA within the same sequence where the HBV-HG 
integration sites can be inferred. The analysis pipeline aimed to accomplish the 
following specific objectives at various analysis steps: 
Specific Objective 1: Remove noise and insignificant reads from the ultra high-
throughput sequencing data 
Hybrid capture strategy to enrich for HBV sequences has limited enrichment 
efficiency. Due to the sequence similarities between HBV and human genomes, 
non-specific hybridization of HBV probes with human genome sequences may 
potentially capture insignificant DNA fragments that do not contain HBV 
sequences or HBV-human integration boundaries. In addition, the last elution step 
of hybrid capture method may also cause noise DNA fragments to be sequenced. 
Thus the pool of millions of raw sequencing reads from ultra high-throughput 
FLX sequencer may contain lots of insignificant and noise reads, which purely 
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belong to human genome and neither contain HBV sequences nor HBV-human 
integration boundaries. To identify HBV-containing reads, the very first step is to 
filter out the pure human sequences and the sequences that do not contain HBV 
sequences, from the large raw sequence library. Mapping the raw sequencing 
reads against human genome and HBV genome respectively may help to achieve 
this objective. 
Specific Objective 2: Identify HBV-host integration boundaries by aligning sequence 
reads against both HBV and human genomes  
Removal of noise and insignificant reads will largely reduce the size of the 
sequencing library. FLX 454 pyrosequencer is reported to have an average read 
length of 400 bases, and thus can largely reduce ambiguities when searching for 
read identities against genome databases. More importantly, this particular long 
read length feature of FLX sequencer could allow us to identify HBV-host 
integration boundaries directly from the raw sequence reads that can be long 
enough to accommodate the junction sites. A sequence read containing a HBV-
host junction site is hypothesized to have at least one region of the sequence 
aligned to human genome and the other region aligned to HBV genome. 
Therefore, after removal of the noise sequence reads from the FLX sequencing 
library, potential HBV-host junction sites could be directly identified from the rest 
of the raw sequence reads by aligning the sequence reads against both human and 




Nevertheless, one should not neglect the possibility that DNA shearing or 
fragmentation in the initial ChIP-Seq experimental step may happen to occur at 
the HBV-host junction sites, in which case, those HBV-host junction sites might 
be disrupted and missed out in the sequencing mapping analysis. Therefore, in 
this study and in my analysis pipeline, a step of de novo assembling of sequence 
reads into longer sequences which we called “contigs” was also incorporated, 
with the purpose of recovering any possible disrupted HBV-host junction sites. 
Furthermore, assembly provides representative or consensus sequences (“contigs”) 
by merging overlapping reads, and this could help us to reconstruct the original 
long DNA sequences from the fragmented DNA sequence reads. Thereby, the 
“contigs” and the remaining unassembled sequence reads could be mapped 
against both human and HBV genomes respectively in order to identify HBV-host 
integration boundaries.  
Specific Objective 3: Perform post-identification analysis to get more detailed 
information on HBV-host integrations 
After identification of HBV-host integration boundaries in HCC patients, more 
detailed post-identification analysis may be performed to understand HBV-host 
integration mechanisms. Questions to be answered may include: whether the 
integration of HBV genome into human genome is a random process or do they 
follow any conserved patterns; whether there are any integration sites conserved 
among different patient tissues; whether there is any obvious difference in the 
integration sites between tumor and adjacent non-tumor tissues of HCC patients; 
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whether there is any HBV gene that is more preferred to be integrated into the 
human genome; whether there is any functional domain of HBV genes that is 
often conserved and integrated in the human genome; whether there is any host 
gene that is disrupted by integration; what is the functional importance of 
disrupted host genes; and so on. Efforts trying to answer these biological 
questions may help us identify genes or factors of HBV that are important for 
hepatocarcinogenesis and further understand the details of HBV-host genome 
integrations in HCC patients with chronic HBV infections.  
1.10.2 Computational Analysis for Identification of Putative 
Deregulated Direct Gene Targets of HBx 
The HBV genome of length 3215bp consists of 4 major genes encoding for core 
protein, surface antigen protein, polymerase, and viral X-gene. Among the four 
genes, the viral X-gene (HBx) of HBV is conserved among all mammalian 
hepadnaviruses and the small protein (154 amino acids) encoded has been 
strongly implicated to play a major role in hepatocarcinogenesis and the 
development of HCC in chronic HBV-infected patients. HBx protein acts as a 
transactivator that disrupts host cellular gene expressions and subsequent cellular 
pathways which may lead to cancer. HBx has been reported to deregulate host 
genes expression through various mechanisms, such as, through interactions with 
transcription factors (Andrisani and Barnabas, 1999; Ganem, 2001; Sung et al., 
2009; Wu et al., 2001), through deregulation of regulatory microRNA expressions 
(Kong et al., 2011; Shan et al., 2011; Wang et al., 2010; Wang et al., 2012; Wu et 
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al., 2011; Yip et al., 2011; Yuan et al., 2012), or through epigenetic modifications 
(e.g. DNA methylation status of genes) (Arzumanyan et al., 2012; Huang et al., 
2010; Jung et al., 2010; Kim et al., 2010; Madzima et al., 2011; Park et al., 2011; 
Su et al., 2008; Um et al., 2011; Zhu et al., 2010). In this project, we focused on 
HBx deregulation of host gene expressions through interactions with transcription 
factors. 
Deregulating host gene expressions through interactions with transcription factors 
has been known to be one of the major underlying mechanisms that HBx plays in 
hepatocarcinogenesis. HBx protein does not bind to DNA directly, but through 
interacting with transcription factors. It regulates gene expression by changing the 
DNA binding affinities of transcription factors. Systematically identifying the list 
of transcription factors that HBx interacts and the direct target genes of HBx-
transcription factor complex could provide further insights into HBx functions in 
the development of HCC. Our laboratory has previously systematically profiled 
HBx genomic binding sites and HBx-interacting transcription factors using ChIP-
chip method on 1.5kb promoter regions of human genes (Sung et al., 2009). 
However, there are various limitations and bias associated with ChIP-chip, as 
discussed in Section 1.6. Therefore, our laboratory has turned to apply ChIP-Seq 
technology coupled with Illumina high-throughput sequencing technique on 
primary liver cell line THLE3 transfected with HBx-expressing adenoviruses, to 
identify a more comprehensive and unbiased list of HBx genomic binding sites. 
ChIP-Seq technique uses antibody specific to the protein of interest to 
immunoprecipitate DNA fragments bound by protein of interest, followed by size 
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selection and sequencing of the enriched DNA fragments. The sequencing step in 
ChIP-Seq enables identification of genome-wide DNA-protein binding sites, and 
has become the major trend in the field of studying protein-DNA interactions. The 
Illumina sequencing approach applied by our laboratory produced millions of 
short sequence reads of 36bp for both control and HBx-expressing THLE3 cell 
samples. In addition, previous studies on HBx deregulation of host genes were 
mainly carried out in cell lines due to lack of patients data. In this study, with the 
availability of HCC patients data in our laboratory, I implemented a 
computational workflow to analyse the ChIP-Seq sequencing data and integrate 
the microarray expression profiles and clinical data of 100 HBV-associated HCC 
patients to identify a more comprehensive list of potential genomic binding sites 
of HBx, HBx-interacting transcription factors and potential HBx deregulated 
direct gene targets with clinical inferences in HCC patients. The analysis process 
aims to accomplish the following objectives: 
Specific Objective 4: Align ChIP-Seq Illumina sequencing reads to human genome 
and remove reads mapped ambiguously to human genome 
The Illumina Solexa sequencer produced millions of single-end sequence reads of 
36bp, out of which, a significant portion might match to multiple positions in the 
human genome, because of the short read length (36bp) and the large human 
genome size. In order to maintain the mapping accuracy, thresholds must be set to 
remove sequence reads that match ambiguously to human genome. An ultrafast 
reference-guided short read aligner Bowtie (Langmead et al., 2009) provides 
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options for users to set the thresholds, such as gapped or un-gapped alignment, 
number of mismatches allowed in the alignment, number of matches to output for 
users, and so on. Mapping criteria/parameters need to be carefully selected in this 
project to achieve a balance between the mapping accuracy and the amount of 
sequencing reads remained usable for downstream analysis. 
Specific Objective 5: Identify significantly enriched peak regions as potential DNA 
binding sites of HBx using peak-calling algorithms 
Following aligning sequence reads to human genome and filtering out reads with 
ambiguous matches in human genome, the next step is to analyse the intensities 
(counts) of reads mapped on genome regions and identify regions, where the 
reads are significantly enriched, as the potential HBx binding sites. This peak-
calling step will compare the read intensities in HBx-expressing THLE3 cells 
against the read intensities in control THLE3 cells, and then identify regions 
(peaks) with reads significantly enriched in HBx-expressing THLE3 cells. Our 
control THLE3 ChIP-Seq data was important because it served as background 
noise model to help filter out false positive regions that might come from DNA 
shearing biases, antibody immunoprecipitation biases or sequencing artefacts. The 
peak-calling step generally can be summarized into three basic sub-components: 
(i) generate signal profiles along each chromosome based on read/tag counts, (ii) 
find enriched peak regions in ChIP data relative to background control data (peak-
calling) and (iii) assign statistical significance to filter out false positives and rank 
high-confidence peak calls. Since the immunoprecipitated DNA fragments are 
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double-stranded with the two strands equally likely to be sequenced from 5’ to 3’, 
the single-ended reads/tags are expected to come from both strands and form two 
density distributions (one for forward strand, and the other for reverse 
complement strand), which occur upstream and downstream with true DNA-
protein crosslinking or binding sites in-between. Thus, the sequencing reads are 
expected to show a bimodal enrichment pattern for a true binding site, and 
therefore, strand-specific shifting or extending of the reads could yield more 
precise prediction of DNA binding sites. Two peak-calling tools MACS 
(http://liulab.dfci.harvard.edu/MACS/) and CCAT (http://cmb.gis.a-
star.edu.sg/ChIPSeq/paperCCAT.html) were utilized in this project to first shift 
the genomic positions of the reads by half of the estimated DNA fragment length 
in a strand-specific manner and then call peaks with significant read enrichments 
in ChIP data relative to background control data. Peaks commonly predicted from 
the two peak-calling algorithms (MACS and CCAT) can be selected as the 
potential genomic binding sites of HBx, and this application of multiple peak-
calling algorithms on the same dataset will give us more confidence on the 
predictions. 
Specific Objective 6: Identify potential HBx-interacting transcription factors from 
motif enrichment analysis 
From the list of enriched peaks representing potential binding sites of HBx over 
human genome, motif enrichment analysis was performed to predict the 
transcription factor binding motifs enriched within the predicted candidate 
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binding sites of HBx, to obtain a list of predicted transcription factors that 
potentially interact with HBx to bind to DNA. This analysis consists of two major 
steps: a) extraction of the genomic DNA sequences for the candidate binding sites 
of HBx, and 2) scanning of these peak sequences against the known human 
transcription factor motifs using known motif finder algorithms. For example, 
HOMER (http://biowhat.ucsd.edu/homer/chipseq/), developed in the Glass lab of 
UCSD (Heinz et al., 2010), first randomly selects a set of background genome 
sequences of similar length and GC content to the target sequences (potential 
binding sites), assesses the occurrences of each known motif in the background 
and target sequences, and calculates significance values for each known motif 
enriched in target sequences relative to background sequences. Thereafter, the 
enriched motifs could then be ranked based on the significance values produced 
by HOMER and those motifs with significance values above the threshold were 
considered as the transcription factors that may potentially interact with HBx and 
bind to genome DNA.  
Specific Objective 7: Identify potential direct gene targets of HBx by integrating 
microarray expression profiles for THLE3 cell line 
A list of differentially expressed genes was identified using a two-colour 
expression profiling array of HBx-expressing and control THLE3 cells. These 
differentially expressed genes were hypothesized to be deregulated (either up- or 
down-regulated) upon the presence of HBx protein in THLE3 cells. In this study, 
through the integration of the microarray gene expression profiles and ChIP-Seq 
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data, a list of putative direct gene targets of HBx deregulated through HBx-
transcription factor interactions could be identified. 
Specific Objective 8: Evaluate the clinical relevance of the potential deregulated 
direct gene targets of HBx 
Since these potential deregulated direct gene targets of HBx were predicted from 
primary liver cell line (THLE3), we evaluated if these deregulated gene targets of 
HBx are clinically relevant. To address this, the microarray gene expression 
profiles and the clinical data collected from 100 HBV-associated HCC patients 
were integrated. The expression values for the potential HBx deregulated direct 
gene targets in the tumor and adjacent non-tumor tissues of the 100 HCC patients 
were first examined. As HBx is reported to have oncogenic potential, gene targets, 
which were appropriately differentially expressed in tumor over adjacent non-
tumor tissues in HCC patients similar to what was observed in THLE3 cells upon 
the presence/expression of HBx protein, were selected for further analysis as these 
are likely to be related to hepatocarcinogenesis. With the availability of the 
clinical data of the 100 HCC patients, associations between these genes and the 
patients’ clinical characteristics and survival potential can then be evaluated by 
performing various statistical tests, such as T-test, One way ANOVA, non-
parametric tests (median test, Mann-Whitney U test and Kruskal-Wallis test), and 
Kaplan-Meier survival test. Gene targets with significant clinical associations 
were considered to be highly likely to have clinical inferences of HCC patients. 
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In summary, in this section of this project, I integrated the ChIP-Seq data and 
microarray expression profiles from both cell line and HCC patients, as well as 
clinical data from 100 HBV-associated HCC patients, and performed a series of 
computational analysis as described above, to identify genome-wide potential 
HBx-binding sites, potential HBx-interacting transcription factors, and putative 
clinically associated HBx direct gene targets that were deregulated indirectly by 
HBx through interactions with transcription factors. Previous studies on HBx 
deregulation of host genes were mainly carried out in cell lines due to lack of 
patients data. In this study, we are the very first to integrate the clinical data of a 
large series of HCC patients and identify potential HBx deregulated gene targets 
with significant clinical inferences. Identification of clinically significant direct 
gene targets of HBx may help us to further understand the underlying mechanisms 
of HBV-induced hepatocarcinogenesis, and facilitate future discovery of potential 
drug targets and novel drug therapies for HCC. 
1.10.3 Summary of Project Objectives 
Figure 1.5 briefly summarizes the various specific objectives of this project. By 
characterization of HBV genome integration sites and identification of clinically 
associated deregulated gene targets of HBx, we aim to get more insights of the 
two essential underlying mechanisms that may potentially contribute to HBV-
induced hepatocarcinogenesis in HCC patients: HBV genome integration into 
human genome and HBx deregulation of host gene expressions through 
interactions with transcription factors. In the following sections of this MSc thesis, 
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Chapter 2 will describe the experimental design, data analysis pipeline, and 
interpretation of results on HBV-host junction sites obtained by analysing the 
FLX high-throughput sequencing data of enriched HBV-containing DNA 
fragments extracted from 48 HBV-associated HCC patients. Chapter 3 will 
describe the ChIP-Seq experimental design, data analysis pipeline and 
interpretation of results on HBx genomic binding sites, HBx-interacting 
transcription factors, and clinically associated deregulated direct gene targets of 
HBx obtained by integrating the ChIP-Seq data, microarray expression profiles 
for both liver cell line (THLE3) and HCC patients, as well as the clinical data of 




Figure 1.5: Aims of the project. Our laboratory has applied a targeted NGS technique 
to identify HBV-human integration sites. I implemented a workflow to analyze the 
high-throughput FLX sequencing data to: 1) first remove pure host and noise reads by 
aligning reads to human and HBV genomes, 2) de novo assemble the reads into 
longer “contigs” to reconstruct original DNA sequences and recover junction sites 
disrupted from DNA shearing; then identify HBV-host junction sites by searching 
“contigs” against human and HBV genomes, and last 3) perform post-identification 
analysis to get more detailed information on HBV-host genome integrations. Our 
laboratory also applied ChIP-Seq technique with HBx antibodies to profile genomic 
binding sites of HBx. I integrated the ChIP-Seq sequencing data, microarray 
expression profiles and HCC patient clinical data to: 4) first remove ChIP-Seq 
sequencing reads that matched ambiguously to the human genome, 5) identify 
significantly enriched peak regions as potential DNA binding sites of HBx using 
peak-calling algorithms, 6) identify potential HBx-interacting transcription factors 
from motif enrichment analysis, 7) identify potential deregulated direct gene targets 
of HBx by integrating microarray expression profiles, and last 8) identify clinically 
significant deregulated direct gene targets of HBx by integrating clinical features and 
survival time data of 100 HBV-associated HCC patients. The high-throughput 
sequencing data used in this project are highlighted in blue, while the microarray 
expression profiles and clinical data used are highlighted in orange and the 
computational analysis processes are highlighted in pink. 
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CHAPTER 2: Computational Characterization of HBV-Host 
Genome Integration Sites 
2.1 Materials and Methods 
2.1.1 Data Collection: HBV-containing DNA Fragments Enrichment and 
FLX Sequencing Library Construction 
DNA samples were extracted from tumor and adjacent non-tumor tissues of 48 
HBV-positive HCC patients, and a total of 96 FLX sequencing libraries were then 
constructed in our laboratory following the protocol briefly shown in Fig 2.1. The 
key step of the HBV sequence enrichment strategy was to use the specifically 
designed HBV probes to pull down HBV-containing DNA fragments from 
extracted patient DNA samples. To ensure maximum coverage of the whole HBV 
genome with minimum bias, 26 3' biotinylated HBV probes which are 70-mer 
long were specifically designed based primarily on conserved regions. 
Nevertheless, probes within some less conserved regions of 96 genotype B and 
genotype C HBV genome sequences downloaded from NCBI data repository had 
to be designed as well. In order to make full use of the sequencing capacity, 
pooled FLX sequencing of all the 96 tissue samples was done, where each sample 
library had a unique 6bp library barcode attached at the 5' of the DNA fragments 
for identification. This enrichment strategy facilitated the capture of novel HBV-
containing sequences from the 48 pairs of patient DNA samples, without prior 




Figure 2.1: Flowchart of the HBV enrichment strategy applied in our laboratory. 
Each extracted DNA sample was first sonicated into small fragments of 300 to 
800bp, and linkers were added for sequencing purpose. The double-stranded DNA 
fragments were then denatured into single-stranded fragments and twenty-six 3’ 
biotinylated HBV probes of length 70-mer were then used to pull down the 
fragments that contain HBV genome sequences. The HBV-containing DNA 
fragments were then undergone pooled FLX sequencing, where each sample 
library had a unique 6bp library barcode added to the 5' of the sequence reads for 
identification. 
2.1.2 Computational Identification of HBV-Host Junction Sites from FLX 
Sequencing Data 
A specific analysis pipeline was developed to identify the HBV-human junctions 




Figure 2.2: Analysis pipeline for identification of HBV-human junctions from 454 
FLX sequencing data. NCBI standalone soft tool BLASTN 2.2.23+ was used to 
search sequence reads against human genome (NCBI reference contig assembly 
of Build37) and HBV genome (human HBV strain genome sequences 
downloaded from NCBI genome database). Reads not assigned to any patient 
samples, or fully matched to human genome, or with no hit to HBV genome were 
filtered out. Then de novo assembly algorithm from DNASTAR SeqMan NGen 
was used to assemble the rest reads into contigs for each patient. Contigs and 
unassembled reads, which were either fully aligned to HBV genome or with at 
least 52 consecutive bases aligned to HBV genome, were selected for further 
identifications. The sequence identities were classified into five groups where the 
two groups “HBV-HG junction” and “Modified HBV-HG junction” contained the 
predicted junction points where HBV sequences insert into human genome. A 
graphic representation of the typical sequences identities is shown in Fig 2.3. 
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From the pool of millions of raw sequence reads, those reads whereby the 6bp 
barcodes were not matched to any patient were first removed, and the remaining 
reads were assigned to different patients based on the unique identification 
barcodes. The assigned reads were then searched against human genome (NCBI 
reference contig assembly Build37) using NCBI standalone soft tool BLASTN 
2.2.23+ (Basic Local Alignment Search Tool) (Altschul et al., 1997). Reads that 
were fully matched to human genome were further removed as “pure” human 
sequences. Full match to human genome was defined based on two criteria: 1) the 
matching identity of the local alignment between sequence read and human 
genome was above 80%; 2) the 3’ and 5’ ends of the sequence read that were not 
covered by the local alignment must be shorter than 12bp. The remaining reads 
were further searched against human HBV genome strains sequences downloaded 
from NCBI Genome database, and those with no hit to HBV genome were further 
removed as insignificant reads. Reads that remained after the above filtering 
process were used for downstream identification of HBV-HG junctions. 
To recover possible HBV-HG junction sites that might be disrupted during DNA 
shearing process as well as to reconstruct the original DNA sequences from 
fragmented sequencing reads, the remaining reads were assembled into longer 
sequences known as “contigs” for each patient sample using de novo assembly 
algorithm DNASTAR SeqMan NGen and LaserGene for visualization of 
assembly. For each patient, the assembled contigs and unassembled reads left 
were then searched against HBV genome, and those either fully matched to HBV 
genome or having HBV hit longer than 52bp were selected. The reason 52bp was 
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used as a threshold is that the longest identical region between human genome 
and most HBV strains genome is 52bp. Thus sequences that had at least 52 
consecutive bases aligned to HBV genome would carry more confidence that the 
aligned part of the sequence were truly derived from HBV genome rather than 
human genome.  
Subsequently, the selected contigs and unassembled reads either fully aligned to 
HBV genome or with at least 52 consecutive bases aligned to HBV genome, were 
searched against both HBV and human genomes for sequence identities. In this 
study, sequence identities were classified into five groups: one group is named 
“intact HBV” referring to sequences that are fully matched to HBV genome; 
second group is “modified HBV” including sequences with one region aligned to 
HBV genome and the other region aligned to a different region of HBV genome; 
the third group is “HBV+Unknown” containing sequences with one region 
aligned to HBV genome but the other region comprising only a few bps that is too 
short to be accurately mapped to either HBV or human genome (“unknown”); the 
fourth group is “HBV-HG junction” representing sequences with one region  
aligned to HBV genome but the other region mapped to human genome; and the 
last group is “modified HBV-HG junction” referring to sequences with one region 
identified as “modified HBV” and the other region aligned to human genome. 
Contigs and unassembled reads grouped into “HBV-HG junction” and “modified 
HBV-HG junction” would contain the predicted junction points where HBV 
sequences insert into human genome. The HBV-HG and modified HBV-HG 
junctions were then further classified into two types for ease of post-identification 
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analysis: Type I has the 5’ end of the HBV genome sequence deleted at the 
integration site, and Type II has the 3’ end of the HBV genome deleted at the 
integration site (Fig 2.3). This classification will facilitate the identification of 
genes or functional domains of HBV genome that are deleted or conserved after 
the integration events. 
 
Figure 2.3: Typical patterns of HBV-containing sequence identities: intact HBV 
that is fully aligned to HBV genome, modified HBV with one region of the 
sequence aligned to HBV genome and the other region aligned to human genome, 
HBV+Unknown with one region aligned to HBV genome and the other region not 
known to both HBV and human genomes, and HBV-HG junctions with one 
region aligned to HBV genome and the other region aligned to human genome. In 
this study, the HBV-HG junctions were further grouped into two types: Type I 
with the 5’ end of HBV genome deleted (pattern1) and Type II with 3’ end of 
HBV genome deleted (pattern2) in the integrations. The red color highlighted the 
junction points on HBV genome. 
 
2.2 Results 
2.2.1 Sequence Identities of the FLX Sequencing Reads 
A total of 1,902,755 raw sequence reads were obtained from 454 FLX 
pyrosequencing of our 48 pairs of DNA samples extracted from tumor and 
adjacent non-tumor tissues of HBV-positive HCC patients. Each sequence read 
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had a 6bp library barcode at the 5' to facilitate the unique identification of the 
specific patient DNA sample. The raw sequence reads were then analysed 
following the pipeline shown in Fig 2.2 and a summary of the sequence identities 
was shown in the Fig 2.4. 
 
Figure 2.4: Summary of sequence identities for all 1,902,755 raw FLX sequencing 
reads. About 2.13% of the raw sequence reads were not assigned to any patient 
sample because of no match of unique 6bp library barcodes. A large portion of the 
raw reads, about 95.22%, were fully matched to human genome and another 
1.74% had no hit to HBV genome. These sequence reads were removed from 
assembly analysis. The rest 0.91% reads with at least one hit to HBV genome 
were then uploaded to SeqMan NGen de novo assembler for assembly into longer 
sequences which we called "contigs". As a result, 1224 contigs were formed and 
5227 raw reads remain unassembled. These contigs and unassembled reads were 
then searched against HBV genome, and 220 contigs plus 158 unassembled reads 
were found either fully matched to HBV genome or with at least 52 consecutive 
bases aligned to HBV genome. These 378 sequences (220+158) were considered 
confidently containing HBV sequences and would be used for downstream 
analysis to identify HBV-host integrations.  
About 2.13% of the raw sequences did not match to the unique 6bp barcodes for 
the patient samples and were thus removed at first place. The remaining reads 
were then assigned to the 48 patients each with paired tumor and adjacent non-
tumor tissue samples based on the barcode identification. The assigned raw reads 
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had average length of 254bp and ranged from 34bp to 1121bp. These reads were 
then searched against human and HBV genomes using BLAST, and a large 
portion of the raw reads (95.22%) were found to be fully aligned to human 
genome and another small proportion of 1.74% did not align to the HBV genome. 
“Fully matched" to human genome was defined as: there are at least 80% identity 
between the query sequence and the reference genome sequence and not more 
than 12bp of the 5’ and 3’ ends of the sequence does not align to the reference 
sequence. Sequences that were either purely human or did not align to HBV 
genome are probably results of non-specific enrichment, and were then removed 
from downstream assembly analysis. The remaining 0.91% of the reads that had 
hits to HBV genome were assembled into longer sequences ("contig") using 
SeqMan NGen de novo assembler. 
The criteria for the de novo assembly are as follows: for two sequence reads to 
assemble into one longer sequence, the overlapping fragment between the two 
reads must be longer than 19bp and the overlapping region should be above 85% 
identical. In addition, the assembler algorithm also calculates the probability that 
an observed overlapping fragment is also observed amongst other input sequences. 
Hence, the longer the overlapping fragment, the less likely that fragment is 
observed in other sequences, thus the more confidence one can have that the 
overlapping fragments are not merely due to a chance event. The assembly was 
done for every single patient sample, and the assembled contigs and unassembled 
reads were then searched against the HBV genome. As a result, a total of 378 
sequences (220 contigs and 158 unassembled reads) were found to either align 
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completely with the HBV genome or have greater than 52 consecutive bases 
identical with the HBV genome. 52bp was chosen as a threshold is because that 
the longest identical region between the HBV and human genome sequences is 
52bp. Thus a sequence, which had greater than 52 consecutive bases locally 
aligned to HBV genome, was most likely derived from the HBV genome rather 
than human genome. 
Hence, a total of 378 sequences (220+158) were found highly likely to be derived 
from the HBV genome, with some aligning to both human and HBV genome 
sequences where potential HBV-host integration sites can be identified. These 
378 HBV-containing sequences were then used for downstream analysis 
including the identification of HBV-host integration sites.   
2.2.2 Sequence Capture Coverage of HBV Genome from FLX data 
To determine if the entire HBV genome can be enriched by the specifically 
designed HBV probes in our laboratory and also to determine if there are 
preferred enrichment on specific regions of the HBV genome, among the 378 
identified HBV-containing sequences, the number of sequences that aligned to 
each position of the circular HBV genome (1 to 3215bp) was counted and then 
plotted as shown in Fig 2.5. As evident in Fig 2.5, the designed HBV probes were 
capable of capturing the entire HBV genome, and in particular, the HBx gene 
(position: 1374-1838) was relatively more abundant than other regions of the 
HBV genome in these patients. Interestingly, the 3' end (near position 1838) of 
the HBx gene had relatively lower abundance than the 5' end (near position 1374). 
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This difference in the abundances of the 5’ and 3’ ends of HBx gene in HCC 
patient liver tissues may indicate the differences of their functions. 
 
Figure 2.5: Coverage of the HBV genome (3215bp) by the 378 HBV-containing 
sequences including 220 assembled contigs and 158 unassembled reads in patients. 
For each position of the HBV genome of length 3215bp, the number of sequences 
that covered the position was counted and then plotted as a distribution over the 
entire HBV genome. It turned out that the entire HBV genome could be captured 
by the HBV probes designed in our laboratory, and the HBx gene (1374-1838) 
may exist more abundantly relative to other parts of the HBV genome in patients. 
And the 3’ end of HBx gene (near position 1838) may have lower abundance than 
the 5’ end (near position 1374) in patient liver tissues.    
 
2.2.3 Identification of Modified HBV and HBV-Human Genome Junctions 
These 378 HBV-containing sequences were searched against HBV and human 
genomes, and then classified them into the five groups, as shown in Table 2.1 and 
Supplementary Table S1. Of the 378 sequences, 221 were fully matched to HBV 
genome ("intact HBV"); 60 were chimeric where one region of the sequences 
aligned to HBV genome and the other region aligned to a different region of HBV 
genome ("modified HBV"); 34 had one region aligned to HBV genome but the 
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other region containing only a few bases that makes it difficult to map uniquely to 
human or HBV reference genomes ("HBV+Unknown"); 56 had one region 
aligned to the HBV genome and the other region aligned to human genome 
("HBV-HG junction"); and 7 had one region identified as "modified HBV" and 
the other region aligning to the human genome sequences ("modified HBV-HG 
junction"). The 221 "intact HBV" sequences were not long enough for us to 
determine whether they come from free HBV species or integrated HBV with 
human genome in patients. The 60 "modified HBV" sequences had various 
alterations and were probably consequences of the complex events (deletions, 
insertions, duplications, inversions and rearrangements) that occurred after the 
HBV genome is integrated into human genome. These 378 HBV-containing 
contigs and unassembled reads were distributed amongst 42/48 (~87.5%) patients. 
Among these 42 patients with HBV-containing sequences, ~35.7% (15/42) had 
various alterations/modifications in their HBV sequences including insertion, 
deletions, duplications and inversions (“modified HBV” and “modified HBV-HG 
junctions”), while ~52.4% (22/42) carried both HBV and human sequences within 
the same sequence from which integration sites can be inferred (“HBV-HG 
junction” and “modified HBV-HG junctions”). Our laboratory has experimentally 
successfully validated a subset of "intact HBV", "modified HBV" and “HBV-HG 
junction” sequences. However, there seems to be no conserved patterns of the 
alterations/modifications of the HBV sequences (“modified HBV”) among 
patients, during integration events. This may suggest that the alterations of HBV 
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genome sequences after insertion into human genome were either very complex 
or relative random as implicated by previous studies.  
Table 2.1: Summary of the identities of the 378 HBV-containing sequences. The 
sequence identities were classified into five categories: intact HBV, 
modified/altered HBV, HBV+unknown, HBV-Human junction, and modified 
HBV-human junction. 
 
Nevertheless, some patterns were apparent when “HBV-HG junction” sequences 
where the HBV and human genomic sequences integrated, were examined. The 
56 “HBV-HG junctions” and 7 “modified HBV-HG junctions” comprised 
junction points that fused HBV sequence to the human sequence. The detailed 
information of these 63 HBV-Human junctions was listed in Supplementary Table 
S2, which illustrated the integration positions of HBV and human genomes, 
junction points, and the HBV and human genes where the junction points resided. 
Twenty seven of the 63 junctions (~42.9%) were predicted to have the junction 
points on HBx gene. Although the HBx gene is only 465bp of the HBV genome 
of 3215bp (~14.5%) as seen in Fig 2.6, the junction sites were almost three times 
more enriched in the vicinity of HBx gene (42.9% ~= 3*14.5%) with significant 
Chi-Square two-sided p-value of 0.0008, compared to other genes of HBV 
genome. Thus, we may conclude that HBV genome integrations may 
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preferentially occur at the HBx gene, indicating potential functions of HBx gene 
in HBV-induced hepatocarcinogenesis. Our laboratory has successfully 
experimentally validated a selected subset of 23 HBV-HG junctions, of which 20 
had the junction points on HBx gene, as indicated in the 8th column of 
Supplementary Table S2. This indicated that our analysis pipeline (Fig 2.2) is 
robust for the FLX sequencing data in identifying novel HBV-human integration 
sites, and at least a subset of 23 novel HBV-human integration sites have been 
experimentally validated to exist in HCC patient liver tumor or adjacent non-
tumor tissues.  
 
Figure 2.6: Enrichment of HBV-HG junctions with integration sites on HBx gene. 
The circular HBV genome consists of four major coding genes: polymerase 
(2307-3215 & 1-1623), pre-core (1814-2452), surface protein (2848-3215 & 1-
835), and HBx (1374-1838). Out of the 63 HBV-human junctions predicted, 27 
(~42.9%) were predicted to occur on HBx gene. HBx gene is a small open reading 
frame of length 465bp which accounts only ~14.5% of the entire HBV genome. 
We could see that the HBV genome integrations were almost three times enriched 
in HBx gene (42.9% ~= 3*14.5%), with significant Chi-Square two-sided p-value 
of 0.0008, compared to other genes of HBV genome. Therefore it could be 
concluded that HBV genome integrations may preferentially occur on HBx gene, 
indicating potential functions of HBx for HBV-associated HCC. 
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Integration of HBV genome into human genome is implicated to have two basic 
functions: disrupting the host gene expressions or expressing chimeric transcripts 
and proteins. Within human genome, most of the junction points were located at 
the non-coding regions, such as, promoter, introns and intergenic regions (Table 
2.2), suggesting that the HBV insertions may potentially disrupt the regulatory 
elements on the human genome of host gene expressions. To check whether these 
junctions potentially change host gene expressions, the expression values of the 
nearest genes for each junction site were examined in patient tumor and non-
tumor tissues from patient cDNA expression microarray profiles. Among the 63 
junctions, there were 13 nearest genes that were differentially expressed between 
tumor and non-tumor tissues by at least 2 fold (Supplementary Table S2). Nine of 
the 13 genes had the HBV junction points on introns, while three genes had 
junction points at downstream of gene regions and one at promoter region. The 
true cellular events leading to the final change of these 13 host gene expressions 
remain unknown, but it might potentially be due to the viral genome integration. 
Nevertheless, most of the 63 viral integrations occur on non-coding regions of 
host genome, and by computationally scanning for opening reading frames in the 
integrated genome, we hypothesized that these viral integrations may result in 
early termination of viral genes (ie, expression of modified viral proteins) or 
expression of viral-host chimeric transcripts that might be potentially oncogenic. 
Our laboratory has experimentally validated the existence of viral-host chimeric 
transcripts and functional evaluation of these chimeric transcripts is still in 
progress in the laboratory.  
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Table 2.2: Summary of the locations of the 63 junction points on human genome.  




Hypothetical pseudo-genes 5 
Intergenic 30 
Not Annotated 1 
Non-coding RNA 1 
Total 63 
 
2.2.4 Analysis of HBV-Host Junctions with Junction Points on HBx gene 
Since HBx gene has been implicated to play a major role in the development of 
HCC in chronic HBV-infected patients, the 27 HBx-HG chimeric junctions were 
further examined. HBx gene of length 465bp codes for HBx protein of 154 amino 
acids which is a multifunctional protein with trans-repression regulatory domain, 
dimerization domain, and DDB1 binding domain at N-terminal, and 
transactivation domain and p53 binding domain at C-terminal (Fig 2.7). To see 
which functional domains of HBx were affected by the integrations, the locations 
of the 27 HBx-HG junction points were plotted on HBx gene as shown in Fig 2.7. 
Since the coding domains of HBx protein were from the positive strand of HBx 
gene, the HBx-HG junctions were grouped into two junction patterns (Fig 2.3 & 
Fig 2.7): pattern 1 with the 5' end of HBx gene (N-terminal of HBx protein) 
deleted at the junction point; and pattern 2 with the 3' end of HBx gene (C-
terminal of HBx protein) deleted at the junction point. Of the 27 junctions with 
fusion point on HBx gene, eight had the N-terminal of HBx deleted in the 
integrations (junction pattern 1), 18 had the C-terminal of HBx deleted in the 
integrations (junction pattern 2), and 1 had a special case of HG-HBV-HG 
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junction pattern which had the first and last part of the sequence aligned to human 
genome while the middle part aligned to HBV genome. Six out of the eight 
junctions with N-terminal of HBx deleted located at the very 3' end of HBx gene 
(e.g. position 1820), with only a few base pairs remained in the junctions, 
indicating that almost the entire HBx gene was deleted in the integrations. In fact, 
it could be regarded that the HBx gene was not involved in these six junctions. 
Nevertheless, the other two pattern 1 junctions with the trans-repression domain 
removed were experimentally validated by our laboratory to exist in patients. 
Furthermore, the 18 junctions with C-terminal of HBx deleted mostly located 
within the p53 binding domain, suggesting that the p53 binding domain of HBx 
was deleted or partially deleted in the integrations. These 18 junctions have all 
been experimentally validated in our laboratory. The single HG-HBV-HG 
junction cannot be experimentally validated and is probably due to assembly 
errors. In summary, the two junctions with N-terminal trans-repression domain 
deleted and the 18 junctions with C-terminal p53 binding domain of HBx deleted 
in the integrations were all experimentally validated and may lead to expression 
of potential chimeric transcripts fusing HBx gene and human sequences.  
Interestingly, the 18 junctions with C-terminal of HBx deleted all had the p53 
binding domain deleted or partially deleted in the integrations. This may implicate 
that the N-terminal two thirds of HBx (amino acids 1 to 100 or nucleotide 1374 to 
1673) preferentially remain intact in the integrations. N-terminal two thirds of 
HBx comprise of trans-repression domain, dimerization domain, DDB1 binding 
domain and transactivation domains, which may be important for HBx functions 
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in patients. On the other hand, deletion or partial deletion of p53 binding domain 
in HBx may potentially abolish its interaction with p53. P53 is a well-known 
tumor suppressor gene regulating apoptosis and thus elimination of HBx 
interaction with p53 may promote hepatocarcinogenesis and development of HCC. 
In addition, this observation of more frequent deletion of C-terminal than N-
terminal of HBx in integrations is consistent with our earlier result of sequence 
coverage over whole HBV genome, shown in Fig 2.5, where the 3' end of HBx 







Figure 2.7: Location plot of the 27 predicted HBV-HG junctions where the junction 
points fall on HBx gene (Supplementary Table S2). a) The reported functional 
domains of HBx protein included trans-repression regulatory domain, dimerization 
domain, DDB1 binding domain, transactivation domain, and p53 binding domain. 
Of the 27 junctions, eight had the N-terminal of HBx deleted (yellow arrow), 18 had 
the C-terminal of HBx deleted (green arrow) and one had a special case of HG-
HBV-HG junction pattern, in which the first and last part of the sequence aligned to 
human genome while the middle part aligned to HBV genome. Six out of the eight 
junctions with N-terminal of HBx deleted located at the very 3' end of HBx gene 
with only a few base pairs of HBx gene remained in the junction, and thus could be 
regarded not involving HBx gene. The other two junctions with N-terminal of HBx 
deleted had the trans-repression domain deleted, and were experimentally validated 
by our laboratory colleagues. The 18 junctions with C-terminal of HBx deleted were 
all experimentally validated and mostly had the p53 binding domain deleted or 
partially deleted in the integrations. The one HG-HBV-HG junction cannot be 
experimentally validated and could possibly be due to assembly errors. In total, the 
two junctions with N-terminal trans-repression domain deleted and the 18 junctions 
with C-terminal p53 binding domain of HBx deleted may potentially lead to 
expression of chimeric transcripts fusing HBx and human sequences. b) Part B 
illustrates the HBV-HG junction patterns in genome integrations: pattern 1 with N-
terminal of HBx deleted; pattern 2 with C-terminal of HBx deleted; and HG-HBV-
HG junction with both N-terminal and C-terminal of HBx deleted. Red color 
highlights the integration sites of HBV genome with human genome. 
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2.3 Discussion and Future Work 
Currently most of the approaches used to study the integration sites of HBV in the 
host genome were all PCR-based methods which required prior information on the 
integrated HBV sequences, or assumption of integration of certain parts of HBV. To 
comprehensively characterize HBV genome integration boundaries in HCC patients, 
our laboratory developed an unbiased HBV enrichment strategy followed by next 
generation sequencing (454 life science FLX sequencer) to capture HBV related 
DNA fragments from the complex genomic DNA samples extracted from the tumor 
and adjacent non-tumor tissues of 48 HBV-positive HCC patients. In this study, I 
implemented a pipeline to analyse the ultra high-throughput sequencing data, and 
was able to identify various novel modified/altered HBV sequences as well as novel 
HBV-host junctions, without much prior knowledge or assumption of which part of 
HBV genome is integrated into host genome. A total of 378 sequences including 
assembled contigs and unassembled reads were found to contain HBV sequences, 
out of which, 60 were altered HBV sequences (e.g. insertion, deletion, duplication 
and inversion) and 63 comprised of HBV-HG junctions. These 378 HBV-containing 
sequences were distributed amongst 42/48 (87.5%) patients. Of the 42 patients, 
35.7% (15/42) had various alterations in their HBV sequences, including insertions, 
deletions, duplications and inversions, while 52.4% (22/42) carried both HBV and 
human sequences within the same sequence from which integration sites can be 
inferred (HBV-HG junctions). 
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Particularly, our laboratory has successfully validated a batch of altered HBV 
sequences and HBV-HG junctions. Presence of the altered HBV sequences in 
patients confirmed that after HBV genome inserted into host genome, complex 
manipulations events may have occurred, such as insertions, deletions and 
duplications, inversions and rearrangements. However, there seemed to be no 
conserved patterns of these alteration events across the 48 patients, which implicate 
that the alteration process might be either very complex or relatively random. 
Nevertheless, we do observe that the junction/fusion points of HBV genome with 
human genome were enriched on HBx gene (27/63 junctions), and more 
interestingly the C-terminal of HBx was often deleted at the integration sites. HBx 
protein of length 154 amino acids has been implicated to play a major role in HBV-
induced hepatocarcinogenesis, and our observation suggested that integration of C-
terminal deleted HBx with human genome may be potentially functionally important 
in hepatocarcinogenesis. P53 has been reported to interact with HBx at C-terminal 
amino acids 100 to 154. Deletion or partial deletion of C-terminal p53 binding 
domain of HBx may potentially abolish its interaction with p53. P53 is a well-
known tumor suppressor gene regulating apoptosis and thus abortion of HBx 
interaction with p53 may promote hepatocarcinogenesis and development of HCC. 
More importantly, the N-terminal two thirds of HBx (amino acids 1 to 100) were 
observed to be preferentially retained in the integrated form. The N-terminal two 
thirds of HBx comprise trans-repression domain, dimerization domain, DDB1 
binding domain and transactivation domains, and may be important for HBx 
functions in HBV-induced hepatocarcinogenesis. 
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Integration of HBV into human genome is implicated to either disrupt host gene 
expressions or express chimeric transcripts and proteins to functionally participate in 
hepatocarcinogenesis. We have observed that most of the 63 HBV-HG junctions 
occurred at the non-coding regions of human genome (Table 2.2), therefore, the 
integration of HBV genome may interrupt the regulatory elements of host genes, 
such as promoters, introns, and intergenic regions. Examining the nearest genes for 
the 63 junctions, we found 13 were differentially expressed in tumor and adjacent 
non-tumor tissues of HCC patients with at least 2 fold changes. Though it might be 
due to the viral genome integration, the true cellular events leading to the change of 
these 13 host gene expressions are still unknown. Nevertheless, by computationally 
scanning for opening reading frames, we hypothesized that in addition to 
interrupting host gene expressions, these viral integrations may also result in early 
termination of viral gene expression (i.e. expression of modified viral proteins) or 
expression of viral-host chimeric transcripts that may be potentially oncogenic. Our 
laboratory has experimentally observed the existence of novel viral-host chimeric 
transcripts. The functional evaluation of these chimeric transcripts/proteins is still in 
progress in the laboratory.  
Identification of novel HBV-human genome integration sites, modified viral protein 
expression and potential viral-host chimeric transcripts could facilitate the 
understanding of the underlying mechanisms of HBV genome integrations into 
human genome, and may give us more knowledge on how HBV infection gradually 
leads to hepatocarcinogenesis. The major benefit of utilizing hybrid capture method 
coupled with single-end high-throughput 454 FLX pyrosequencing is that the reads 
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could be long enough to permit the identification of precise virus insertion sites in 
human genome at single-base resolution with one region of the read aligned to 
human genome and the other region aligned to virus genome. Last but not least, this 
has been among the very first to comprehensively characterize HBV integrations 
utilizing high throughput sequencing techniques in a large series of samples from 48 
HCC patients on a genome-wide basis without much prior knowledge of the 
integration sites. By the identification and characterization of these genome 
integration sites, we are now better positioned to understand the underlying 
mechanism of how HBV genome integrations may contribute to HBV-induced 














CHAPTER 3: Computational Identification of Putative 
Direct Gene Targets of HBx 
 
3.1 Materials and Methods 
HBx protein has been implicated to play an important role in HBV-induced 
hepatocarcinogenesis, and one of the reported underlying mechanisms is that HBx 
binds to DNA indirectly through interactions with transcription factors and deregulate 
host gene expressions by changing transcription factor binding affinities to DNA. In 
order to profile the genome binding sites of HBx-transcription factor complex on a 
genome-wide basis with single-base resolution, our laboratory has utilized antibodies 
specifically against HBx protein to immunoprecipitate DNA fragments potentially 
bound by HBx-transcription factor complex in primary immortalized liver cell line 
(THLE3) transfected with HBx-expressing adenoviruses, and then applied high-
throughput Illumina sequencer to sequence the immunoprecipitated DNA fragments. 
This ChIP-Seq technology produced millions of sequence reads of uniform length 36 
bp for HBx-expressing THLE3 cells (AdHBx) and control THLE3 cells (AdEasy). In 
this project, I implemented an analysis pipeline to integrate the THLE3 ChIP-Seq 
sequencing data, microarray expression profiles for THLE3 cells and 100 HCC 
patients, and 100 HCC patient clinical data to identify global genome binding sites of 
HBx and predict putative clinically associated direct gene targets of HBx, as shown in 
Fig 3.1.   
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Figure 3.1: Workflow of computational analysis to identify genomic binding sites of 
HBx and putative clinically associated direct target genes of HBx. With the Illumina 
sequencing reads of 36bp generated from ChIP-Seq technique in THLE3 cells 
transfected with HBx-expression adenoviruses (AdHBx) and control THLE3 cells 
(AdEasy), I first aligned the short reads to human genome using Bowtie and removed 
those reads matched ambiguously to human genome. The remaining reads were then 
analyzed using peak-calling tools MACS and CCAT to identify significantly enriched 
peaks as potential HBx binding sites. Location of the predicted HBx binding sites 
relative to the genome structures can be plotted and examined. The genomic 
sequences of the predicted HBx binding sites were retrieved and scanned against 
TRANSFAC motif database using HOMER motif enrichment algorithm for potential 
HBx-interacting transcription factors, which were then compared with the previously 
predicted transcription factors from the ChIP-chip data (Sung, Lu et al. 2009). 
Additionally, the microarray expression profiles for the nearest genes of the potential 
HBx binding sites were analyzed using R packages “Loess” for normalization and 
“Limma” for differential expressions to identify potential HBx deregulated direct 
gene targets in THLE3 cells. Microarray expression profiles for 100 HBV-associated 
HCC patients were also analyzed using “Loess” and “Limma” and integrated to get a 
list of potential HBx direct gene targets that were also differentially expressed in 
HCC patient tumor and adjacent non-tumor tissues. Integration and analysis of the 
HCC patient clinical data using statistical analysis package SPSS further narrowed 
down a list of clinically significant potential direct gene targets of HBx. 
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I analyzed the ChIP-Seq Illumina sequencing data, microarray expression profiles, 
and HCC patient clinical data obtained in our laboratory (highlighted in blue in Fig 
3.1). For the Illumina high-throughput sequencing reads of 36bp generated from the 
ChIP-Seq technique on THLE3 cells transfected with HBx-expressing adenoviruses 
(AdHBx) and control THLE3 cells (AdEasy), the short reads were first mapped into 
human genome using reference-guided aligner Bowtie (Langmead et al., 2009), and 
those reads that matched ambiguously to human genome were removed. Peak-calling 
software tool MACS (Model-based Analysis for ChIP-Seq) (Zhang et al., 2008) was 
then used to scan the remaining reads with unique best match to human genome. 
Significantly enriched peaks identified from MACS were then re-confirmed using 
another peak-calling tool CCAT (Control-based ChIP-Seq Analysis Tool) (Xu et al., 
2010). Common enriched peaks predicted from both MACS and CCAT were 
identified as the potential HBx binding sites in human genome. Genomic locations of 
the potential HBx binding sites were then examined for possible patterns of HBx 
binding sites relative to genome structures (e.g. promoters, introns, exons, and 
intergenic regions). The genomic DNA sequences of the potential HBx binding sites 
were also retrieved and scanned against TRANSFAC transcription factor known 
motif database (Wingender et al., 1996) using HOMER motif enrichment algorithm 
(Hypergeometric Optimization of Motif Enrichment) (Heinz et al., 2010) to identify 
significantly over-represented motifs as the potential HBx-interacting transcription 
factors. Our laboratory has previously utilized ChIP-chip technique on UV-treated 
liver cell line HepG2 cells transfected with HBx-expressing adenoviruses, and 
published a list of predicted HBx-interacting transcription factors (Sung et al., 2009). 
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Therefore, the potential HBx-interacting transcription factors predicted from the 
ChIP-Seq data were also compared to those from ChIP-chip data for commonly 
predicted HBx-interacting transcription factors. Further, microarray expression 
profiles for THLE3 cells (AdHBx vs AdEasy) was analyzed using R packages 
“Loess” for microarray normalization and “Limma” for identification of differentially 
expressed genes in THLE3 cells. Expression values for the nearest genes of the 
potential HBx binding sites were then examined to identify potential HBx deregulated 
direct gene targets in THLE3 cells. Microarray expression profiles for the 100 HBV-
associated HCC patients (tumor vs adjacent non-tumor tissues) were also analyzed 
and integrated to identify potential HBx direct gene targets that were differentially 
expressed in HCC patients. To check whether these potential HBx direct target genes 
identified from THLE3 cells are truly related to HCC, clinical data of 100 HCC 
patients including survival profile etc., were also integrated to identify significant 
clinically associated gene targets of HBx using statistical analytic package SPSS 
(Statistical Package for the Social Sciences) (Mather and Austin, 1983). The 
following sub-sections under Materials and Methods will elaborate in details of the 
computational analysis shown in Fig 3.2  
3.1.1 Data Collection: ChIP-Seq Libraries, Expression Profiles & 100 HCC 
Patients Clinical Data 
As shown in Fig 3.2, Chromatin immunoprecipitation (ChIP) was performed on 
DNA samples extracted from control immortalized primary normal liver cell line 
THLE3 cells (AdEasy) and HBx-expressing adenoviruses transfected THLE3 
cells (AdHBx), using antibodies specifically against HBx protein to 
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immunoprecipitate sheared DNA fragments that are bound indirectly by HBx. 
High throughput Illumina sequencing of the immunoprecipitated DNA fragments 
were then performed to construct AdEasy and AdHBx THLE3 ChIP-Seq libraries, 
which can be further analysed to detect the potential global genomic binding sites 
of HBx and predict HBx-interacting transcription factors. The sequence reads are 
of length 36bp.  
           
 
Figure 3.2: Flowchart of experimental design for generation of ChIP-Seq data and 
gene expression profiles performed in the laboratory. DNA samples were first 
extracted from control immortalized primary normal liver cell line THLE3 cells 
(AdEasy) and HBx-expressing adenoviruses transfected THLE3 cells (AdHBx), 
then sonicated into small fragments, followed by chromatin immunoprecipitation 
using anti-HBx antibodies. After size selection, the immunoprecipitated DNA 
fragments were then sent for high throughput Illumina sequencing (36bp) to 
construct AdEasy and AdHBx THLE3 ChIP-Seq libraries. RNA samples were 
also extracted in our laboratory from the same sets of AdEasy and AdHBx 
THLE3 cells for Agilent two-color expression microarray in order to examine the 
change of gene expressions upon the presence of HBx protein in THLE3 cells.  
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To examine the change of gene expressions upon expression of HBx protein in 
THLE3 cells, RNA samples were also extracted in our laboratory from the same 
sets of AdEasy and AdHBx THLE3 cells for Agilent two-colour expression 
microarray, where control AdEasy sample was labelled as Cy3 (green) and 
AdHBx sample was labelled as Cy5 (red). Similarly, Agilent two-colour 
microarray of 100 HCC patients were performed by labelling the DNA sample 
extracted from the tumor tissue of a patient as Cy3 (green) and that from the 
adjacent non-tumor tissue in the same patient as Cy5 (red). Clinical data of the 
100 HCC patients were also available for analysis. The patient clinical data 
include tumor grade (1, 2, 3 & 4), tumor encapsulation (Yes/No), tumor necrosis 
(Yes/No), vascular invasion (Yes/No), multifocality (Yes/No), local tumor 
extension (confined tumor: Yes/No), normal liver cirrhosis (Yes/No), normal liver 
steatosis (Yes/No), hepatic dysplasia (Yes/No), and survival time. Seventy five 
out of the 100 HCC patients have survival time data: 16 patients died from HCC 
and the other 59 patients were considered "censored cases" (48 alive at the time of 
recording, 6 dead but not due to HCC, and 5 lost of follow up). The HBx protein 
expression levels in both tumor and adjacent non-tumor tissues of the 100 HCC 
patients had also been determined in the laboratory.  
3.1.2 Computational Identification of DNA Binding Sites of HBx  
The short sequence reads of length 36bp from ChIP-Seq Illumina high-throughput 
sequencing platform for THLE3 AdEasy and AdHBx cells were first aligned to 
human genome (HG19) with no gaps permitted and a maximum of 2 mismatches 
allowed using an ultrafast and memory-efficient short read aligner Bowtie. Reads 
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that aligned ambiguously to human genome were removed (i.e. reads matched to 
multiple regions of human genome with the same best alignment score and 
significance), and reads with unique best match to human genome were selected 
for downstream peak finding process. An existing ChIP-Seq peak calling 
algorithm MACS was applied taking AdEasy sample as negative control and 
AdHBx sample as ChIP. MACS algorithm will (1) first remove duplicate reads in 
the datasets that may arise from ChIP-DNA amplification and sequencing library 
preparation, (2) linearly scale the total number of reads in control data to be the 
same with that in ChIP data, (3) empirically model the size of the true protein 
binding site based on the bimodal enrichment pattern, (4) shift the genome 
locations of the reads in a strand-specific manner by half of the estimated size of 
the protein binding site, (5) scan the genome using sliding windows of user-
defined width to identify candidate peaks with significant read enrichment in 
AdHBx sample based on p-values calculated from dynamic Poisson distribution 
of reads, (6) swap ChIP and control datasets and call peaks in control data, and (7) 
calculate FDR for each detected peak in ChIP data and rank them using p-values 
and FDR. In this study, MACS was applied using the threshold of at least 10 folds 
enrichment in AdHBx sample over control AdEasy sample and enrichment 
significance p-value less than 0.00005 for finding candidate enriched peaks. 
Another peak calling soft tool CCAT was used simultaneously to re-confirm the 
list of potential enriched peaks. CCAT adopts similar algorithm with MACS but 
is superior over MACS by estimating noise rate and resampling datasets to 
balance ChIP and control sample size instead of linear scaling as in MACS. Only 
 74 
 
enriched peaks predicted from MACS with their peak summits covered also by 
regions predicted from CCAT were considered as the potential DNA binding sites 
of HBx.  
3.1.3 Annotation of Genome-wide Potential HBx Binding Sites   
The potential HBx binding sites identified from ChIP-Seq data were mapped to 
the in-house human reference genome annotation database (HG19) from HOMER 
package (Hypergeometric Optimization of Motif Enrichment) developed in the 
Glass lab of UCSD (Heinz et al., 2010). This annotation database includes 
detailed information on human gene promoters, transcription start sites (TSS), 
introns, exons, gene 5’ and 3’ un-translated regions (UTRs). Promoter region was 
defined as 5kb upstream to the TSS of reference genes, and intergenic regions 
were defined as genomic regions other than promoters and gene body regions. 
Peaks located within multiple annotation categories (e.g. peaks fall in promoter of 
one gene but exon of another gene) were classified based on the precedence order 
that promoter comes first followed by 5' UTR and 3' UTR which then precede 
introns and exons. Mapping of peaks to annotation database was done using 
Microsoft SQL server 2005 software which stores relational databases and 
provides comprehensive functions for users to search and manipulate the cross-
linked data tables. 




Genomic DNA sequences of the potential HBx binding sites were extracted from 
human genome (HG19) for transcription factor motif enrichment analysis. 
HOMER known motif enrichment algorithm scripts (Heinz et al., 2010) were 
downloaded (http://biowhat.ucsd.edu/homer/) and applied using transcription 
factor position weight matrices from TRANSFAC motif database version 11.3  
(Wingender et al., 1996) which covered 601 vertebrate motif matrices for 389 
transcription factor families. As mentioned earlier, HOMER motif enrichment 
algorithm comprises of the following steps: (i) first, the program randomly selects 
a set of background genomic sequences with similar length and GC contents to 
the potential binding site sequences named as “target sequences”, (ii) it then 
assigns weights to each background sequence to minimize the imbalance in 
sequence contents with the target sequences, (iii) it further calculates the 
occurrence of each known motif in the target and background sequences and (iv) 
then computes a significance value (e.g. p-value) for the enrichment of the motif 
in the target sequences over background sequences (Heinz et al., 2010). 
Transcription factor motifs were ranked according to their enrichment p-values 
reported by HOMER and those with p-value below 0.05 were considered as 
significantly enriched/over-represented within the potential HBx binding sites. 
These significantly over-represented ones were known as transcription factors that 
may potentially interact with HBx to form a complex and bind to DNA.  
The list of significantly enriched HBx-interacting transcription factors predicted 
in this study was also compared to the list HBx-interacting transcription factors 
discovered previously in our laboratory from ChIP-chip method (Sung et al., 
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2009). This is to see whether there is any HBx-interacting transcription factor that 
is commonly predicted in different liver cell lines under different experimental 
conditions (UV-treated HepG2 vs THLE3) using different experimental methods 
(ChIP-chip vs ChIP-Seq).  
3.1.5 Analysis of THLE3 Microarray Expression Profiles to Predict 
Deregulated Direct Gene Targets of HBx 
The Agilent two-colour microarray data with four biological replicates for THLE3 
AdHBx (labelled as Cy5) and AdEasy (labelled as Cy3) cells were analysed using 
R packages “Loess” for array normalization and “Limma” for detection of 
differentially expressed genes in AdHBx over AdEasy cells. Genes with at least 
1.5-fold expression change in AdHBx relative to AdEasy cells were selected as 
differentially expressed genes. These differentially expressed genes were 
hypothesized to be deregulated (either up- or down-regulated) either directly by 
HBx or due to downstream regulation effect of HBx. Expression values for the 
corresponding nearest genes of the potential HBx binding sites were then 
examined, and those differentially expressed with at least 1.5-fold change were 
selected as candidate deregulated direct gene targets of HBx.  
3.1.6 Gene Ontology Analysis for Deregulated Gene Targets of HBx 
The list of candidate HBx deregulated direct gene targets were uploaded to a web-
based gene ontology analysis application DAVID (Database for Annotation, 
Visualization and Integrated Discovery) (http://david.abcc.ncifcrf.gov/) for 
enriched biological processes, molecular functions, KEGG pathways and so on. 
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Gene ontology terms with Benjamini-corrected p-values below 0.05 were 
considered as significantly enriched among the deregulated direct gene targets of 
HBx, and might be potentially deregulated by HBx. 
3.1.7 Analysis of Microarray Expression Profiles of 100 HCC Patients 
The Agilent two-colour microarray data for the 100 HCC patients’ tumor 
(labelled as Cy5) and adjacent non-tumor tissues (labelled as Cy3) were analysed 
using R packages “Loess” for array normalization and “Limma” for detection of 
differentially expressed genes. Genes with at least 2-fold average expression 
change in tumor relative to adjacent non-tumor tissues of the 100 HCC patients 
with multiple test corrected p-values below 0.05 were selected as significantly 
differentially expressed genes in HCC patients.  
3.1.8 HCC Patients Clinical Data Analysis to Identify Clinically 
Associated Deregulated Gene Targets of HBx 
From the list of candidate HBx deregulated gene targets identified from THLE3 
ChIP-Seq data, those genes that were also significantly differentially expressed in 
HCC patients’ tumor over adjacent non-tumor tissues were first selected. HBx is 
reported to have oncogenic potential, thus, the gene targets displaying the same 
deregulation direction in THLE3 cells (AdHBx over AdEasy) and in HCC 
patients (tumor over adjacent non-tumor tissues) were further selected. That is, if 
the gene targets were down-regulated when HBx is expressed in THLE3 cells and 
also down-regulated in tumor compared to adjacent non-tumor tissues of HCC 
patients, they were considered likely to be related to HCC; and similarly for up-
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regulation. Thereby those gene targets deregulated consistently in THLE3 cells 
(AdHBx over AdEasy) and in HCC patients (tumor over adjacent non-tumor 
tissues) were selected for downstream clinical statistical tests to investigate 
whether these gene targets had any clinical inferences in HBV-associated HCC.  
Statistical tests were performed on these selected deregulated gene targets, using 
IBM statistical analytical soft tool SPSS 19 (Statistical Package for the Social 
Sciences ) (Mather and Austin, 1983) to find the gene targets significantly 
associated with HCC patient clinical features. The categorical clinical data of the 
100 HCC patients include tumor grade (1, 2, 3 & 4), tumor encapsulation 
(Yes/No), tumor necrosis (Yes/No), vascular invasion (Yes/No), multifocality 
(Yes/No), local tumor extension (confined tumor: Yes/No), normal liver cirrhosis 
(Yes/No), normal liver steatosis (Yes/No), and hepatic dysplasia (Yes/No). Each 
of the selected HBx deregulated gene targets was tested against each of these 
clinical features. For a statistical hypothesis testing on the association between a 
deregulated gene target and a clinical categorical feature, the 100 HCC patients 
were first divided into two or more than two groups based on the number of 
different factor groups (e.g. Yes/No) in that clinical feature, and the gene 
expression values (log2 fold change in tumor over adjacent non-tumor tissues) 
were then compared across these patient groups, with the null hypothesis that the 




Figure 3.3: Flowchart of the statistical hypothesis testing on the association of 
HBx deregulated gene targets with patient clinical data. Each of the gene targets 
was tested on each clinical feature. In a hypothesis testing on a clinical feature, 
the normality of the gene expression distributions in patient groups (e.g.  Yes/No) 
was first checked: if the normality was valid, T-test or one-way ANOVA was 
applied depending on the number of patient groups (2 or >2 groups); if the 
normality not valid, non-parametric tests, like Median test, Mann-Whitney U test 
and Kruskal-Wallis test, were performed. For clinical features with more than 2 
patient groups, Bonferroni multiple test correction was applied to adjust the two-
sided p-values obtained from post-hoc pair-wise comparisons between the patient 
groups. Bonferroni multiple test correction was also conducted when the same 
hypothesis testing on the same clinical feature was repeatedly performed on a set 
of gene targets. A significant association between a gene target and a clinical 
feature was obtained if the corrected two-sided p-value was less than 0.05. 
As shown in Fig 3.3, for a hypothesis testing of the association between a gene 
target and a clinical feature, the normality of the distribution of the target gene 
expression in each patient group (e.g. Yes/No) was first checked: if the gene 
expression for all patient groups were normally distributed, T-test or one-way 
ANOVA was applied depending on the number of patient groups (T-test for two 
groups and one-way ANOVA for more than two groups); if normality not valid, 
 80 
 
non-parametric tests, like Median test, Mann-Whitney U test for two patient 
groups and Kruskal-Wallis test for more than two patient groups, were performed. 
For clinical features with more than two groups (e.g. tumor grade: 1, 2, 3 &4), 
Bonferroni multiple test correction was applied to adjust the two-sided p-values 
obtained from post-hoc pair-wise comparisons among patient groups. Bonferroni 
multiple test correction of two-sided p-values was also conducted when the same 
hypothesis testing on the same clinical feature was repeatedly performed on a set 
of HBx deregulated gene targets. A significant association between a gene target 
and a clinical feature was established if the corrected two-sided p-value from the 
statistical tests were less than 0.05. 
In addition to clinical categorical data, 75 out of the 100 HCC patients had the 
survival profiles: 16 died from HCC and the other 59 patients were considered 
"censored cases" (48 alive at the time of recording, 6 dead but not due to HCC, 
and 5 lost of follow up). These "censored cases" were also included in survival 
time analysis. For survival time analysis on each HBx deregulated gene target, the 
75 patients were first divided into 2 groups based on the gene expression in 
patients: one group with higher expression of that gene in tumor than adjacent 
non-tumor tissues, and the other group with lower expression of that gene in 
tumor than adjacent non-tumor tissues. The survival time between the two 
patients groups were then compared using Kaplan-Meier mean and median 
survival time tests, with the null hypothesis that the two patient groups have 
similar survival profiles. Genes with two-sided p-value less than 0.05 were 
regarded highly likely to be associated with patients’ survival time.  
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3.1.9 Correlation of Expressions of HBx and HBx Deregulated Gene 
Targets in 100 HCC Patients Tumor and Adjacent Non-Tumor Tissues 
With HBx protein expression values measured by our laboratory in tumor and 
adjacent non-tumor tissues of the 100 HCC patients, a linear regression model for 
each clinically significant HBx deregulated gene target was built to investigate 
whether there is any linear correlation/relationship between the expressions of the 
gene target and HBx protein in HCC patients. Pearson correlations were 
calculated to measure the strength of the linear relationships between HBx and 
HBx gene targets expressions, and two-sided p-values measuring the significance 
of the correlations were also computed using SPSS tool.  
3.2 Results 
3.2.1 Analysis of ChIP-Seq Data and Identification of Potential DNA 
Binding Sites of HBx 
A previous study (Sung et al., 2009) done by our laboratory using ChIP-chip 
technique on gene promoter regions for UV-treated liver cell line HepG2 cells has 
suggested that HBx deregulated host gene expressions not by binding directly to 
gene promoter but through interactions with transcription factors. ChIP-Seq 
technique is advantageous over ChIP-chip primarily in terms of the capability of 
predicting the DNA binding sites of HBx globally with larger genome coverage, 
since ChIP-chip is restricted to the limited number of probes used in array chip. 
Therefore our laboratory has utilized ChIP-Seq technique on primary liver cell 
line THLE3 cells (AdHBx vs AdEasy) to comprehensively profile HBx binding 
sites globally with single-base resolution. 
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As shown in Fig 3.4, after chromatin immunoprecipitation of DNA fragments 
bound by HBx-transcription factor complexes and Illumina sequencing of the 
enriched DNA fragments (ChIP-Seq), we got 14,270,900 and 11,885,806 raw 
short reads of length 36bp for THLE3 AdEasy and AdHBx cells respectively. 
 
Figure 3.4: Processing of ChIP-Seq raw reads to identify potential HBx binding 
sites. In total our laboratory got 14,270,900 and 11,885,806 raw reads of length 
36bp for THLE3 AdEasy and AdHBx cells respectively from Illumina sequencing. 
The raw reads were first searched against human genome (HG19) using Bowtie 
with criteria of no gaps permitted and a maximum of 2 mismatches allowed, and 
reads with unique best match to human genome were then selected. In the end, 
67.12% of raw reads for AdEasy and 55.93% for AdHBx cells were used for 
downstream peak finding process. While treating AdEasy as control, MACS was 
applied searching for enriched peak regions, and 3083 peaks were found enriched 
in AdHBx over AdEasy cells. To re-confirm the enrichment of peaks, CCAT was 
also applied, and 2860 out of the 3083 peaks from MACS were finally obtained 
with their MACS peak summits falling within enriched regions predicted by 
CCAT. These 2860 peak regions were the final list of potential genomic binding 
sites of HBx and used for further analysis. 
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Following the workflow pipeline illustrated in Fig 3.1, an ultra-fast aligner 
Bowtie with comparable accuracy was first used to map these short reads to 
human reference genome, with no gaps permitted and a maximum of two 
mismatches allowed in the alignments. Because of the short read length (36bp) 
and the large human genome size, a remarkable portion of these reads could 
match to multiple regions of human genome. To maintain the balance of mapping 
accuracy and the number of reads retained for downstream analysis, those reads 
that matched to multiple regions of human genome with the same best alignment 
score and significance were removed. Reads with unique best match to human 
genome were remained for downstream analysis. As a result, 67.12% and 55.93% 
of the raw reads for AdEasy and AdHBx cells were selected respectively for 
peak-calling step.  
After removal of reads that matched ambiguously to human genome, the peak-
calling software tool MACS (Zhang et al., 2008) was applied treating AdEasy 
sample as negative control, with the criteria of 600bp sliding window, at least 10 
folds enrichment in ChIP over control samples and  enrichment significance of p-
value less than 0.00005. In the end, a list of 3083 peaks was obtained with 
enriched reads in AdHBx relative to AdEasy cells. To re-confirm the enriched 
peaks, another peak-calling tool CCAT (Xu et al., 2010), which adopts similar 
algorithm with MACS but is superior in its way to balance the ChIP and control 
sample size, was simultaneously applied. Of the 3083 peaks, 2860 had their peak 
summits predicted from MACS falling within the enriched regions predicted from 
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CCAT, and these 2860 enriched peaks were considered as the potential DNA 
binding sites of HBx in human genome. 
3.2.2 Genome-Wide Distribution of Potential DNA Binding Sites of HBx  
Since ChIP-Seq is capable of detecting genome-wide protein binding sites, we 
may wonder how these predicted potential HBx binding sites distribute over 
human genome. The 2860 potential HBx binding sites were aligned to the in-
house human genome annotation database of HOMER developed by the Glass lab 
of UCSD (Heinz et al., 2010), which include detailed position information on 
gene promoters, introns, exons, un-translation regions (5’ or 3’ UTR), and 
transcription start sites (TSS). The promoter regions were defined as 5kb 
upstream to the TSS of reference genes, and the intergenic regions were defined 
as genomic regions other than promoters and gene body regions. Potential HBx 
binding sites located within multiple genome annotation categories (e.g. peaks fall 
in the promoter of one gene but exon of another gene) were classified based on 
the precedence order that promoter comes first followed by 5' UTR and 3' UTR 
which then precede introns and exons. Distributions of the 2860 potential HBx 




Figure 3.5: Genome-wide distribution of the 2860 potential DNA binding sites of 
HBx predicted from ChIP-Seq data in THLE3 cells. Promoter is defined as 5kb 
upstream to transcription start sites (TSS) of human genes. A) Distribution of the 
2860 potential HBx binding sites on different regions of genome: promoters, 
introns, exons, 5'UTR, 3'UTR, and intergenic regions. Since introns and 
intergenic regions are the two longest categories in human genome, most potential 
binding sites located within introns of genes (37.45%) and intergenic regions 
(34.58%). Next abundant is the promoter, followed by exons, 5'UTR and 3'UTR. 
Importantly, these 2860 predicted HBx binding sites were found to be 
significantly enriched in exons and promoter regions of genes and significantly 
less distributed in intergenic regions with binomial two-tailed p-values less than 
0.00001. B) Almost half of the binding sites within introns located in the first and 
last introns. C) Almost half of the binding sites within exons located in the first 
and last exons. Enrichment on the first and last introns/exons relative to other 





We could see that most of the potential HBx binding sites located within introns 
of genes (37.45%) and intergenic regions (34.58%), which is not surprising since 
introns and intergenic regions are the two longest categories in human genome. 
Next abundant are the promoters, exons, 5'UTR and 3'UTR in descending order. 
However, these 2860 predicted HBx binding sites were found to be significantly 
enriched in exons and promoter regions of genes and significantly less distributed 
in intergenic regions with binomial two-tailed p-values less than 0.00001. Among 
the potential binding sites within introns and exons (Fig 3.5B and 3.5C), we found 
almost half were located within the first and last introns or exons of genes. 
Enrichment of the potential binding sites of HBx in the first and last introns and 
exons of genes relative to other middle introns and exons might suggest the 
potential regulatory effect of HBx on gene expression. 
3.2.3 Potential HBx-Interacting Transcription Factors Predicted from 
HepG2 ChIP-chip and THLE3 ChIP-Seq Data 
To identify the transcription factors that may potentially interact with HBx in 
THLE3 cells, the genomic DNA sequences for the 2860 global potential HBx 
binding sites were extracted and scanned against the known transcription factor 
binding motifs in TRANSFAC database (Wingender et al., 1996) using motif 
finding scripts from HOMER (Heinz et al., 2010). Of the 601 vertebrate motif 
matrices tested, 195 transcription factor motifs were found significantly 
enriched/over-represented within the 2860 potential HBx binding sites in THLE3 
cells (with HOMER p-value < 0.05). These 195 transcription factor motifs were 
ranked according to the p-values, shown in Supplementary Table S2.  
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As mentioned earlier, a previous ChIP-chip study done by our laboratory (Sung, 
Lu et al. 2009) has identified 144 potential HBx-interacting transcription factors 
in UV-treated and HBx-expressing adenoviruses transfected HepG2 cells. Among 
these 195 potential HBx-interacting transcription factors predicted from THLE3 
cells, 129 were commonly predicted from the previous ChIP-chip study on 
HepG2 cells (Sung et al., 2009) (Table 3.1).  
Table 3.1: Comparisons of ChIP-chip data on HepG2 cells (Sung et al., 2009) and 
ChIP-Seq data on THLE3 cells. 
 ChIP-chip ChIP-Seq Overlap 
Liver cell line HepG2 (UV-treated) immortalized THLE3 N.A 
Differential gene 






1213 (646 same 
deregulation direction; 
567 opposite) 
Genome coverage 1.5kb gene promoters whole genome N.A 
Potential HBx binding sites 971 2860 7 
Potential HBx deregulated 





2 (1 same deregulation 
direction; 1 opposite) 
Potential HBx-interacting 
transcription factors 144 195 129 
 
The 129 potential HBx-interacting transcription factors commonly predicted from 
THLE3 ChIP-Seq data and HepG2 ChIP-chip data include previously reported 
ones that either interact with HBx or are activated by HBx, such as, SP1 (Lee et 
al., 1998), AP1 (Benn et al., 1996), AP2 (Kim and Rho, 2002), E2F  (Weinmann 
et al., 2001), E2F1 (Choi et al., 2002; Sung et al., 2009), CREB (Maguire et al., 
1991), SMAD4 (Sung et al., 2009), YY1 (Sung et al., 2009), NFKAPPAB50 (Su 
and Schneider, 1996), STAT3 (Waris et al., 2001), and so on. The 195 enriched 
transcription factors from THLE3 ChIP-Seq data also include C-Myc (Li et al., 
2003; Zeller et al., 2006) and P53 (Wei et al., 2006), that were previously reported 
to interact with HBx but not predicted by HepG2 ChIP-chip data. This could be 
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an evidence of the improvement of ChIP-Seq over ChIP-chip in reducing false 
negative rates, since the ChIP-chip data only covered 1.5kb promoter regions of 
human genes while ChIP-Seq was able to detect binding sites over entire genome. 
Though around 90% of the potential HBx-interacting transcription factors 
(129/144) in HepG2 cells were also found in THLE3 cells, only 7 out of the 971 
HBx binding sites predicted in HepG2 cells overlapped with the 2860 HBx 
binding sites predicted in THLE3 cells, as shown in Table 3.1. There is also very 
little overlap on HBx deregulated direct gene targets predicted in the two datasets 
(Table 3.1). This indicates that, even though THLE3 ChIP-Seq and HepG2 ChIP-
chip data predicted most similar sets of potential HBx-interacting transcription 
factors, the deregulated gene targets of HBx were very different between the two 
cell lines. Possible explanations for this gene targets difference may be that: a) 
HepG2 and THLE3 are two different primary liver cell lines and they might be 
physiologically very different; and b) HepG2 cells were UV-treated before 
chromatin immunoprecipitation while THLE3 cells were not. From the 
microarray gene expression profiles shown in Table 3.1, it was also observed that 
gene expressions changed much more drastically in UV-treated HepG2 cells than 
genes in THLE3 cells: 10,145 genes with above 2 fold change in UV-treated 
HepG2 AdHBx over AdEasy cells (Sung et al., 2009), while only 3,876 genes 
with above 1.5 fold change in THLE3 AdHBx over AdEasy cells. This indicated 
that UV-treatment might have enforced the regulation effect of HBx on gene 
expressions in HepG2 cells and this may possibly contribute to the differences in 




Figure 3.6: Summary of the computational analysis results for identification of 
HBx binding sites, potential HBx-interacting transcription factors and HBx 
deregulated direct gene targets. Genomic sequences for the 2860 potential HBx 
binding sites were extracted and scanned against TRANSFAC transcription factor 
binding motif database, and 195 transcription factors were found significantly 
enriched. Compared with the 144 transcription factors predicted from HepG2 
ChIP-chip data (Sung et al., 2009), there were 129 transcription factors commonly 
found in ChIP-chip and ChIP-Seq data. Analysis of microarray expression 
profiles identified 3,876 genes differentially expressed in THLE3 cell AdHBx 
over AdEasy with fold change above 1.5. Integration of the expression values for 
the nearest genes of the 2860 potential HBx binding sites allowed identification of 
161 potential binding sites corresponding to 143 differential genes in THLE3 cells. 
Analysis of microarray expression profiles in HCC patients predicted 3,407 genes 
differentially expressed with average fold change above 2 in patient tumor over 
adjacent non-tumor tissues. Of the 143 genes, 18 were differentially expressed in 
patients with the same deregulation direction in THLE3 cells. HCC patients’ 
clinical data were also integrated and statistical tests were performed on the 18 
genes, of which, 7 were found clinically associated. These 7 clinically associated 
genes were considered as the candidate HBx deregulated direct gene targets that 
may potentially be related to hepatocarcinogenesis.  
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3.2.4 Potential HBx Deregulated Direct Gene Targets in THLE3 Cells 
HBx has been implicated to interact with transcription factors, change the DNA 
binding affinity of the transcription factors, and consequently regulate gene 
transcription and expression. To identify the deregulated direct gene targets of 
HBx, expression profiles for the nearest genes of the 2860 potential HBx binding 
sites were examined in THLE3 cells. As summarized in Fig 3.6, of the 2860 
potential HBx binding sites, 161 sites corresponding to 143 genes displayed 
differential gene expressions (fold change above 1.5) in THLE3 cells (AdHBx 
over AdEasy). These 143 differentially expressed genes with potential HBx 
binding sites nearby were identified as the potential deregulated direct gene 
targets of HBx. Gene ontology analysis of these 143 potential deregulated direct 
gene targets of HBx showed that the top two significantly enriched biological 
processes are developmental process (Benjamini-corrected p-value: 4.14E-06) and 
multicellular organismal process (Benjamini-corrected p-value: 1.08E-04). These 
two biological processes were also found significantly enriched in the 184 
potential deregulated gene targets of HBx predicted from the ChIP-chip data on 
UV-treated HepG2 cells (Sung et al., 2009). The top significantly enriched 
molecular function of the 143 potential deregulated gene targets of HBx in 
THLE3 cells is transcriptional factor activity (Benjamini-corrected p-value: 
0.045388), which, however, was not significantly enriched in the 184 potential 
deregulated direct gene targets of HBx in HepG2 cells. 
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3.2.5 Clinically Associated Potential HBx Deregulated Gene Targets 
3.2.5.1 Expression of Potential HBx Deregulated Gene Targets in HCC Patients 
These 143 potential deregulated gene targets of HBx were identified in primary 
liver THLE3 cell line. Analysis of the microarray expression profiles in 100 
HBV-associated HCC patients found 3,407 genes differentially expressed in 
patients’ tumor over adjacent non-tumor tissues with average fold change above 2 
and adjusted p-values less than 0.05. To further examine whether these 143 
potential gene targets were truly related to HCC, their expression values in the 
100 HCC patients were investigated, and 23 out of the 143 genes were found 
significantly differentially in HCC patients’ tumor and adjacent non-tumor tissues 
with average fold change above 2.  
As shown in the hierarchical clustering graph of the 23 genes’ expressions in the 4 
biological replicates of THLE3 cells and the 100 HCC patients (Fig 3.7), 18 out of 
the 23 genes had the same deregulation direction in THLE3 AdHBx over AdEasy 
cells and in HCC patients’ tumor over adjacent non-tumor tissues. That is, these 
18 genes were deregulated consistently in THLE3 cells (AdHBx over AdEasy) 
and in 100 HCC patients (tumor over adjacent non-tumor tissues). Of these 18 
genes, 15 were consistently down-regulated in THLE3 cells and HCC patients; 
while the other 3 genes were consistently up-regulated. HBx is of oncogenic 
potential, so having the same deregulation direction in tumor over adjacent non-
tumor tissues of HCC patients and in THLE3 cells when HBx is expressed 
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indicates that these 18 genes might be potentially associated with hepatocellular 










Figure 3.7: Hierarchical clustering of the 23 potential HBx deregulated gene 
targets that are significantly differentially expressed between tumor and adjacent 
non-tumor tissues of the 100 HCC patients with average fold change above 2. The 
log2 fold change of tumor over adjacent non-tumor tissues on each patient, and 
the log2 fold change of THLE3 AdHBx over AdEasy cells (four biological 
replicates), were used for clustering (average linkage). Green represents down-
regulation in HCC patients’ tumor over adjacent non-tumor tissues or in THLE3 
AdHBx over AdEasy cells, while red represents up-regulation. The 5 genes 
marked with black star are the ones with opposite deregulation directions in 
THLE3 cells and HCC patients, while the remaining 18 genes are consistently 
deregulated in THLE3 cells and HCC patients indicating potential clinical 
inferences in HCC patients. 
3.2.5.2 Association of Potential HBx Deregulated Gene Targets with HCC 
Patient Survival Time 
As shown in Fig 3.6, to further evaluate the association of the 18 HBx deregulated 
gene targets with HCC, the gene expression profiles and clinical data including 
survival profiles of the 100 HCC patients were integrated, and various statistical 
tests were conducted searching for gene targets with significant associations with 







patient clinical features. Of these 100 patients, 75 had survival time data 
consisting of 16 patients dead from HCC cancer and the other 59 patients 
classified as “censored cases” (48 still alive at the time of recording, 6 dead due to 
reasons other than HCC and 5 lost of follow-up). These “censored cases” cases 
were still used in survival time analysis. Kaplan-Meier survival time analysis 
were performed for each of the 18 potential HBx deregulated gene targets by first 
dividing the patients into two groups (one group with gene expression in tumor 
tissue higher than adjacent non-tumor tissue, and the other group with gene 
expression in tumor tissue lower than adjacent non-tumor tissue) and then 
comparing the survival time between the two patient groups. The null hypothesis 
was that patient group with gene expression higher in tumor than adjacent non-
tumor tissue have the same survival time with the patient group with gene 
expression lower in tumor than adjacent non-tumor tissue. The significance p-
values obtained from Kaplan-Meier survival time analysis for each of the 18 






Table 3.2: Summary of corrected two-sided significance values from the clinical 
statistical tests on the 18 potential HBx deregulated gene targets. For a hypothesis 
testing of a gene target on a clinical categorical feature, the patients were first 
divided into different categorical groups and the gene expressions were then 
compared between patient groups. If the gene expressions in each patient group 
follow normal distribution, T-test (for features with 2 sub-groups) or one-way 
ANOVA (for features with >2 sub-groups) were performed; else, median test and 
Mann-Whitney U test (2 sub-groups) or Kruskal-Wallis test (>2 sub-groups) were 
performed. In this table, cells with only single number represents p-values from 
T-test or one-way ANOVA, while cells with two numbers in a bracket had the 
first number being the p-value from median test and the 2nd number from Mann-
Whitney U test or Kruskal-Wallis test. For Kaplan-Meier survival time analysis, 
patients were first divided into two groups based on gene expressions in patient 
tumor and adjacent non-tumor tissues and the survival time were then compared 
between the two patient groups. The 2nd column shows the two-sided p-values 
for survival time analysis. For clinical features with only 2 sub-groups, 
Bonferroni multiple test correction was applied to adjust the two-sided p-values 
(column 3 to 10). For clinical features with more than 2 sub-groups, the p-values 
from one-way ANOVA or Kruskal-Wallis tests were first checked, and if a p-
value was significant (less than 0.05), pair-wise comparisons and post-hoc 
Bonferroni corrections were then further performed. The feature in column 11 had 
3 sub-groups but the p-values were all not significant, so pair-wise comparisons 
were not conducted. The category "Tumor Grade" had 4 sub-groups, and column 
12 shows the p-values from one-way ANOVA, median test, or Kruskal-Wallis 
tests. Pair-wise comparisons (6 comparisons for 4 sub-groups) were then 
conducted for those with p-values less than 0.05 in column 12, and the Bonferroni 
corrected p-values for pair-wise comparisons were shown in the last column. In 
total, 6 genes showed significant clinical associations (shaded in yellow): BANK1, 
STK32B, DAO, C20orf74, FYB and CRDT1. Though DAO and TTR had 
survival time p-values not significant (shaded in grey), they did show a clear 
survival difference between patient groups (Fig.3.7). 
>2 groups pair-wise comparisons
TTR 0.063 1 1 1 1 0.318 1 1 1 0.324 (0.179, 0.332)
EPHA7 0.104 1 1 1 1 1 1 1 1 0.473 0.13
C20orf174 0.691 0.66 1 1 1 0.072 1 1 1 0.508 0.167
CD180 0.427 1 (1, 1) 1 1 0.528 1 1 1 0.951 (0.258, 0.152)
BANK1 0.957 1 (1, 1) 1 0.756 (0.012, <0.012) 1 0.54 (1, 1) 0.169 0.772
STK32B 0.017 (1, 1) 1 <0.008 1 1 1 (1, 1) 1 0.778 (0.117, 0.143)
CDH19 0.157 (0.384, 1) (1, 1) (1, 0.91) (1, 1) (1, 1) (1, 1) (1, 1) (1, 1) (0.953, 0.591) (0.767, 0.114)
C7 0.542 (1, 1) (1, 1) (1, 0.51) (0.187, 0.792) (0.588, 1) (1, 1) (1, 1) (1, 0.71) (0.769, 0.731) (0.030, 0.035)
(1;1;1;0.48;0.426;0.192, 
1;1;1;1;0.288;0.114)
LRRC4 0.669 (1, 1) 1 (1, 1) (1, 1) (0.936, 1) 1 (1, 1) (1, 1) (0.670, 0.925) (0.328, 0.807)
C3orf41 0.948 (1, 1) (1, 1) 1 (1, 1) (1, 1) (1, 1) (1, 1) (0.42, 0.13) (0.663, 0.166) (0.561, 0.594)
PCDH21 0.121 (1, 1) 1 (1, 1) (1, 1) 1 (1, 1) (1, 1) (1, 1) (0.464, 0.876) (0.346, 0.381)
LIPC 0.178 (1, 1) 1 1 (1, 1) (1, 1) 1 1 1 (0.464, 0.481) (0.767, 0.453)
DAO 0.094 (1, 1) 1 (1, 1) (1, 0.748) (1, 0.66) (1, 1) (1, 1) 0.232 0.183 (0.097, 0.015)
1;1;0.827;0.07;0.059; 
0.013 (grade 2&4)
C20orf74 0.003 (1, 1) (1, 1) (1, 1) (1, 1) (0.588, 0.012) 0.572 (1, 1) (1, 1) (0.822, 0.826) (0.767, 0.800)
IRF4 0.452 1 1 (1, 1) 0.567 (1, 0.612) (1, 0.917) (1, 1) (1, 1) 0.399 0.152
FYB 0.364 (1, 1) 1 (1, 1) (0.044, 0.638) (0.588, 0.204) 1 (1, 1) 1 (0.743, 0.847) (0.062, 0.040)
1;1;0.75;0.642;0.462; 
0.174
CDRT1 0.955 (1, 1) (1, 1) (1, 1) (1, 1) (1, 1) 0.022 (1, 1) (1, 1) (0.232, 0.234) (0.301, 0.523)



































Two genes C20orf74 and STK32B were found showing significant differences in 
survival time between patient groups with two-sided p-value less than 0.05. As 
illustrated in Fig 3.8, HCC patients with lower C20orf74 expression in tumor than 
adjacent non-tumor tissues were more likely to have longer survival time than 
patients with higher C20orf74 expression in tumor than adjacent non-tumor 
tissues (two-sided p-value: 0.003). Patients with higher STK32B expression in 
tumor than adjacent non-tumor tissues were more likely to have longer survival 
time than patients with lower STK32B expression in tumor than adjacent non-
tumor tissue (two sided p-value: 0.017). Another two genes DAO and TTR 
showed clear differences in survival time between patient groups though not 
statistically significant. Similar to STK32B, patients with higher DAO and TTR 
expressions in tumor than adjacent non-tumor tissues appear to have longer 
survival time than patients with lower DAO and TTR expressions in tumor than 
adjacent non-tumor tissues (not statistically significant).  
In summary, higher expressions of STK32B, TTR, and DAO, and lower 
expression of C20orf74 in tumor over adjacent non-tumor tissues in HCC patients 
are associated with longer survival time. These four genes were also functionally 
important (Table 3.4): C20orf74 is a Ral GTPase activating protein involving in 
regulation of signal transduction; STK32B is a serine/threonine kinase which is 
important for protein amino acid post-translational modifications; DAO is a D-
amino acid oxidase participating in cellular amino acid metabolic process; and 
TTR possesses transporter activity. Together with the evidence of being 
potentially directly deregulated by HBx in THLE3 cells and being significantly 
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differentially expressed in tumor over adjacent non-tumor tissues of HCC patients, 
these four survival-associated genes, C20orf74, STK32B, DAO and TTR, might 
be important for HCC development and worth further investigations. 
 
Figure 3.8: Survival plots for the four survival-associated potential HBx 
deregulated gene targets. For each potential HBx gene target, patients were 
divided into two groups: one with higher expression of that gene in tumor than 
adjacent non-tumor tissues; and the other with lower expression of that gene in 
tumor than adjacent non-tumor tissues. Kaplan-Meier survival analysis was 
conducted comparing the survival time between the two patient groups. Two 
genes C20orf74 and STK32B showed significant survival time differences 
between patient groups (2-sided p-value: 0.003 and 0.017 respectively), and 
another two genes TTR and DAO showed clear differences though not 
statistically significant. Higher expression of STK32B, TTR, and DAO, and lower 
expression of C20orf74 in tumor over adjacent non-tumor tissues in HCC patients 
are associated with longer survival time. The plus sign on the survival curve refers 
to “censored” cases defined as those patients either still alive at the time of 
recording or dead from reasons other than HCC or lost of follow-up. These 
“censored” cases were also used in Kaplan-Meier survival analysis. 
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3.2.5.3 Association of Potential HBx Deregulated Gene Targets with HCC 
Patients’ Categorical Clinical Features 
In addition to HCC patients’ survival profiles, other categorical clinical data were 
also available in our laboratory, including tumor grade (1, 2, 3 & 4), tumor 
encapsulation (Yes/No), tumor necrosis (Yes/No), vascular invasion (Yes/No), 
multifocality (Yes/No), local tumor extension (confined tumor: Yes/No), normal 
liver cirrhosis (Yes/No), normal liver steatosis (Yes/No), and hepatic dysplasia 
(Yes/No). Statistical analytic soft tool SPSS version 19 (Mather and Austin, 1983) 
was applied to perform T-test, one-way ANOVA, or non-parametric tests, such as 
median test, Mann-Whitney U test and Kruskal-Wallis test. Each of the 18 
potential HBx deregulated genes was tested on each of the clinical categorical 
features, with statistical tests that were well chosen based on the properties of 
gene expression data in patients as described in Fig 3.3 and Table 3.2. For a 
hypothesis testing of a gene target on a clinical feature, the 100 HCC patients 
were first divided into two or more than two groups based on the sub factor 
groups of that clinical feature (e.g. Yes/No), and the gene expressions were then 
compared between these patient groups. The log2 fold change in patients’ tumor 
over adjacent non-tumor tissues were used as gene expression values. The null 
hypothesis was that these patient groups have similar gene expression profiles. 
Bonferroni multiple test correction was also applied in the end to adjust the two-
sided p-values when the same hypothesis testing was performed repeatedly on a 
set of gene targets or when post-hoc pairwise comparisons were conducted for 
clinical features with more than two sub factor groups (e.g. tumor grade: 1, 2, 3 & 
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4). A significant association of a gene target with a patient clinical feature was 
established when the corrected p-value was less than 0.05. Table 3.2 listed the 
multiple test corrected p-values of all the statistical tests that have been performed 
for the 18 potential HBx deregulated gene targets on the various clinical features, 
and the significant p-values obtained were highlighted in yellow. 
In summary, among the 18 potential HBx deregulated gene targets, 6 genes were 
found displaying significant associations with various HCC patients’ clinical 
categorical features. These 6 genes were BANK1, STK32B, DAO, C20orf74, 
FYB and CDRT1, and were significantly associated with tumor grade, liver 
invasions, multifocality of patients, normal liver cirrhosis, and tumor 






Figure 3.9: Plots for the six potential HBx deregulated gene targets that showed 
significant associations with the 100 HCC patients’ categorical clinical features. X-axis 
represents the sub factor groups of the clinical features, and y-axis shows the log2 fold 
change expression values of genes in tumor over adjacent non-tumor tissues of HCC 
patients. Of the 18 potential gene targets, the following significant associations with 
corrected p-values less than 0.05 were found: A). Patients with tumor grade 4 are highly 
likely to have stronger down-regulation of DAO in tumor over adjacent non-tumor tissues 
than patients with tumor grade 2, with corrected p-value of 0.013 obtained from non-
parametric Kruskal-Wallis test. B). Patients with local tumor invasion are highly likely to 
have stronger up-regulation of STK32B in tumor over adjacent non-tumor tissues than 
patients with tumor confined to liver, with corrected p-values below 0.008 obtained from 
2-independent samples T-test. C). Patients with normal liver cirrhosis are highly likely to 
have stronger down-regulation of BANK1 and C20orf74 in tumor over adjacent non-
tumor tissues than patients with no normal liver cirrhosis, with corrected p-values of 
0.012 obtained from median test and Mann-Whitney U tests. D). Patients with tumor 
encapsulation are highly likely to have stronger up-regulation of CDRT1 in tumor over 
adjacent non-tumor tissues than patients with no tumor encapsulation, with corrected p-
value of 0.022 obtained from Mann-Whitney U test. E). Patients without multifocality are 
likely to have stronger down-regulation of FYB in tumor over adjacent non-tumor tissues 
than multifocal patients, with corrected p-value of 0.044 obtained from median test. 
Adj-P < 0.008 
Adj-P: 0.012 
 Adj-P: 0.012 





 Adj-P < 0.012 
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As plotted and explained in Fig 3.9, the associations of the six potential HBx 
deregulated gene targets with various categorical clinical features could be 
interpreted and summarized as follows: 
a) Patients with tumor grade 4 are highly likely to have stronger down-regulation 
of DAO in tumor over adjacent non-tumor tissues than patients with tumor 
grade 2, with Bonferroni multiple test corrected p-value of 0.013 obtained 
from post-hoc pair-wise comparisons following non-parametric Kruskal-
Wallis test.  
b) Patients with local tumor invasion are highly likely to have stronger up-
regulation of STK32B in tumor over adjacent non-tumor tissues than patients 
with tumor confined to liver, with Bonferroni multiple test corrected p-values 
below 0.008 obtained from 2-independent samples T-test. 
c) Patients with normal liver cirrhosis are highly likely to have stronger down-
regulation of BANK1 and C20orf74 in tumor over adjacent non-tumor tissues 
than patients with no normal liver cirrhosis, with Bonferroni multiple test 
corrected p-values of 0.012 obtained from median test and Mann-Whitney U 
tests. 
d) Patients with tumor encapsulation are highly likely to have stronger up-
regulation of CDRT1 in tumor over adjacent non-tumor tissues than patients 
with no tumor encapsulation, with Bonferroni multiple test corrected p-value 
of 0.022 obtained from Mann-Whitney U test. 
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e) Patients without multifocality are likely to have stronger down-regulation of 
FYB in tumor over adjacent non-tumor tissues than multifocal patients, with 
Bonferroni multiple test corrected p-value of 0.044 obtained from median test. 
3.2.5.4 Summary of Associations of Potential HBx Deregulated Gene Targets 
with HCC Patient Clinical Features 
As shown in Fig 3.8 & 3.9 and summarized in Table 3.3, there were in total seven 
potential HBx deregulated direct gene targets that might be associated with HCC 
patients’ survival profiles and various categorical clinical features including 
tumor grade, liver invasions, multifocality of patients, normal liver cirrhosis, and 
tumor encapsulations. The potential clinical associations and inferences of these 7 
potential HBx gene targets could be summarized as following points:  
a) HCC patients with tumor grade 4 were highly likely to have stronger down-
regulation of DAO in tumor over adjacent non-tumor tissues than patients 
with tumor grade 2 (adjusted p-value: 0.013). Furthermore, DAO also 
displayed clear survival differences between patient groups with higher and 
lower DAO expressions in tumor over adjacent non-tumor tissues, though 
statistically not significant with two-sided p-value of 0.094. Higher 
expressions of DAO in tumor over adjacent non-tumor tissues in HCC 
patients are likely to be associated with longer survival time (statistically not 
significant). In other words, lower expressions of DAO in tumor over adjacent 
non-tumor tissues in HCC patients are likely to be associated with shorter 
survival time. Therefore, in summary, lower expression of DAO in patients’ 
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tumor over adjacent non-tumor tissues is associated with shorter survival time 
and larger tumor grade. These associations of DAO with shorter survival time 
and larger tumor grade seemed to be valid, in the sense that, HCC patients 
with larger tumor grade are more likely to have shorter survival time.  
b) Two other significant survival-associated potential HBx gene targets STK32B 
and C20orf74 were also found significantly associated with tumor extension 
(adjusted p-value <0.008) and normal liver cirrhosis (adjusted p-value: 0.012) 
respectively. Higher expression of STK32B in tumor than adjacent non-tumor 
tissues of HCC patients was correlated with longer survival time and local 
tumor extension, while lower expression of C20orf74 in tumor than adjacent 
non-tumor tissues of HCC patients was correlated with longer survival time 
and normal liver cirrhosis. These established associations of STK32B and 
C20orf74 with longer survival time, local tumor extension and normal liver 
cirrhosis seemed to be valid, with the reasoning that, HCC patients who 
survived longer time might be more likely to have local tumor extension and 
develop normal liver cirrhosis. 
c) Higher expression of TTR in tumor over adjacent non-tumor tissues in HCC 
patients is associated with longer survival time, though statistically not 
significant with two-sided p-value of 0.063. 
d) In addition, another three potential HBx deregulated gene targets FYB, 
BANK1 and CDRT1 were found significantly associated with patients’ 
multifocality, normal liver cirrhosis and tumor encapsulation respectively.  
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• Patients not multifocal were likely to have stronger down-regulation of 
FYB expression in tumor over adjacent non-tumor tissues than multifocal 
patients (adjusted p-value: 0.044). 
• Patients with normal liver cirrhosis were highly likely to have stronger 
down-regulation of BANK1 expression in tumor over adjacent non-tumor 
tissues than patients with no normal liver cirrhosis (adjusted p-value: 
0.012).  
• Patients with tumor encapsulation were highly likely to have stronger up-
regulation of CDRT1 expression in tumor over adjacent non-tumor tissues 
than patients without tumor encapsulation (adjusted p-value: 0.022). 
Table 3.3: Summary of the clinical associations for the seven potential HBx 
deregulated gene targets. Five out of the seven genes were down-regulated (green) 
in both THLE3 cells (AdHBx over AdEasy) and HCC patients (tumor over 
adjacent non-tumor tissues), while the other two were up-regulated (red). Down-
regulation of DAO in patients (tumor over adjacent non-tumor tissues) was 
associated with shorter survival time (statistical not significant) and larger tumor 
grade. Down-regulation of C20orf74 in patients was related to longer survival 
time and normal liver cirrhosis. Down-regulation of TTR in patients was 
associated with shorter survival time (statistical not significant). Down-
regulations of FYB and BANK1 in patients were associated with patient non-
multifocality and normal liver cirrhosis respectively. Up-regulation of STK32B in 
patients was related to longer survival time and tumor invasion. Up-regulation of 
CDRT1 in patients was related to tumor encapsulation. 
*: association observed statistically significant after Bonferroni multiple test correction (adjusted p-value < 0.05) 
#: association statistically not significant but clear difference were observed (DAO: 0.094; TTR: 0.063) 
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Other than the four genes found associated with survival time (C20orf74, 
STK32B, DAO and TTR), the additional three genes associated with categorical 
clinical features (CDRT1, FYB and BANK1) were also functionally important. 
CDRT1 acts as protein-ubiquitin ligase; FYB involves in protein amino acid 
modifications and immune system process; and BANK1 involves also in immune 
system process. As annotated in Table 3.4, these seven putative HBx gene targets 
functionally involve in amino acid metabolic process, protein post translational 
modifications, regulation of signal transduction, protein transport, and immune 
responses. These seven potential HBx gene targets are likely to have clinical 
inferences in HCC patients and worth further investigation. 
Table 3.4: Functional annotations of the seven clinically associated potential HBx 
deregulated gene targets. These genes functionally involve in amino acid 
metabolic processes, protein post translational modifications, regulation of signal 
transduction, protein transport, and immune responses. 
Gene Gene Name Molecular Function Biological Process 
DAO D-amino-acid oxidase catalytic activity, D-amino-acid oxidase activity, oxidoreductase activity 
cellular amino acid metabolic process, cellular nitrogen 
compound metabolic process, primary metabolic 




protein, alpha subunit 2) 
GTPase activator activity, enzyme 
activator activity, nucleoside-
triphosphatase regulator activity 
regulation of signal transduction, regulation of cell 
communication, regulation of biological process, 
regulation of small GTPase mediated signal transduction 
STK32B serine/threonine kinase 32B 
nucleotide & nucleoside binding, ion 
binding, catalytic activity, protein kinase 
activity, ATP binding, transferase 
activity, phosphotransferase activity, 
ribonucleotide binding 
protein modification process, protein amino acid 
phosphorylation, phosphate metabolic process, 
phosphorylation, biopolymer modification, post-
translational protein modification 
TTR transthyretin receptor binding, transmembrane transporter activity, hormone binding transport, localization 
CDRT1 CMT1A duplicated region transcript 1 zinc ion binding, ion binding, cation binding, metal ion binding Members of the F-box protein family; act as protein-ubiquitin ligases  
FYB FYN binding protein receptor binding, protein binding, 
immune system process, post-translational protein 
modification, protein amino acid phosphorylation, 
protein targeting, protein import into nucleus, 
phosphorus metabolic process, nucleocytoplasmic 
transport, signal transduction, protein kinase cascade, 
protein transport, biopolymer modification, response to 
stimulus,  




3.2.6 Correlation of Clinically Associated HBx Deregulated Gene Targets 
with HBx Protein Expression in the 100 HCC Patients 
The seven clinically associated potential HBx deregulated gene targets were not 
only deregulated when HBx is expressed in THLE3 cells, but also deregulated in 
tumor over adjacent non-tumor tissues of HCC patients. To examine whether 
there is any direct correlation between these gene targets and HBx protein, linear 
regression models were built and Pearson correlations were calculated based on 
these genes and HBx protein expression values in the 100 HCC patients (log2 fold 
change in tumor over adjacent non-tumor tissues). However, it turned out that 
none of these seven potential gene targets showed significant correlations with 
HBx protein expression, and all the correlation R square values were quite small, 
as seen in the scatter plots of Fig 3.10. This observation of low linear correlation 
between potential HBx deregulated gene targets and HBx protein expressions in 
HCC patients may be explained that patients were physiologically very complex 
and many other factors, such as, medication, diet, other diseases and 
environmental factors, could also affect the gene expressions in patients. In that 
case, the deregulation effect of HBx on gene expressions could possibly be 
masked or disturbed by other factors in patients. As a result, the relationship 
between gene expressions and HBx expressions in patients was no longer linear. 
Thus, the low linear correlations could not prove that these genes were completely 
unrelated to HBx. Nevertheless, these seven potential HBx gene targets with 
predicted HBx binding sites nearby were shown deregulated in THLE3 cells upon 
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expression of HBx protein, and this could be the evidence supporting the 
deregulation potential of HBx on these genes expressions.  
 
Figure 3.10: Scatter plots for the expressions of the seven potential HBx 
deregulated gene targets and expressions of HBx protein in 100 HCC patients. 
The log2 fold change of tumor over adjacent non-tumor tissues on each patient for 
genes (y-axis) and HBx protein (x-axis) were plotted. The Pearson correlations (R 
square value) calculated between the genes and HBx were quite low with highest 
value 0.074. HCC patients are physiologically very complex and there are many 
other factors that may affect gene expressions. Thus, the deregulation effects of 
HBx on gene expressions could be masked or disturbed, which may explain the 
low linear correlations between genes and HBx expressions in HCC patients. 
3.3 Discussion and Future Work 
HBx was reported not to bind DNA directly, but though interactions with 
transcription factors. HBx binds to transcription factors and regulate gene by chaning 
the DNA binding affinities of transcription factors. To unravel the genome-wide 
binding sites of HBx, our laboratory applied chromatin immunoprecipitation followed 
by Illumina high-throughput sequencing (ChIP-Seq) with antibodies specifically 
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against HBx protein in primary liver cell line THLE3 cells transfected with HBx-
expressing adenoviruses. Our laboratory has also previously utilized chip-based 
chromatin immunoprecipitation (ChIP-chip) in ultraviolet (UV)-treated primary liver 
cell line HepG2 cells transfected with HBx-expressing adenoviruses, to profile 
genomic binding sites of HBx. Compared to the ChIP-chip study, this ChIP-Seq 
strategy has overcome the limitations of ChIP-chip technology, such as, limited 
number of probes used in ChIP-chip hybridization array, hybridization noise and dye 
bias. It has also eliminated the possible artificial effects introduced by UV-treatment 
on HepG2 cells. In this study, an analysis pipeline was implemented to integrate the 
ChIP-Seq sequencing data, microarray expression profiles and 100 HBV-associated 
HCC patients’ clinical data. In the end, a list of potential genomic binding sites of 
HBx was discovered on a single-base resolution from the ChIP-Seq data, and a list of 
putative HBx deregulated direct gene targets was predicted to have significant clinical 
inferences in HBV-associated HCC patients.  
The millions of ChIP-Seq short sequencing reads of 36bp were first aligned to human 
genome and those with unique best match to human genome were remained for peak-
calling. THLE3 cells transfected with HBx-expressing adenoviruses (AdHBx) were 
compared against control THLE3 cells (AdEasy), and a total of 2860 potential 
genomic binding sites of HBx were predicted using peak calling algorithm MACS 
and CCAT. Most of these 2860 potential HBx binding sites located within gene 
introns and intergenic regions, and this is not surprising since introns and intergenic 
regions are the two longest categories in human genome. Next abundant locations of 
the 2860 potential binding sites are promoters, exons, 5'UTR and 3'UTR in 
 108 
 
descending order. However, these 2860 predicted HBx binding sites were found to be 
significantly enriched in exons and promoter regions of genes (p<0.00001). 
Interestingly, among the binding sites within introns and exons, over half were in the 
first and last introns and exons. This may suggest the potential regulatory effect of 
HBx on gene expressions. 
The genomic sequences of the 2860 potential HBx binding sites were then retrieved 
for known motif enrichment analysis using HOMER. 195 transcription factor binding 
motifs were found significantly over-represented within the 2860 potential HBx 
binding sites. These 195 transcription factors are the potential candidate co-factors 
that HBx may interact to bind to DNA and deregulate gene expressions in HBx-
expressing THLE3 cells. Surprisingly, of the 195 potential HBx-interacting 
transcription factors, 129 were also found to be significantly over-represented within 
the HBx binding sites predicted from our previous ChIP-chip data done in our 
laboratory on UV-treated liver HepG2 cells (Sung et al., 2009) (Supplementary Table 
S3). This evidence further confirmed the list of potential transcription factors that 
HBx may interact in cell lines, even though the potential deregulated direct gene 
targets of HBx in these two liver cell lines did not overlap much which is probably 
due to their physiological differences and the artificial effects introduced by UV-
treatment on HepG2 cells. In addition, these 129 commonly predicted HBx-
interacting transcription factors include most of the transcription factors that were 
previously reported by other studies to interact with HBx or being activated by HBx. 
This could suggest that our computational workflow is robust to analyse ChIP-Seq 
data for identification of HBx-interacting transcription factors.  
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In this study, microarray gene expression profiles in THLE3 cells (AdHBx over 
AdEasy) were also integrated and a list of 143 potential deregulated direct gene 
targets of HBx were identified, indicating the pleiotropic nature of HBx: interact with 
a variety of transcription factors and deregulate a large set of genes. Though the 
potential HBx deregulated direct gene targets predicted from the two cell lines 
THLE3 and HepG2 were very different, they were enriched in similar biological 
pathways with top two being developmental process and multicellular organismal 
process. Nevertheless, the 143 potential HBx deregulated gene targets predicted from 
THLE3 ChIP-Seq data were significantly enriched in transcription factor activities, 
which however are not significant in HepG2 ChIP-chip data. In addition, the potential 
HBx-interacting transcription factors predicted from ChIP-Seq data include c-Myc 
and P53 that were previously reported to interact with HBx but not significantly 
found in ChIP-chip data. These two observations may possibly indicate that ChIP-Seq 
techniques could help to reduce false negative rates compared to ChIP-chip 
techniques. 
Previous studies on HBx deregulated gene targets were limited to cell lines due to 
lack of patient data. In this study, to further evaluate whether the putative HBx 
deregulated gene targets predicted from liver cell lines are truly related to HCC, 
microarray expression profiles and clinical data of 100 HBV-associated HCC patients 
were integrated, and statistical tests were performed to identify potential HBx 
deregulated gene targets that have significant clinical inferences in HCC patients. 18 
out of the 143 putative HBx deregulated gene targets were demonstrated to be 
significantly differentially expressed in tumor over adjacent non-tumor tissues in the 
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100 HCC patients with the same deregulation direction in THLE3 cells when HBx is 
expressed (AdHBx over AdEasy) (Fig 3.7). HBx is of oncogenic potential, so these 
18 potential HBx deregulated gene targets having the same deregulation direction in 
tumor over adjacent non-tumor tissues of HCC patients and in THLE3 cells when 
HBx is present might be potentially associated with HCC. To further confirm the 
association, statistical tests were performed for each of these 18 genes on each of the 
clinical features of the 100 HCC patients. It turned out that seven out of the 18 genes 
had obvious association with patient survival time, tumor grade, tumor invasion, 
normal liver cirrhosis, tumor encapsulation and multifocality (Fig 3.8, Fig 3.9 and 
Table 3.3). Particularly, higher expression of STK32B in tumor than adjacent non-
tumor tissues of HCC patients was significantly correlated with longer survival time 
and local tumor extension, while lower expression of C20orf74 in tumor than 
adjacent non-tumor tissues of HCC patients is significantly correlated with longer 
survival time and normal liver cirrhosis. Patients with higher DAO and TTR 
expressions in tumor than adjacent non-tumor tissues appeared clearly to have longer 
survival time than patients with lower DAO and TTR expressions in tumor than 
adjacent non-tumor tissues, though not statistically significant. Other three genes 
BANK1, CDRT1 and FYB were significantly related to normal liver cirrhosis, tumor 
encapsulation and multifocality respectively. Furthermore, these seven genes were 
functionally important involving in amino acid metabolic process, protein post-
translational modifications, protein transport, regulation of signal transduction, and 
immune responses (Table 3.4). Thus these seven potential HBx deregulated gene 
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targets are highly likely to have clinical inferences in HCC patients and worth further 
investigations. 
With the clinically associated potential HBx deregulated direct gene targets, we may 
wonder whether there is any linear correlation between the gene expression and HBx 
protein expression. To answer this question, linear regression models were 
constructed for each of the seven genes with HBx protein expressions in the 100 HCC 
patients. Pearson correlations and correlation significance were also calculated to 
evaluate the strength and significance of the linear relationships. Unfortunately, none 
of the seven genes were significantly correlated with HBx protein expressions in 
patients, and the correlation R square values were all very low (Fig 3.9). One possible 
explanation for the low correlations is that HCC patients were physiologically very 
complex and many other factors could also affect gene expressions in patients, such 
as, environmental factors, medication, other diseases, emotions, and so on. In that 
case, unlike in cell line, the HBx protein was no longer the only factor affecting gene 
expressions in patients, and the deregulation effect of HBx might be masked or 
disturbed by other factors. Therefore the low linear correlations do not conclude weak 
relationships between HBx and gene expressions in patients. More importantly, it has 
been shown that these potential HBx target genes with HBx binding sites nearby were 
deregulated upon the expression of HBx proteins in THLE3 cells, which supports the 
deregulation effect of HBx on gene expressions.  
In summary, by analysing the THLE3 ChIP-Seq sequencing data and comparing with 
HepG2 ChIP-chip data, a list of potential global HBx binding sites on a single-base 
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resolution was identified, and a more comprehensive list of potential HBx-interacting 
transcription factors was confirmed. In this study, the pleiotropic nature of HBx has 
been further concluded as a transactivator deregulating a large set of genes indirectly 
through interactions with a variety of transcription factors. To date, the underlying 
mechanism of how HBx deregulation of host gene expressions through interactions 
with transcription factors contributes to hepatocarcinogenesis in HCC patients was 
still unclear due to lack of patient data. In this study, the microarray expression 
profiles and clinical data of 100 HBV-associated HCC patients were first ever utilized, 
and seven putative HBx deregulated gene targets were identified to be significantly 
associated with patients’ clinical features including survival profiles. These putative 
HBx gene targets with significant clinical inferences may potentially involve in HBx-
induced hepatocarcinogenesis. However, this study may only identify a small portion 
of HBx gene targets that potentially play a role in hepatocarcinogenesis. Nevertheless, 
we gained more knowledge on the potential genomic binding sites of HBx, HBx-
interacting transcription factors and putative deregulated direct gene targets of HBx 
with potential clinical inferences in HCC patients. By identification of clinically 
associated HBx deregulated direct gene targets, we are now in a better position to 
explore the roles of the HBx in HBx-induced carcinogenesis. Future work on 
examining the pathways that HBx may deregulate by targeting these clinically 
associated genes through interactions with transcription factors is to be done. This 
may facilitate future discovery of potential drug targets and development of new 
therapies for HCC patients. 
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CHAPTER 4: Conclusion and Future Work 
Chronic HBV infections have been identified as a major risk factor for HCC accounting 
for 50-55% of all HCC cases in the world, and may gradually induce the development of 
HCC in patients (Arbuthnot and Kew, 2001; Bonilla Guerrero and Roberts, 2005; 
Buendia, 1992; Chang, 2003; Lupberger and Hildt, 2007; Parkin et al., 2001; Robinson, 
1994; Tan, 2011). Various mechanisms have been proposed currently by scientists for 
HBV-associated development of HCC, such as, multi-locus HBV genome integrations 
into human genome (Bill and Summers, 2004; Bonilla Guerrero and Roberts, 2005; 
Buendia, 1992; Goto et al., 1993; Jiang et al., 2012; Murakami et al., 2005; Pineau et al., 
1998; Robinson, 1994; Saigo et al., 2008; Tan, 2011; Tu et al., 2006), HBx deregulation 
of host genes expression through interactions with transcription factors (Andrisani and 
Barnabas, 1999; Ganem, 2001; Sung et al., 2009; Wu et al., 2001) or through epigenetic 
modifications of genes (e.g. alteration of DNA methylation status of genes) (Arzumanyan 
et al., 2012; Huang et al., 2010; Jung et al., 2010; Kim et al., 2010; Madzima et al., 2011; 
Park et al., 2011; Su et al., 2008; Um et al., 2011; Zhu et al., 2010) or through 
deregulation of regulatory microRNA expressions (Kong et al., 2011; Shan et al., 2011; 
Wang et al., 2010; Wang et al., 2012; Wu et al., 2011; Yip et al., 2011; Yuan et al., 2012), 
etc. Understanding these underlying mechanisms for HBV-induced carcinogenesis in 
HCC patients will help future identification of potential drug targets and development of 
new therapies for HCC treatment. However, the molecular pathogenesis of HBV-induced 
hepatocarcinogenesis in HCC patients is still unclear (Ng and Lee, 2011; Tan, 2011). In 
this project, we focused on two essential underlying mechanisms: HBV genome 
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integrations and HBx deregulation of host genes expression through interactions with 
transcription factors.  
4.1 Characterization of HBV-Host Genome Integration Sites in 
HCC Patients 
To understand HBV genome integration events, we first need to know where the 
HBV genome is fused with human genome. Previous studies on HBV genome 
integration sites are mainly PCR-based methods, which are labour-intensive and 
require prior-knowledge of HBV DNA that are fused with human DNA, which 
however is very limited currently (Saigo et al., 2008; Tamori et al., 2003; Tamori et 
al., 2005; Tu et al., 2006; Urashima et al., 1997). To comprehensively characterize 
HBV genome integration sites with human genome and to study the variation of 
HBV DNA in HCC patients, our laboratory has applied targeted deep sequencing 
(454 FLX sequencer) techniques to enrich for HBV-containing DNA fragments 
extracted from 48 HBV-positive HCC patients’ tumor and adjacent non-tumor 
tissues. In this study, I implemented a computational workflow to analyse the high 
throughput FLX sequencing data to identify integrated sequences carrying both 
HBV and human DNA within the same sequence from which the HBV-HG 
integration sites can be inferred. In the end, a set of 60 novel altered HBV sequences 
and 63 HBV-HG integrated sequences were successfully identified. Various 
alteration events such as insertion, deletion, duplication, and inversion were 
observed from the 60 altered HBV sequences. Novel HBV genome integration 
boundaries were also inferred from the HBV-HG integrated sequences which carried 
both HBV and human DNA within the same sequence. Interestingly, it was found 
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that the HBV-HG integrations preferentially occurred on the small HBx gene 
(27/63=42.9%) and the C-terminal of HBx carrying p53 binding domain was often 
removed to fuse with human genome. Deletion of p53 binding domain of HBx may 
potentially promote carcinogenesis, as p53 is a well-known tumor suppressor. The 
N-terminal two third of HBx gene carrying transactivation domains (amino acid 1 to 
100) were often retained in the integrated form, indicating the transactivator nature 
of HBx. Significantly, our laboratory has successfully experimentally validated the 
existence of altered HBV sequences and HBV-HG integration sites in HCC patients. 
These findings concluded the potential important role of HBx in HBV-associated 
carcinogenesis in HCC patients. By computational scanning of the HBV-HG 
integrated sequences for open reading frames, it has been observed that HBV-HG 
integrations may potentially lead to either early termination of HBV genes (e.g. HBx 
gene) or expression of chimeric transcripts. More significantly, based on my 
prediction results, our laboratory has experimentally proved the existence of 
chimeric transcripts in vivo, and functional evaluation on the oncogenic potential of 
these chimeric transcripts is still in progress in the laboratory.  
4.2 Future Work on the Computational Analysis Pipeline in 
Identifying Virus-Host Genome Integration Sites 
The major benefit of utilizing single-end high-throughput 454 FLX 
pyrosequencing is that the reads produced could be long enough to allow 
identification of precise virus insertion sites in human genome at single-base 
resolution with one region of the read aligned to human genome and the other 
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region aligned to virus genome. Analysing the millions of long sequencing reads 
of variable lengths has always been a challenge, which requires intensive 
computational power to map the reads to reference genome. Even though there 
are many software tools available specifically designed to map high throughput 
sequencing reads to reference genome, it is simply far from enough in the case of 
identifying viral-host integration sites. To extract the most biological meaningful 
results from high throughput sequencing data generated from specifically 
designed experiments, a carefully implemented analysis workflow is always 
needed to best fit the data. When analysing the FLX sequencing data in this study, 
mapping of the sequencing reads to reference genomes was only the very first 
step, after which, noise and insignificant reads that do not contain HBV sequences 
were removed to clean the data. Before proceeding to identify HBV-HG 
integration sites, a step of de novo assembly was incorporated to recover possible 
integration sites that were disrupted by DNA fragmentation. When identifying 
HBV-HG integrated sequences, the sequences were searched against both human 
and HBV genomes, and each sequence must be carefully examined to identify 
possible integration sites based on its alignments with human and HBV genomes. 
Sequences containing HBV genome integration sites were hypothesized to have at 
least one region of the sequence aligned to human genome and the other region 
aligned to HBV genome. Fortunately, findings in this study have promisingly 
proved the robustness of my computational approach to analyse the high 
throughput sequencing data for comprehensive identification of viral-host genome 
integrations. Future work to compact the analysis workflows as an integrated 
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standalone platform is to be done, such that other researchers can also submit their 
high throughput sequencing data and perform similar analysis to identify viral-
host genome integration sites. Previous studies on HBV genome integration sites 
were mainly PCR-based methods (Saigo et al., 2008; Tamori et al., 2003; Tamori 
et al., 2005; Tu et al., 2006; Urashima et al., 1997). This has been among the very 
first to comprehensively characterize the HBV-HG integration sites in a large 
series of samples from 48 HCC patients, and we are now in a better position to 
understand how HBV genome integration may potentially contribute to 
hepatocarcinogenesis in HCC patients. 
4.3 Identification of HBx Genomic Binding Sites, HBx-interacting 
Transcription Factors, and Clinically Associated Deregulated 
Direct Gene Targets of HBx 
Other than HBV genome integration into human genome after long term HBV 
infection in patients, HBx deregulation of host gene expression through 
interactions with transcription factors was reported also to potentially contribute 
to hepatocarcinogenesis. HBx is a small protein of length 154 amino acids which 
is reported to have oncogenic potential. HBx protein has been implicated to play 
an important role in HBV-induced development of HCC. HBx does not have a 
DNA-binding domain, and is found to bind to DNA indirectly through 
interactions with transcription factors. Interaction of HBx with transcription 
factors may change the DNA binding affinities of transcription factors and 
consequently lead to regulation of host gene expression. Our laboratory has 
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previously systematically profiled the HBx genomic binding sites, HBx-
interacting transcription factors and HBx deregulated direct genes in a large-scale 
using ChIP-chip method in UV-treated liver cell line (HepG2) on 1.5kb promoter 
regions of human genes (Sung et al., 2009). However, the detailed mechanism of 
how HBx deregulation of host gene expressions through interactions with 
transcription factors may contribute to hepatocarcinogenesis is still incompletely 
understood (Ng and Lee, 2011; Sung et al., 2009).  
There are various limitations and bias associated with ChIP-chip method, such as 
limited genome coverage (e.g. 1.5kb promoter regions of genes), hybridization 
noise, dye bias, and low reproducibility. To overcome the limitations associated 
with ChIP-chip and to obtain a more comprehensive and unbiased list of HBx 
genomic binding sites on single-base resolution, our laboratory has turned to 
apply chromatin immunoprecipitation coupled with high throughput sequencing 
technology (ChIP-Seq) to sequence immunoprecipitated DNA fragments bound 
by HBx in primary liver cell line THLE3 cells transfected with HBx-expressing 
adenoviruses. In this study, I implemented an analysis pipeline to integrate and 
analyse the ChIP-Seq sequencing data, microarray expression profiles for both 
THLE3 cells and 100 HCC patients, as well as the clinical data for the 100 HCC 
patients. In the end, a list of 2860 potential HBx binding sites, a list of 195 
potential HBx-interacting transcription factors, and a list of 143 potential HBx 
deregulated direct gene targets were identified in THLE3 cells. Among these 143 
potential HBx deregulated direct gene targets, seven were found also deregulated 
with significant clinical inferences in 100 HCC patients. These seven genes were 
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associated with various patients’ clinical features including survival time, tumor 
grade, liver invasions, patients’ multifocality, normal liver cirrhosis, and tumor 
encapsulations. 
The 2860 potential HBx genomic binding sites were mostly located within introns 
and intergenic regions. It is not surprising since introns and intergenic regions are 
the two longest categories in human genome. Next abundant locations of the 
potential HBx binding sites are promoters, exons, 5'UTR and 3'UTR in 
descending order. However, these 2860 predicted HBx binding sites were found 
to be significantly enriched in exons and promoter regions of genes, and 
significantly less located in intergenic regions (p<0.00001). Interestingly, among 
the binding sites within introns and exons, over half were in the first and last 
introns and exons, suggesting the potential regulatory effect of HBx on gene 
expressions. Among the 195 transcription factors significantly over-represented 
within the 2860 potential HBx binding sites identified from the THLE3 ChIP-Seq 
data in this project, 129 were also found significantly over-represented within the 
971 potential HBx binding sites identified from the UV-treated HepG2 ChIP-chip 
data done previous in our laboratory. Though THLE3 ChIP-Seq and HepG2 
ChIP-chip data predicted similar sets of potential HBx-interacting transcription 
factors with 129 motifs in common, the two datasets had very different sets of 
potential HBx deregulated gene targets, which might be due to the physiological 
differences of the two different cell lines and the artificial effects introduced by 
UV-treatment on HepG2 cells. Nevertheless, this has confirmed a list of 129 
transcription factors that may potentially interact with HBx and bind to DNA for 
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gene regulations. These 129 transcription factors include previously reported ones 
that either interact with HBx or are activated by HBx, such as, SP1 (Lee et al., 
1998), AP1 (Benn et al., 1996), AP2 (Kim and Rho, 2002), E2F  (Weinmann et al., 
2001), E2F1 (Choi et al., 2002; Sung et al., 2009), CREB (Maguire et al., 1991), 
SMAD4 (Sung et al., 2009), YY1 (Sung et al., 2009), NFKAPPAB50 (Su and 
Schneider, 1996), STAT3 (Waris et al., 2001), and so on. The 195 enriched 
transcription factors predicted from THLE3 ChIP-Seq data also include C-Myc 
(Li et al., 2003; Zeller et al., 2006) and P53 (Wei et al., 2006), that were 
previously reported to interact with HBx but not predicted from the HepG2 ChIP-
chip data. This may suggest ChIP-Seq is advantageous over ChIP-chip in 
reducing false negative rates, since the ChIP-chip data only covered 1.5kb 
promoter regions of human genes while ChIP-Seq was able to detect the binding 
sites over entire genome. 
Integration of microarray expression profiles in THLE3 cells (AdHBx over 
AdEasy) for the corresponding nearest genes of the 2860 potential HBx binding 
sites identified 143 potential HBx deregulated direct gene targets in THLE3 cells. 
These 143 potential gene targets were significantly enriched in developmental 
process and multicellular organismal process, and these two biological processes 
were also found significantly enriched by the 184 potential gene targets of HBx 
predicted from the HepG2 ChIP-chip data (Sung et al., 2009). The top 
significantly enriched molecular function of the 143 potential HBx gene targets 
from THLE3 ChIP-Seq data is transcriptional factor activity, which, however, 
was not significantly enriched in the 184 potential HBx gene targets from HepG2 
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ChIP-chip data. This may further confirm the advantage of ChIP-Seq over ChIP-
chip in reducing false positive rates. 
Further integration of microarray expression profiles for the 100 HBV-associated 
HCC patients (tumor over adjacent non-tumor tissues) found 18 out of the 143 
potential HBx direct gene targets also displaying differential expressions in HCC 
patients with consistent deregulation directions in THLE3 cells. To evaluate 
whether these 18 genes were truly related to HCC, statistical tests were performed 
on the 100 HCC patients’ clinical data, and seven out of the 18 genes were found 
to have significant clinical inferences. These seven potential HBx deregulated 
gene targets (DAO, C20orf74, TTR, STK32B, FYB, BANK1 and CDRT1) are 
associated with various patients’ clinical features including survival time, tumor 
grade, liver invasions, patients’ multifocality, normal liver cirrhosis, and tumor 
encapsulations. These seven clinically associated target genes were also 
functionally important involving in amino acid metabolic process, protein post-
translational modifications, protein transport, regulation of signal transduction, 
and immune responses. However, these seven genes were found to have very low 
linear correlations with HBx protein expressions in the 100 HCC patients, which 
could be explained by the physiological complexities of HCC patients. Other than 
HBx, there are many other factors affecting gene expressions in HCC patients, 
such as environmental factors, medications, diets, other diseases, emotions and so 
on. Therefore, the low linear correlations cannot exclude the relatedness between 
genes and HBx expressions in HCC patients. Thus, these seven potential gene 
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targets of HBx with clinical inferences in HCC patients are worth further 
investigations.  
4.4 Future Work on the Clinically Associated Gene Targets of HBx 
Future work should examine the pathways that HBx may deregulate. By targeting 
these clinically associated genes, it may help in the future discovery of potential 
drug targets and development of new therapies for HCC treatment. ChIP-Seq 
techniques have been widely utilized by researchers to comprehensively profile 
the genomic binding sites of proteins of interest. By doing motif enrichment 
analysis, co-factors that potentially interact with the proteins of interest when 
binding to DNA could also be identified. Integration of the microarray expression 
profiles enables identification of potential deregulated direct gene targets for the 
proteins of interest. Previous studies profiling HBx genomic binding sites are 
mainly in cell lines due to lack of patients data. In this study, we have utilized 
ChIP-Seq techniques, and successfully predicted HBx genomic binding sites, 
HBx-interacting transcription factors and HBx deregulated direct gene targets in 
primary liver cell line THLE3 cells. With the availability of 100 HCC patients’ 
microarray expression profiles and clinical data, we are the very first to integrate 
patient data and identified seven HBx gene targets with significant clinical 
inferences in HCC patients. Novel analysis pipeline integrating the cell line ChIP-
Seq sequencing data, microarray expression profiles for both cell lines and HCC 
patients, and HCC patient clinical data was successfully implemented in this study. 
Consistency between the THLE3 ChIP-Seq data and HepG2 ChIP-chip data in 
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terms of HBx-interacting transcription factors has proved the robustness of the 
analysis pipeline. More studies on the functions and pathways for the seven 
clinically associated deregulated gene targets of HBx need to be done, to identify 
the potential pathways that HBx may deregulate. In short, by identification of 
deregulated direct gene targets of HBx with significant clinical inferences in HCC 
patients, we are now better positioned to explore the roles of HBx contributing to 
the hepatocarcinogenesis in HCC patients.  
4.5 Conclusion 
In conclusion, this project has focused on two underlying mechanisms both of 
which may contribute to HBV-induced hepatocarcinogenesis in HCC patients: 
HBV multi-locus genome integrations into the human genome and HBx 
deregulation of host gene expressions through interactions with transcription 
factors. In this study, computational analysis pipelines have been implemented 
and successfully analysed the high throughput FLX pyrosequencing data, ChIP-
Seq Illumina sequencing data, microarray expression profiles and HCC patient 
clinical data. Our findings provided comprehensive characterization of the HBV 
genome integration sites with human genome and preliminary identification of 
putative HBx deregulated direct gene targets with significant clinical inferences in 
HCC patients. We are now better positioned to explore the underlying 
mechanisms of HBV-induced hepatocarcinogenesis in HCC patients, which may 




CHAPTER 5: Supplementary Tables 
Supplementary Table S1: Number of sequences (assembled contigs and unassembled 
reads) that were classified into the five major groups in each patient sample. In total, our 
laboratory obtained 378 sequences including 221 "intact HBV", 60 "modified HBV", 34 
"HBV+unknown", 56 "HBV-HG junctions", and 7 "modified HBV-HG junctions".  
Patient 
Intact HBV modified HBV HBV+Unknown HBV-HG Junction modified HBV-HG 
Total 
Contig Unasm Read Total Contig 
Unasm 
Read Total Contig 
Unasm 
Read Total Contig 
Unasm 
Read Total Contig 
Unasm 
Read Total 




Supplementary Table S2: Information for 56 HBV-HG junctions and seven modified 
HBV-HG junctions predicted in different patient samples. The 3rd and 4th column 
displays the positions of the sequence matched to HBV genome and human genome 
respectively, with the number in red color highlighting the junction point and the 
plus/minus sign in bracket representing the strand of HBV or human genome that the 
sequence matched to. The 5th column shows the type of junction patterns for each 
sequence (See Fig 2.3). The 6th and 7th columns specify the HBV genes and human genes 
where the junction points reside. There are four major HBV genes: polymerase, precore, 
HBx and S (surface protein). Out of the 63 junctions, 27 had the junction points on HBx 
gene. The 8th and 9th columns show the junctions that have been validated and the 
chimeric transcripts that have been detected expressed in patient samples. The 10th 
column displays the expression fold change in patient tumor over non-tumor tissues for 
the nearest genes of the junctions. Positive fold change represents up-regulation of genes 
in tumor over non-tumor tissues in patient and negative value represent down-regulation. 
Genes highlighted are the ones differentially expressed in patient tumor over non-tumor 
tissues with at least 2 fold change: red for up-regulation and yellow for down-regulation. 
The last column shows the molecular functions and pathways involved for the genes 




Total HBV part HG Part Junction 
Pattern







1966-2059(+) NT_005403.17:Chr2:20541731-20542059 (+) 1 precore BBS5-Promoter(-3.4kb) BBS5: -1.164
1477-1975(+) NT_010498.1:Chr16:2993363- 2993419  (-) 2 precore 29kb upstream to  C16orf78 C16orf78: -1.262
1853-2206(-) NT 030059.13:Chr10:10089307 -10089419 (+) 1 precore 500kb upstream to Loc100128586 pseudogene
p5T 1 1820-2095(+) NT_006576.16:Chr5:792307 -792457 (-) 1 HBx&precore  ZDHHC11-intron 11 yes ZDHHC11: -1.333
p6T 1 1495-1790(+) NT_016354.19:Chr4:60468621- 60468770  (-) 2 HBx 30kb upstream to  LOC389223 yes Expressed pseudogene
p7N 1 2295 -2403(+) NT 005612.16:Chr3:76198699 -76198537 (-) 1 precore SEC62-Intron 5 yes SEC62
1878-2660 (-) NT 167187.1:Chr8:20552236-20552413 (+) 2 polymerase 50kb downstream to  NRG1 NRG1: 1.161
1678-1836(-) NT_167214.1: unplacedHG:128734-128832  (+) 2 HBx&precore 11kb downstream to LOC100286895 pseudogene
1590-1804(-) NT_010783.15:Chr17:17240216-17240371 (+) 2 HBx 60kb upstream to Loc100128713 yes pseudogene
p8T 1 1302-1780(-) NT_008046.16:Chr8: 10474414-10474450 (-) 2 HBx GDF6-intron 1 yes Expressed GDF6: -8.739 growth differentiation factor (formation 
of bones, joints, skull & axial skeleton)
133-331(-)* NT_009714.17:Chr12:15724057-15724089 (+);
NT 009714.17:Chr12:15723951-15724001(-)
1 polymerase&S 120kb donstream to ETNK1 ETNK1: 1.119
1682-1795(+) NT_011109.16:Chr19:20259097 -20259209  (-) 2  HBx KPTN-Promoter (-4kb) yes KPTN: 2.146 actin binding protein (cell motion) 
(filament organization)
1111- 172(-) NT_011362.10:Chr20:25100849- 25100967 (-) 1 polymerase 30kb upstream to C20orf108 C20orf108: -1.107
274-449 (+) NT_007592.15:Chr6:55255483-55255635 (-) 1  polymerase&S  HMGCLL1-intron6  HMGCLL1: -2.139 hydroxymethylglutaryl-CoA lyase 
activity;metal ion binding (metabolic 
788-911(+) NT_005403.17:Chr2: 63523480 -63523666 (-) 1  polymerase&S ERBB4-intron1 ERBB4: 1.039
1104-1325(-) NT_010194.17:Chr15:2204668-2204696  (-) 1 polymerase 20kb upstream to TRPM1 TRPM1: -1.491
1720-1806(-) NT_026437.12:Chr14:42942788 -42942818 (-
)
2  HBx PRKCH-intron9 PRKCH: -2.063 protein kinase C (protein modification & 
phosphorylation)
1666-1811(-) NT 024524.14:Chr13:16958192-16958260 (-) 2  HBx NBEA-intron yes NBEA: 1.624
967-1122(+) NT_022135.16:Chr2:1113100-1113176 (-) 1 polymerase LOC100507581-promoter(-4kb) hypothetical RNA gene 
36- 210(+) NT_024862.14:Chr17:582722- 582856  (-) 2 polymerase&S 44kb downstream to LOC100129683 yes pseudogene
1631-1820(-) NT 006576.16:Chr5:1287850-1287993 (+) 2 HBx TERT-promoter(-2688bp) yes TERT: 1.648
569-1192(+) NT_030059.13:Chr10:44588143 -44588334 2 polymerase BTAF1-Intron BTAF1: -1.256
1268-1316(-) NT_167206.1:ChrY:327776-327740 (-) 2 polymerase LOC100506481-promoter(-11bp) pseudogene 
1014-1316(-) NT 167206.1:ChrY:327749- 327805  (+) 2 polymerase LOC100506481-promoter(-20bp) pseudogene 
581-954(+) NT 006576.16:Chr5:1446416-1446477 (+) 2 polymerase 11kb upstream to SLC6A3 yes SLC6A3: -1.089
2-39(-), 3018-3215(-), 1631-
1820(+)
NT_011651.17:ChrX:28754024-28754062  (-) 2 HBx&precore 5kb downstream to MUM1L1 MUM1L1: -28.148 melanoma associated antigen (mutated) 1-
like 1
1080-1316(-), 1608-2115(+) NT_167206.1:ChrY:327761-327805  (+) 2 polymerase LOC100506481-promoter(-15bp) pseudogene 
1755-2613(-), 1818-2007(+), 
2068-3215(+), 2- 1316(+) 
NT_167206.1:ChrY:327746- 327805  (-) 2 polymerase LOC100506481-promoter(-32bp) pseudogene 
2220- 2337 (-), 1968-2122(-) NT 010783.15:Chr17:2948900-2948982  (+) 2 precore&polymerase CDK12-Intron10 CDK12: -1.049
p13T 1 688 -794(-) NT_011109.16:Chr19:10488025 -10488401 (+) 1 polymerase&S 9kb upstream to ZNF607  ZNF607: 1.703
p15T 1 536-956(-) NT_010718.16:Chr17:11715113-11715178 (-) 2 polymerase 65kb downstream to MAP2K4 MAP2K4: -7.013 mitogen-activated protein kinase kinase 
(MAPKKK cascade,protein modification)
p16N 1 618-822(-) NT 026437.12:Chr14:15744062-15744190 (+) 1 polymerase&S 47kb downstream to Loc100128921 pseudogene 
401-561(-) NT_029419.12:Chr12:23883663- 23883778  (-) 1 polymerase&S 113kb downstream to PGBD3P1 PGBD3P1
1822-2215(-) NT_167197.1:ChrX:27303621-27303669  (-) 1 HBx&precore  IL1RAPL1-inton 5  IL1RAPL1: -1.006
395-737(-) NT 010966.14:Chr18:18433732- 18433844  (-) 1 polymerase&S LOC647946 (non-coding RNA) non-coding RNA
392 -569(+) NT_167190.1:Chr11:2270409 -2270226 (-) 1 polymerase&S 3kb downstream to LRRC55; 36kb 
upstream to APLNR
LRRC55: -1.079;  APLNR:-
1.736
p19T 1 1522-1802(-) NT_030059.13:Chr10:68127017-68127161 (-) 2 HBx ATRNL1-intron 26 yes Expressed ATRNL1: 14.765 attractin-like 1 (cell surface receptor 
linked signal transduction)
1628-1819(-) NT_008413.18:Chr9: 33938611-33938663 (-) 2  HBx&precore UBAP2-intron12 UBAP2:-1.128
937-1792(+) NT_010718.16:Chr17:8745855-8745951 (+) 2 HBx NTN1-LastIntron yes NTN1:7.036 netrin 1 (axon guidance and cell migration) 
(variation of netrin may involve in cancer 
1481-1741(-)** NT_030059.13:Chr10:16274412-16274458 (+); 
NT 030059.13:Chr10:2366039 -2366072(+)




p22T 1 141-1819(-), 2974-3092(+) NT_167187.1:Chr8:30951033-30951157 (+) 2 HBx&precore 50kb upstream to POTEA; 26kb 
downstream to HGSNAT
yes Expressed POTEA,HGSNAT:1.475
p23N 1 1837-2014(+) NT_033899.8:Chr11:7899487- 7899717 (+) 1 HBx&precore 300kb upstream to  PDGFD yes PDGFD 
p24T 1 1472-1647(-) NT 167190.1:Chr11:2563743-12563941 (-) 2 HBx AIP-intron 5 yes Expressed AIP:1.911
962- 1663(-) NT_007933.15:Chr7:41050503-41050539 (-) 2 HBx SLC26A5-intron yes Expressed SLC26A5
2143-2516(+) NT_010718.16:Chr17:13143919-13144021 (-) 1 precore 35kb upstream to HS3ST3A1 yes in T&N HS3ST3A1:1.588
p28T 1 446- 1663(-) NT 007933.15:Chr7:41050503-41050619 (-) 2  HBx  SLC26A5-intron yes Expressed  SLC26A5
p29T 1 1883-2078(+) NT 025741.15:Chr6:28145055-28145220 (-) 1 precore 18kb upstream to TRDN yes TRDN:1.439
p30T 1 1820-1897(+) NT_010783.15:Chr17:4893254 -4893516 (-) 1 HBx&precore KRT32-intron6 & Exon6 KRT32:41.256
p31T 1 1575-1761(+) NT_008183.19:Chr8: 32531628 -32531673 (+) 1  polymerase&HBx 9kb downstream to HEV1 yes Expressed HEV1 
p36T 1 1093-1152(-), 874-1826(-) NT 008413.18:Chr9: 25075832- 25076007 (-) 2 polymerase 591kb upstream to TUSC1 yes Expressed  TUSC1:-1.428
p37N 1 1417-1678(-) NT 011109.16:Chr19:10829043 -10829084 (-) 2  HBx SIPA1L3-intron2 SIPA1L3:-1.649
2006 -2578(-) NT_030059.13:Chr10:41254724-41255047 (+) 1 precore 12kb downstream to LIPF yes LIPF:-1.234
1442-1796(+) NT_030059.13:Chr10:41577178-41577115 (-) 2 HBx FAS transcript variant 1-Intron 7 yes Expressed FAS:-2.847
TNF receptor superfamily (regulate 
programmed cell death & apoptosis) 
(transduce proliferation in normal cells)
1952-2307(-) NT 029490.4:Chr21:370831- 370944  (-) 1 precore 10kb upstream to BAGE2&BAGE3 BAGE2, BAGE3
108-400(+) NT_005612.16:Chr3:89972106- 89972186  (+) 1 polymerase&S  YEATS2-Intron 13 YEATS2:1.266
1821-2552(+) NT_029289.11:Chr5:5912940- 5913134 (+) 1 HBx&precore 140kb downstream to ASSP10 pseudogene 
1952-2041(+) NT 025028.14:Chr18:10744807-10745097 (-) 1 precore 500kb upstream to CDH7 CDH7:1.011
394 -490(-) NT_006713.15:Chr5:15433615-15433668  (-) 1 polymerase&S CENPK-Intron 5 CENPK:5.836
centromere protein (mitotic cell cycle) ( 
regulation of transcription from RNA 
polymerase II promoter )
1546-1600(-) NT_008470.19:Chr9:33306748- 33306795  (-) 1 polymerase&HBx BAAT-intron 1 BAAT:-2.439
liver amino acid N-acyltransferase (lipid 
metabolic process) (bile acid metabolic & 
transport process)
2574-2710(-) NT_022459.15:Chr3: 4187591-4187654 (-) 2  polymerase 193kb upstream to LOC100128160 hypothetical
1819-1934(+) NT_030059.13:Chr10:58098120 -58098199 (-) 1 HBx&precore 268kb downstream to SORCS3  SORCS3:3.269
sortilin-related VPS10 domain containing 
receptor 3 (cell surface receptor linked 
signal transduction) (strongly expressed 
in the central nervous system)
1 3010-3215(+), 53-366(+) NT_011520.12:Chr22:5748454-5748491 (-) 1  polymerase&S MYO18B-Intron 39 MYO18B:9.699
myosin 18B (regulate muscle-specific 
genes & intracellular trafficking)  
(Mutations associated with lung cancer)




























Supplementary Table S3: List of the 195 enriched transcription factors from ChIP-Seq 
data in THLE3 cells, among which 129 were common with the transcription factors 
predicted from ChIP-chip data in HepG2 cells. The ranking of the enriched 
transcriptional factors was based on significance p-values from motif enrichment analysis. 










HEB GCCAGCTG 1.68E-55 1 39 1.4E-31 - 
MYOD CNGNNNCAGGTGNCGNAG 3.96E-54 2 53 1.1E-23 (Barnabas et al., 1997) 
MINI20 NNCCGGCCCCACGCAGGNGCA 7.01E-53 3 47 7.7E-26 - 
AP4 CTCAGCTGGT 1.03E-49 4 37 2.7E-33 - 
LRH1 CNGACCTTGNAC 2.38E-47 5       
E12 GGCAGGTGNCG 1.18E-46 6 73 3.3E-17 - 
E47 NCNGCAGGTGTNCNC 1.03E-41 7 35 5E-36 - 
AP2 GCCCCCAGGCGGNGNN 3.81E-39 8 4 2E-198 (Kim and Rho, 2002) 
HIC1 NCCGGGTGCCCGGGG 1.73E-37 9       
AP2ALPHA GCCNNNGGG 2.77E-37 10 7 3E-159 - 
USF CCACGTGN 2.77E-37 11 63 7E-21 - 
VMAF ANATGCTGACTCAGCACNN 4.50E-37 12 110 2.4E-05 - 
HEN1 NTGGGNCNCAGCTGCGNCCCNN 1.10E-36 13 33 2.9E-38 - 
ZF5 NGGGGGCGCGCTT 4.45E-34 14 14 9.4E-76 - 
DR1 GGGNCAAAGGTCA 4.45E-34 15 113 6.4E-05 - 
LBP1 CAGCTGC 3.74E-32 16 34 1.5E-36 - 
MUSCLE NNCCGCCNCCACCCCGGNGCC 3.19E-31 17 11 4.3E-86 - 
SMAD4 GTGGGGCAGCCANCT 4.85E-31 18 30 1.9E-43 - 
MZF1 AGTGGGGA 7.51E-31 19 80 3.4E-15 - 
AREB6 CTGCACCTGTGC 2.68E-30 20 142 0.0321 - 
MYOGENIN GGCAGCTG 4.14E-30 21 38 2.9E-32 - 
E2A CACCTGNC 6.26E-30 22 69 5.6E-18 - 
COUP TGACCTTTGACCC 2.72E-29 23 121 0.00149 - 
TAL1 TCCAGCTGCT 1.57E-28 24 107 1.1E-05 - 
LMO2COM CNNCAGGTGCNG 1.72E-28 25 60 1.4E-21 - 
LMAF GGTCAGCAG 2.56E-28 26       
HNF4 NGGNCA 1.28E-27 27 119 0.00057 - 
MAZR NGGGGGGGGGCCA 4.24E-27 28 25 2.4E-50 - 
CBF NNNNCTGCGGTTANNN 2.06E-26 29       
CP2 GCNCNACCCAG 4.51E-26 30 48 3.9E-25 - 
CACCCBINDINGFACTOR CANCCCNTGGGTGTGG 8.37E-26 31 29 6.5E-44 - 
AP2GAMMA GCCCNNGGG 3.05E-25 32 6 3E-167 - 
HES1 ANGNCTCGTGGCNNG 3.05E-25 33 36 8E-35 - 
ER CAGGTCACGGT 6.61E-25 34       
ETS1 ACAGGAAGTGNNTGC 6.26E-24 35       
ZIC1 TGGGTGGTC 1.31E-23 36 54 3.3E-23 - 
ATF3 CTCTGACGTCANCG 4.22E-23 37 88 4.6E-11 (Barnabas et al., 1997) 
MYC CACGTGN 1.69E-22 38 66 1E-18 - 
PAX4 NANNCCCACCCN 2.39E-22 39 40 3.9E-31 - 
MEIS1 NNNTGACAGGNC 3.44E-22 40       
AP2REP CAGTGGG 4.86E-22 41 70 6.1E-18 - 
AML1 TGTGGT 4.86E-22 42       
TAL1ALPHAE47 NCGAACAGATGGTNNN 9.91E-22 43 134 0.01206 - 
AR TGAGCACGN 1.42E-21 44 122 0.00181 (Zheng et al., 2007) 
PAX5 TCGAGGCGCANTGATGCGTAGCCGCCCC 5.29E-21 45 23 2E-54 - 
EBOX CCACGTGNCN 1.13E-20 46 67 1.6E-18 - 
TBX5 TNAGGTGTTA 1.13E-20 47       
MINI19 NNCNGNCNCCACNCAGGNGCC 3.15E-20 48 12 3.7E-82 - 
LRF NGGGCCCCC 3.15E-20 49       
TFE TCATGTGN 3.15E-20 50       
NMYC TNCCACGTGNCN 4.43E-20 51 72 2.2E-17 - 
MOVOB GNGGGGG 8.65E-20 52       
NRSF GCGCTGTCCGTGGTGCTGA 2.12E-19 53 19 5.3E-58 - 
KAISO NTCCTGCTAN 2.33E-19 54       
CLOCKBMAL ACACGTGG 2.49E-19 55       
ETS2 GACAGGAAGTANTT 9.23E-19 56       
PPAR TGACCTTTGNCCC 1.20E-18 57 116 0.00014 - 
GR TNTGTTCT 1.20E-18 58       
ZNF219 CGCCCCCCNCCC 3.13E-18 59       
NERF TGNCAGGAAGTAGGTNNC 5.55E-18 60 71 1.9E-17 - 
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HIF1 GCGTACGTGCGGNN 5.96E-18 61 15 1.3E-69 (Moon et al., 2004) 
NANOG GGGNCCATTTCC 1.92E-17 62       
MTF1 TNTGCACACGGCCC 9.71E-17 63 45 1.1E-26 - 
R NTGGCCGCGNANCGTGGTGCA 2.73E-16 64 51 7.2E-24 - 
YY1 NCNCGGCCATCTTGNCTGNT 4.15E-16 65 106 1.1E-05 - 
RFX CTGTTGCCA 4.40E-16 66 137 0.01492 - 
ATF CNCTGACGTCNNCC 8.11E-16 67 62 2.5E-21 (Maguire et al., 1991) 
EGR2 NTGCGTGGGCGT 1.98E-15 68       
KROX CCCGCCCCCGCCCC 2.61E-15 69 5 8E-197 - 
SREBP GNNATCACCCCA 4.68E-15 70       
NRF2 ACCGGAAGAG 1.09E-14 71 46 2.5E-26 - 
ZIC3 TGGGTGGTC 1.44E-14 72 96 2.7E-08 - 
STRA13 NNGTCACGTGANNN 1.96E-14 73 101 4.6E-07 - 
TAL1BETAITF2 GNNAACAGATGGTNTN 2.42E-14 74       
EGR GTGGGGGCGAC 2.53E-14 75 10 9E-125 (Yoo and Lee, 2004) 
CACD CCACACCC 2.53E-14 76       
TAL1BETAE47 NNGAACAGATGGTCNN 2.53E-14 77       
WT1 CCCNCCCNC 2.53E-14 78       
NFE2 TGCTGAGTCAC 3.21E-14 79       
CREB CGTCAN 3.35E-14 80 21 1.3E-57 (Maguire et al., 1991) 
CMYB CCNAANGGCNGTTGGGGG 1.01E-13 81 55 5.1E-23 - 
PPARA TNGGGTCATTGGGGTCANG 1.05E-13 82 82 6E-13 (Kim et al., 2007) 
P53 AGACATGCCT 1.33E-13 83       
GABP ACCGGAAGTGCA 1.71E-13 84       
CETS1P54 ACCGGAAGTN 2.94E-13 85 89 8.5E-11 - 
SP1 GGGGCGGGGC 3.91E-13 86 3 2E-262 (Lee et al., 1998) 
DEC CCCCAAGTGAAGG 3.91E-13 87 141 0.02661 - 
HAND1E47 ANNGGNGTCTGGCATT 5.08E-13 88       
MYCMAX NGACCACGTGGTCN 6.42E-13 89 81 4.3E-13 - 
VDR GGGTNAANGGGGTGA 8.61E-13 90 58 4.4E-22 - 
E2F1DP1 TTTCCCGC 1.10E-12 91 17 2.9E-63 - 
RP58 NAAACATCTGGA 1.40E-12 92       
ELK1 NNNNCCGGAAGTNN 1.46E-12 93 61 1.4E-21 (Goto et al., 2003) 
E2F1 NTTCGCGC 4.02E-12 94 9 8E-132 - 
LFA1 GGGGTCAG 4.02E-12 95 20 8.7E-58 - 
CETS168 CAGGAAGC 5.28E-12 96 65 9E-20 - 
NFY TAACCAATCAC 5.28E-12 97 75 3.1E-16 - 
EBF GTCCCTTGGGA 9.48E-12 98 114 6.5E-05 - 
NFMUE1 CGGCCATCT 1.27E-11 99 78 1.5E-15 - 
STAT3 NNNTTCCN 3.78E-11 100 97 3.4E-08 (Waris et al., 2001) 
MAZ GGGGAGGG 4.82E-11 101 16 9.2E-69 (Su et al., 2007) 
STAF NTTACCCANAATGCATTGCGNN 5.29E-11 102       
SMAD3 TGTCTGTCT 6.11E-11 103 140 0.02596 - 
OLF1 NNCNANTCCCCAGGGAGNNTGN 8.86E-11 104 84 2.9E-12 - 
CAAT NNTAGCCAATCA 1.24E-10 105 118 0.00042 - 
MIF1 NNGTTGCTAGGCAACNGG 1.25E-10 106 99 1.8E-07 (Zhang et al., 2006) 
SREBP1 NATCACGTGAC 1.60E-10 107 31 3.1E-42 (Kim et al., 2007) 
NF1 NTGGNNNNNTGCCAANN 1.60E-10 108       
MYB NNNGNCAGTTN 2.01E-10 109       
ETS ANCCACTTCCTG 2.53E-10 110 105 5.6E-06 - 
TFIII AGAGGGAGG 3.19E-10 111 42 5.3E-30 - 
AML ANGTNTGTGGTTANC 6.33E-10 112       
NRF1 CGCATGCGCA 7.29E-10 113 22 2.4E-55 - 
CACBINDINGPROTEIN GAGGGTGGG 9.85E-10 114 32 4.2E-41 - 
USF2 CACGTG 9.85E-10 115 68 3.5E-18 - 
AP1 GGTGACTCAGA 9.85E-10 116       
EGR1 ATGCGTGGGCGT 1.12E-09 117       
MAF TGCTGAGTCAN 1.55E-09 118 115 8.1E-05 - 
MYOGNF1 CACCTGTTNNNTTTGGCACGGNGCCAACN 1.77E-09 119 104 5E-06 - 
CMYC NACCACGTGCTC 1.84E-09 120       
SRF GNCCATATAAGGAC 1.84E-09 121       
AHRHIF TGCGTGCGN 1.94E-09 122 59 5.3E-22 - 
E2F TTTCGCGC 5.75E-09 123 8 3E-144 (Choi et al., 2002) 
ACAAT GATTGGTGG 1.26E-08 124 131 0.00658 - 
E4F1 GCTACGTCAC 1.33E-08 125 130 0.00651 (Rui et al., 2006) 
P300 NCNGGGAGTGNGNG 1.65E-08 126 98 6.6E-08 (Cougot et al., 2007) 
SF1 TGACCTTG 1.65E-08 127       
SZF11 CCAGGGTATCAGCCG 2.30E-08 128       
PR GANAGAACAN 3.74E-08 129       
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DR4 TGACCTNTACTGACCCC 4.54E-08 130 132 0.00659 - 
GC NGGGGGCGGGGCTN 1.01E-07 131 13 5.9E-82 - 
VMYB NCTAACGGN 1.47E-07 132 95 1.9E-08 - 
PEBP GNTAACCACAAANNT 1.47E-07 133       
TGIF AGCTGTCANNA 1.47E-07 134       
ROAZ GCACCCAAGGGTGC 1.81E-07 135       
ZID NGGCTCTATCATC 2.17E-07 136 129 0.00643 - 
AP1FJ GGTGACTCAGT 2.17E-07 137       
DELTAEF1 NNTCACCTNAN 3.84E-07 138       
DR3 GATGAACTTNCTGAACCGTTT 3.87E-07 139 109 2.3E-05 - 
ALPHACP1 CAGCCAATGAG 5.45E-07 140 143 0.03746 - 
ATF4 CCTGACGCAATG 5.61E-07 141 102 8.7E-07 - 
ZIC2 GGGGTGGTC 7.99E-07 142 57 3.4E-22 - 
CREBATF GTGACGTCA 1.40E-06 143 90 5.8E-10 - 
RREB1 CCCCAAACCACCCC 1.54E-06 144 41 4.7E-31 - 
AHR CTTGCGTGNGN 2.37E-06 145 50 2.7E-24 - 
OSF2 ACCACAAA 2.37E-06 146       
TEL2 CTACTTCCTG 2.92E-06 147       
PU1 AGAGGAAG 3.31E-06 148 144 0.04264 - 
SP3 AGCCTTGGGGAGGG 6.19E-06 149 43 7.5E-29 - 
HMX1 CAAGTGCGTG 6.39E-06 150 108 1.2E-05 - 
GATA1 CNNGATNGNN 6.56E-06 151 56 1.7E-22 - 
EGR3 NTGCGTGGGCGT 8.79E-06 152       
AHRARNT TNNGGNTTGCGTGCCC 1.07E-05 153 52 7.7E-24 - 
XPF1 TCAGAAGAAC 2.36E-05 154 125 0.00379 - 
RBPJK TTCCCACG 3.24E-05 155       
COUPTF NNNNNTGACCTTTGCCCNCTGCN 5.07E-05 156 87 1.6E-11 - 
PAX9 GAGACGCAGCGAGGAGTGACCACC 5.42E-05 157 76 1.3E-15 - 
E2 NNACCGNNANCGGTGC 6.85E-05 158 100 2.7E-07 - 
GCM CANACCCGCATT 6.85E-05 159 124 0.00282 - 
TTF1 CNCTCAAGNGNN 6.85E-05 160       
MEF3 GGGTCAGGTTTCA 8.03E-05 161 112 3.5E-05 - 
GEN_INI CCTCANTC 9.18E-05 162       
T3R CANTGAGGTCACGCNN 1.04E-04 163 103 4.2E-06 - 
BACH2 CGTGAGTCATC 1.05E-04 164 120 0.00092 - 
E2F1DP2 TTTCCCGC 1.62E-04 165 26 2.1E-49 - 
SMAD TAGNCAGACAG 1.62E-04 166 94 1.1E-08 - 
NGFIC ATGCGTGGGCGG 1.75E-04 167       
ARNT GTTGTCACGTGNNCGN 2.14E-04 168 83 6E-13 - 
MAX NAANCACGTGNTTN 2.54E-04 169 85 9.9E-12 - 
STAT6 GNCTTCCT 3.66E-04 170       
RFX1 NNGTNGCCTGGCAACNN 5.44E-04 171       
PAX6 CTGACCTGGAACTC 7.88E-04 172       
TFIIA TATAAAAGGACC 9.74E-04 173       
NFKAPPAB50 GGGGATTCCC 1.85E-03 174 77 1.5E-15 (Su and Schneider, 1996) 
CDPCR3 CACCAATANGTATNG 1.95E-03 175       
STAT1 CANTTCCG 3.22E-03 176 117 0.00025 - 
CREBP1 GGTGACGTAACT 3.33E-03 177 92 1.1E-09 (Cougot et al., 2007) 
GATA2 NNNGATAGNN 3.62E-03 178 93 6.2E-09 - 
UF1H3BETA GGTGGGGGAGGGGC 4.48E-03 179       
GLI NNTGGGTGGTCC 5.59E-03 180 86 9.9E-12 - 
BRCA TTNNGTTG 6.72E-03 181       
ATF1 CTCTGACGTCA 7.40E-03 182 91 9.9E-10 - 
ATF6 TGACGTGG 7.94E-03 183 64 2E-20 (Li et al., 2007) 
SPZ1 GNNGGAGGGTATGGC 1.00E-02 184 44 7.3E-28 - 
ZEC CAAGGTTGGTTGC 1.04E-02 185       
DEAF1 CCGCCCTCGGGTATTTCCGGAGNNG 1.11E-02 186 24 9.1E-52 - 
PPARG AACTAGGNCAAAGGTCA 1.21E-02 187       
TCF11 GTCATNNTNNNNN 1.47E-02 188       
TEF1 GGAATG 2.11E-02 189       
HSF1 NTTCTAGAANNTTCTCC 2.36E-02 190       
E2F4DP2 TTTCCCGC 2.72E-02 191 27 6.9E-49 - 
PEA3 ACATCCT 3.24E-02 192       
ERR1 NNNTCAAGGTCANA 3.77E-02 193       
E2F4DP1 TTTCGCGC 4.43E-02 194 28 2.4E-46 - 
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